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ZUSASMMENFASSUNG 
Das Säugetier Herz reagiert besonders empfindlich auf traumatische Verletzungen 
oder andauernde Herz-Kreislaufkrankheiten. Narbenbildung und Schwächung des 
Gewebes führt zu einem Verlust der kontraktilen Funktion des Herzens und damit zu 
einer Verschlechterung des Gesundheitszustandes insgesamt. Der Versuch 
Herzverletzungen oder Schädigungen vorzubeugen oder die verheerenden Folgen 
derselben zu beheben waren bisher wenig erfolgreich, was unter anderem auf die 
begrenzten regenerativen Fähigkeit des Herzens zurückzuführen ist.  
In der vorliegenden Arbeit wurde die regenerierende Fähigkeit einer lokal agierenden 
Isoform des Insulin-ähnlichen Wachstumsfaktors-I (mIGF-1) auf verletztes 
Herzmuskelgewebe untersucht, indem die Expression des mIGF-1 Transgens auf das 
Myocardium des Mausherzens beschränkt wurde. Durch die Herz-spezifische 
Expression des Transgens können endokrine Effekte auf andere Organe 
ausgeschlossen werden.    
Die Herzen, die das Transgen tragen zeigten beschleunigtes postnatales Wachstum, 
wobei die Größe des Herzens nicht über die Normalgröße von erwachsenen Wildtyp-
Herzen hinausging.  
Das frühe hypertrophe Wachstum der transgenen Herzen wurde begleitet von einer 
kurzzeitigen Aktivierung von MAP-Kinasen, einer erhöhten Funktion der 
translationalen Maschinerie und einer moderaten Erhöhung von Hypertrophie 
Markern, wobei die Herzfunktion unverändert war. Es ist hervorzuheben, dass Akt, 
einer der Haupteffektoren von IGF-1, nicht aktiv war, was darauf hindeutet, dass eine 
andere Kinase als Effektor von IGF-1 agiert. 
Die Fähigkeit von IGF-1 die Regeneration des Mausherzens zu stimulieren, wurde auf 
zwei Wegen untersucht. Wir nutzen LAD-Ligation oder direkte Injektionen von 
Cardiotoxin (CTX) in das linke Ventrikel von erwachsenen Mäusen, um eine 
Verletzung des Herzgewebes herbeizuführen. Die Verletzung von Wildtyp und 
transgenen Mäusen war reproduzierbar und führte zu lokalen Infarkten, verbunden mit 
frühem Zelltod und ausgeprägter Entzündung der betroffenen Bereiche. Im Gegensatz 
zu der charakteristischen Narbenformierung in Wildtyp Herzen, fanden wir, dass 
mIGF-1 in den transgenen Herzen innerhalb eines Monats eine komplette 
Wiederherstellung des verletzten Gewebes herbeiführte, ohne Narben zu bilden. 
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Die Regenerierung des Gewebes ging einher mit einer ausgeprägten Erniedrigung von 
Entzündungsstimulierenden Zytokinen und einer Erhöhung von 
Entzündungshemmenden Zytokinen. Diese Ergebnisse deuten darauf hin, dass mIGF-
1 seine regenerierende Funktion teilweise durch Modulierung des 
Entzündungsprozesses ausübt. Die transgenen Herzen zeigte ausserdem erhöhte 
proliferative Aktivität in Infarktnähe und konnten die normale Herztätigkeit wieder 
herstellen. 
Durch die Wiederherstellung des Herzgewebes nach einer Verletzung, scheint mIGF-
1 die evolutionären Einschränkungen der Regenerierung von Säugetier Herzen zu 
umgehen. 
Die Verbesserung kardialer Regeneration durch die lokale Expression dieses 
Wachstumsfaktors verspricht neue klinische und therapeutische Strategien zur 
Eindämmung von Entzündungsreaktionen und Wiederherstellung von verletztem 
Herzgewebe. 
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ABSTRACT 
The mammalian heart is particularly susceptible to traumatic injury or sustained 
disease, suffering tissue deterioration, scarring and loss of contractile function. 
Clinical interventions to prevent or reverse the devastating effects of cardiac damage 
have met with limited success, presumably due to restricted cardiac regenerative 
potential.  We tested the ability of a locally acting mIGF-1 isoform to regenerate the 
injured heart, restricting expression of a mIGF-1 transgene to the mouse myocardium 
to exclude endocrine effects on other tissues. Transgenic mIGF-1 hearts displayed 
accelerated postnatal cardiac growth that never exceeded the wild-type adult cardiac 
size. Early remodelling of the transgenic hearts was accompanied by transient 
activation of MAPKs and increased function of the translational machinery, without 
perturbing cardiac performance, and by modest upregulation of hypertrophic markers 
at one and two months. Notably, AKT the downstream effector of IGF-1 signalling 
was not activated in the hearts of transgenic mIGF-1 animals, indicating that a 
different kinase regulates mIGF-1 downstream signalling in the heart. 
 
The regenerative capacity of mIGF-1 was analyzed either by LAD ligation or by 
direct cardiotoxin (CTX) injection into the ventricles of adult mice. Injury to both 
wild-type and transgenic mIGF-1 hearts produced reproducible and localized 
infarctions coupled with early cell death and marked inflammation. In contrast to the 
characteristic progression of scar formation in wild-type hearts, transgenic mIGF-1 
hearts induced complete repair of the injured tissue after 1 month, without scar 
formation. mIGF-1-induced regeneration was associated with a marked decrease in 
pro-inflammatory cytokines and an increase in anti-inflammatory cytokines, 
indicating that mIGF-1 drives regeneration in part by modulating the inflammatory 
response in pathological conditions. At later stages, mIGF-1 transgenic hearts 
displayed increased proliferative activity proximal to the infarct, and restored cardiac 
functionality. By enabling myocardial reconstruction following injury, the mIGF-1 
isoform appears to bypass the evolutionary restrictions on mammalian regeneration. 
The enhancement of cardiac regeneration by localized expression of this growth factor 
suggests novel and clinically feasible therapeutic strategies to decrease inflammation 
and increase cell replacement after tissue damage. 
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PROJECT AIMS  
Two important aspects prompted us to investigate IGF-1 signalling in the heart: the 
regenerative properties of IGF-1, and the complete absence of a regenerative program 
in most of the adult tissues, such as the myocardium. Our principle aim was to analyze 
whether overexpression of IGF-1 in the heart could overcome the barrier of tissue 
deterioration, normally occurring in case of extended injury, and restore heart 
functionality following severe damage. 
 
The regenerative properties of the mIGF-1 isoform have been previously documented 
in skeletal muscle. In regenerating transgenic mouse muscle, overexpression of the 
mIGF-1 isoform under a muscle-specific promoter, enhanced myogenic progenitors, 
maintaining tissue integrity during exercise and aging, countered muscle decline in 
degenerative disease and cachexia, and promoted healing following injury (1, 2). 
These results define a mechanism, enhanced at every level by supplementary mIGF-1, 
whereby injury stimulates local regenerative signals to rebuild damaged tissue.   
 
Empirically, complete regeneration of complex organs in mammals is 
characteristically precluded by inadequate tissue replacement and fibrotic reactions, 
leading to scar formation. The mammalian heart is particularly susceptible to 
traumatic injury or sustained disease, suffering irreversible tissue deterioration, 
scarring and loss of contractile function.  Although cell hypertrophy can increase 
cardiac mass in response to stress, organ function is compromised by tissue loss 
during myocardial infarction and ischemia-reperfusion. Interventions to prevent or 
reverse the devastating effects of human heart attacks have met with limited success, 
presumably due to the restricted regenerative potential of the heart. 
 
Based on these considerations and the data mentioned above, we tested the ability of 
the locally acting IGF-1 isoform, mIGF-1, to regenerate the injured heart. We 
generated transgenic mice with a rat mIGF-1 cDNA driven by the mouse cardiac 
myosin heavy chain (α-MHC) promoter to restrict expression of mIGF-1 to the mouse 
myocardium. Our analysis addressed the physiological and the pathological features 
of mIGF-1 overexpression. 
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- In physiological conditions, postnatal transgenic mIGF-1 hearts displayed 
accelerated cardiomyocyte hypertrophy, precociously attaining wild-type adult heart 
size. We found a significant increase in the size of cardiomyocytes in transgenic 
hearts compared to wild-type hearts, induction of the hypertrophic marker ANP and a 
sustained activation of the translational machinery, mediated through PDK1 signaling. 
Measurement of cardiac function by echocardiography and electrocardiography 
showed that mIGF-1 induced a transient 20% concentric left ventricular hypertrophy, 
and a mild impairment in systolic and diastolic components of cardiac function. 
Transgenic mIGF-1 did not otherwise affect cardiac output and blood pressure, which 
were maintained at normal levels. 
- The regenerative capacity of mIGF-1 was analysed by direct cardiotoxin (CTX) 
injection into the ventricles of four months old mice. CTX injection in both wild-type 
and transgenic mIGF-1 hearts produced a reproducible, titratable and localized 
infarction with evident cell death and marked inflammation. In contrast to the 
characteristic progression of scar formation in wild-type hearts, transgenic mIGF-1 
induced repair of the injured tissue after one month, without scar formation. Down-
regulation of specific inflammatory cytokines suggests that mGF-1 improves cardiac 
regeneration in part by modulation of the inflammatory response. Moreover, 
transgenic mIGF-1 hearts contained dramatically increased numbers of proliferative 
cells in the area of damage after one month, suggesting that the regeneration program, 
following an earlier survival/repair program, is activated as a later step in response to 
mIGF-1. Cardiac functionality, measured by echocardiography, showed normal 
cardiac parameters and restoration of the posterior wall thickness and contractility. 
 
Our results need further analyses to cover the intracellular signaling activated by 
mIGF-1 and to exhaustively explain the remarkable regenerating capacity of this 
isoform, but the study clearly demonstrated that tissue-specific supplementary mIGF-
1 expression is an effective and potentially powerful approach to counter a number of 
prevalent and life-threatening cardiovascular pathologies. Our data further suggest 
that the enhancement of cardiac regeneration by localized expression of this growth 
factor can be the basis for novel and clinically feasible therapeutic strategies to 
decrease inflammation and increase cell replacement after tissue damage. 
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THESIS ORGANIZATION 
A helpful guide throughout the thesis is meant to connect the different parts of this 
work. I divided the thesis in two parts. The first part contains the Introduction, while 
the second part describes Materials and Methods, Results and Discussion.  
 
Part I: 
The Introduction consists of three different Chapters. Each Chapter analyzes in details 
the most important findings in the field of heart development, IGF-1 and regeneration. 
Chapter I covers the past and recent discoveries of pre- and post-natal heart 
development; Chapter II is entirely dedicated to IGF-1 gene structure and tissue 
specific function, and Chapter III analyzes the major aspects of tissue and organ 
regeneration. In the latter two Chapters, the most important discoveries that connect 
IGF-1 signaling and regeneration are discussed with particular reference to the heart. 
 
Part II: 
Chapter IV contains Materials and Methods, Chapter V describes Results and Chapter 
VII the discussion. The last chapter (Chapter VII) will be dedicated to the future aims 
of this work that are inspired by a group of results that need to be further analyzed, 
but that open an interesting window on mIGF-1-induced recruitment of stem cells. 
We think that contributions of stem cells may be important for complete regeneration 
of an injured tissue and that mIGF-1 plays multiple role in regulating survival and 
proliferation, not only of most known components of the heart, such as 
cardiomyocytes and endothelial cells, but also of a possible cardiac or circulating 
progenitor cell pool.  
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1. HEART FORMATION AND SPECIFICATION 
The heart is one of the first structures to form during organogenesis (3, 4). It is 
initially established as a single tube consisting of two epithelial layers: the inner 
endocardium and outer myocardium (5). The primitive tubular heart partitions further 
into two chambers, atrial and ventricular, confined by atrioventricular septa. 
Myocardial contractions begin during this double-walled stage of heart formation. 
Initial pulsations are generated at the right myocardium and spread posteriorly to 
anteriorly over the whole myocardium. Except for the pacemaker cells, the cardiac 
conduction system has not yet developed at this stage. The two-chambered heart is the 
mature form in the primitive vertebrates such as fish. In contrast, the heart of higher 
vertebrates further undergoes a series of morphogenetic steps: looping, septation, 
which generates the four compartments characteristic of the adult heart, trabeculation 
and thickening of the ventricular walls, and the cranial shift of the atrial chambers that 
assume their adult position rostrodorsal to the ventricles (Figure 1.1). The survival of 
the thickened ventricular myocardium relies on the coronary vessel system.  
 
The initiation of cardiac differentiation has been the topic of vigorous investigation (6, 
7). The heart precursors are localized together with the cranial mesoderm in the 
embryonic mesoderm domain. Further lineage analysis of the embryonic cardiac 
precursor cells has shown that descendants of this population contribute 
predominantly to the myocardium and to a lesser extent to the endocardium and to the 
pericardium (8). Transplantation experiments were not sufficient to reveal whether 
cardiac lineages share a common progenitor. Nevertheless, it has been suggested that 
in zebrafish blastula, the endocardium and the myocardium may be derived from 
common progenitors, and that these two lineages may segregate later during 
development (9, 10). Although no single transcription factor that is responsible for the 
differentiation of lateral plate mesoderm into cardiac cells has been identified, the 
localization of the heart precursors in the mesoderm of 7.0- to 7.5-day mouse embryos 
coincides with the distribution of the transcripts of the endothelial-specific GATA4 
and Flt1 genes (11, 12), and the Nkx2-5 gene, which is expressed in the precursors of 
the myocardium (13). The following sections describe the remodelling of the embryo 
heart and the intracellular and extracellular signalling involved. 
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1.1. INTRACELLULAR SIGNALING 
1.1.1 Cardiogenesis and cardiac differentiation 
The GATA family of zinc-finger containing transcription factors appears to be 
potentially critical for differentiation of precardiac cells. Three GATA family genes 
have been identified as being expressed in the developing heart: gata4, gata5 and 
gata6 (14). GATA factor function has been well conserved throughout evolution: in 
Drosophila the gata4 homologue pannier is required for normal proliferation of 
cardiogenic precursors (15), and in zebrafish the faust mutation, which results in 
cardia bifida and impaired cardiac differentiation, lies in the GATA5 gene (16). Gene 
deletion of GATA factors in the mouse has not been as informative as one would 
predict, due either to the role of GATAs outside the heart field in early 
embryogenesis, or to genetic redundancy (17-20). The early endodermal defect in 
gata4 knockouts and the peri-implantation lethality of gata6 knockouts preclude the 
analysis of this GATA factors in further steps of myocardial differentiation. In vitro 
studies showed that in P19 embryonal carcinoma cell lines induced to differentiate in 
cardiac cells, gata4 and gata6 antisense oligonucleotides cause an arrest in cardiac 
differentiation and apoptotic death (21, 22). Moreover, the potential of gata4-null 
embryonic stem cells to undergo cardiac differentiation is reduced (23). 
 
Much excitement was generated by the discovery of the tinman gene in Drosophila, 
which is required, although not sufficient, for the generation of cardiac cells (24). The 
tinman gene encodes a NK-class homeodomain-containing transcription factor, 
homologue to the vertebrate gene Nkx2-5. This gene is a predominantly cardiac gene. 
Generation of mice lacking Nkx2-5 results in a poorly developed myocardium, 
characterized by the inability of this primitive cardiac structure to grow beyond the 
earliest stages of heart looping (25-27). In mice Nkx2-5 is required for the 
establishment and maintenance of a ventricular gene expression program (25, 26). 
Other NK-class transcription factors have been identified, such as Nkx2-3 and Nkx2-
6, but genetic ablation studies indicate no discernable role in cardiac development (28, 
29).  
 
Myocardin is a specific cardiac transcription factor important for the early 
differentiation of cardiac cells (30). Powerful in vitro activation of several cardiac 
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gene promoters via serum response factor (SRF)-binding sites has been identified as a 
major function of myocardin. Experiments in frog embryos using a dominant-negative 
myocardin molecule indicate that it may be necessary for high level expression of 
Nkx2-5 (30). Although the importance of this molecule is undisputed, the role of 
myocardin in vivo remains to be defined. 
 
1.1.2 Migration of cardiac precursors 
GATA is involved in the movement of the paired progenitor pools that coalesce to 
form the linear heart tube. In this regard, it has been shown that GATA4 in the mouse 
and GATA5 in zebrafish are primarily controlling normal formation of the endoderm 
underlying the myocardial precursors (16, 18, 19). If the function of GAT4/5 is 
reduced, endodermal cells do not normally differentiate, their ventral migration is 
inhibited, and this prevents the concomitant movement of myocardial cells with 
consequent generation of cardia bifida (16, 18, 19). 
 
The basic helix-loop-helix (bHLH) transcription factor MesP1 has been shown to be 
required for an earlier step in the migration of cardiac precursors. In the absence of 
MesP1, mesodermal cells, fated to become cardiac myocytes, fail to migrate normally 
out of the primitive streak during gastrulation, resulting in complete or partial cardia 
bifida (31). Mice lacking MesP1 and its related gene MesP2 have a complete block in 
migration of the mesoderm from the primitive streak, resulting in the lack of cardiac 
and other mesodermal derivatives (32). Interestingly, double knockouts for 
MesP1/MesP2 reveal a specific cell autonomous role for these transcription factors in 
ventricular, but not atrial, formation. This analysis argues for a distinct lineage 
difference between atrial and ventricular precursors (33, 34). 
 
1.1.3 Regulation of chamber morphogenesis and chamber-specific gene expression 
Although individual cardiac chambers do not become morphologically distinguishable 
until after cardiac looping, their cell fates seem to be genetically programmed much 
earlier. The linear heart tube is segmentally patterned along the anterior posterior axis 
into precursors of the aortic sac, outflow tract (conotruncus), ventricles and atria 
(Figure 1.2). Each cardiac chamber differs in its morphological and contractile 
properties and its pattern of gene expression.  
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Few regulators of chamber-specific gene expression have been identified to date. 
Iroquois homeobox gene 4 (Irx4) is a member of the Iroquois family of 
homeodomain-containing transcription factor genes, which have been implicated in 
patterning events in Drosophila. Expression of Irx4 is restricted at all stages of 
development to the ventricular myocardium in all species examined (25, 35, 36) . Irx4 
expression is reduced in mice lacking Nkx2-5 or dHand, in which ventricular 
differentiation is compromised, suggesting that Nkx2-5 and dHand specifically 
regulate Irx4 (25). Experiments in avian embryos have demonstrated that Irx4 is 
involved in positive and negative regulation of chamber-specific myosin heavy chain 
gene expression in the ventricular myocardium. Mice with targeted disruption of Irx4 
have only a disturbance of ventricle-specific gene expression, including decreased 
eHand expression in the embryonic heart, and atrial natriuretic factor (ANF) 
derepression in the ventricle after birth, leading to impaired cardiac function and 
further cardiomyopathy (37). The expression of additional Irx genes in the developing 
heart suggests the possibility of genetic redundancy. Interestingly, it has been found 
that Irx4 controls the expression of atrium-specific slow myosin heavy chain 3 
(SmyHC3) gene in the ventricle (35, 38). Irx4 does not bind directly to SmyHC3 
promoter elements required for ventricular repression, but may interact with the 
retinoic acid receptor/vitamin D receptor  (RAR/VDR) complex of proteins (38). 
Another factor involved in the regulation of chamber specific gene expression is 
Hey2. It is a ventricle-specific transcription factor related to the Hairy family of 
bHLH transcription factors (39-41) . Mice lacking Hey2 do not have aortic coarctation 
and develop a severe postnatal cardiomyopathy (42) .  
 
Chamber morphogenesis is controlled in part by dHand and eHand genes, which are 
expressed in the right ventricle (RV) and in the left ventricle (LV) respectively. In 
mammals both Hand genes appear to be required for normal growth of the developing 
myocardium of the chamber in which they are restricted (43-48) . The role of eHand 
in the LV development is not clear, due to early embryonic lethality caused by extra-
embryonic defects (46, 47). Interestingly, the RV and the outflow tract are initially 
formed in dHand-null embryos, but subsequently the RV precursors undergo dramatic 
apoptosis, impairing the expansion of this segment and resulting in the absence of the 
RV (49) . 
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Another factor determining the chamber morphogenesis is Tbx5. Tbx5 is expressed 
initially throughout the cardiac mesoderm in the earliest stages, but its expression 
pattern is rapidly refined to a posterior-anterior gradient in the linear heart tube, until 
mid gestation, when it is restricted to the atria and LV. Tbx5 levels decrease in the LV 
during subsequent stages of development (50, 51). Lack of Tbx5 results in severely 
hypoplastic atria and LV, with RV and outflow tract growth remaining intact (52).  
Expression of Irx4 and Hey2 decreases in the Tbx5 deficient embryos, and overall 
ventricular differentiation is impaired. In lower verterbrates, such as frogs and fish, 
Tbx5 as well as Hand genes are expressed throughout the single ventricle and appear 
to be involved in the morphogenesis of the entire heart (53, 54). This implies that in 
higher vertebrates, with the addition of the pulmonary circulation and the acquisition 
of the RV chamber, duplication and specialization of these two genes occurred to 
regulate chamber-specific morphogenesis. This was presumably accompanied by 
restricted expression of Tbx5 and Hands to specific segments of the developing heart.  
 
An unexpected role for MEF2C transcription factor in ventricular growth has been 
elucidated from the generation of mice with disrupted Mef2c genes, in which 
cardiogenesis is initiated, but in which the segments of the heart corresponding to 
both RV and LV are severely hypoplastic. However, ventricle-specific gene 
expression appears normal in Mef2c-/- embryos (55). 
 
Considerably less is known about the genetics of atrial development. The orphan 
nuclear receptor COUP-TFII is expressed in atrial precursors and is required for atrial, 
but not ventricular, growth (56). A major player in establishing atrial identity is the 
transcription factor Pitx2. Mice lacking Pitx2 have a single right atrium with abnormal 
connection of veneae cavae and pulmonary veins (57-60). 
 
1.1.4 Chamber Maturation and Septation 
Maturation of the heart into fully functional trabeculated chambers, and septation of 
the atria and the ventricles from one another and between their left and right sides, are 
important processes that require precise integration of growth and differentiation 
signals. Defects in this processes account for the majority of congenital heart 
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malformations in humans, including atrial and ventricular septal defects (ASDs and 
VSDs respectively), tetralogy of Fallot (TOF), common atrio-ventricula canal, and 
double-outlet right ventricle. Genetic analysis of inherited cardiac septation defects 
has shown that mutations, conferring sustained function or depleted function in Nkx2-
5 and Tbx5, are the major factor in septal morphogenesis. One example is the Holt-
Oram syndrome, which is characterized by a spectrum of cardiac defects including 
hypoplastic left ventricle, atrial septal and ventricular septal defects (52). The cardiac 
defects occurring in this syndrome resemble those caused by Nkx2-5 mutations and it 
is thought that haploinsufficiency of Tbx5 is the cause of the syndrome (61-64).  
 
The multi-type zinc finger transcription factor FOG-2 has been implicated in cardiac 
septation. FOG 2 is similar to the Drosophila U-shaped proteins, which function as 
positive or negative regulators of transcription via interaction with GATA proteins 
(65). In Drosophila U-shaped proteins negatively regulate cardiac cell numbers, and 
repress a cardiac-specific promoter regulated by tinman and pannier (65). 
Surprisingly, deletion of FOG2 in mice does not lead to increased cardiac 
proliferation, but instead to ventricular and atrio-septal defects, accompanied by a 
general failure of coronary vessel formation (66).  
 
The transcription enhancer factor-1, TEF-1, regulates Troponin C and alpha skeletal 
actin genes in cardiac myocytes (67). A retroviral gene trap insertion into the mouse 
TEF1 gene resulted in embryonic lethality, in part due to defects in trabeculation and 
thinned ventricular myocardium (68). Although it has not yet been determined which 
are the genes regulated by TEF-1, it is intriguing to note that mice deficient in the 
protoncogene transcription factor N-myc also have identical defects (69). 
 
1.1.5 Downstream targets 
A major gap in our knowledge is the identification of specific targets of transcription 
factors, as well as the physical interactions in signalling that are responsible for the 
formation and specification of the heart. ANF and connexin 40 (cx40) have been 
identified as bona fide targets of Nkx2-5 and Tbx5 (27, 52). Tbx5 regulates in dose-
dependent ANF promoter activation in vivo and in vitro (52, 70), as well as Cx40 
promoter, by occupancy of multiple sites (52). A 50% decrease in Tbx5 expression 
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leads to complete elimination of cx40 and ANF transcription in the mouse heart (52). 
Nkx2-5 plays an important role in the regulation of both promoters, but less critical 
than that of Tbx5. In fact, a complete lack of Nkx2-5 causes only a partial decrease in 
ANF expression in vivo (27). 
 
The cardiac ankryn repeat protein (CARP) and Pitx2 genes have also been identified 
as bona fide targets of Nkx2-5 (71, 72). GATA 4 and other GATA factors have been 
shown to be potentially important for the regulation of multiple cardiac genes, such as 
ANF, several contractile genes, gata6, Nkx2-5 and dHand (14, 73). Embryonic cardiac 
expression of the SM22α and α-skeletal actin genes is regulated in vivo under the 
control of CarG boxes, which are bound by SRF and probably by myocardin (74, 75). 
It is interesting to note that SRF-binding sites, as well as MEF2-binding sites, are 
required for muscle-specific expression rather than cardiac specific expression; it is 
possible that GATA4, Nkx2-5, or myocardin must be required to specify cardiac 
regulation in the developing heart (42). 
 
A more complicated aspect of cardiac specification has been revealed by the 
identification of multiple physical interactions between factors on DNA regulatory 
elements. Nkx2-5 physically interacts with Tbx5 and GATA4 to synergistically 
activate transcriptional target genes (52, 70, 76). GATA4 can also interact with FOG-
2 to activate or repress transcription of GATA-dependent targets (65). Mice with 
GATA4 mutation, designed to abolish GATA-FOG interactions, have phenotypes 
similar to those found in FOG-2 deficient mice (66, 77). It is important to underline 
that the GATA4 missense mutations lead to impaired outflow tract septation, resulting 
in mice with double-outlet right ventricle, a phenotype not present in FOG-2 deficient 
mice. This suggests that other factors bind to GATA4 at this site (66, 77).  Finally, 
although a direct in vivo interaction between Nkx2-5 and dHand was not shown, mice 
deficient for both proteins do not form a ventricle and have abolished Irx4 expression 
(49). 
 
From this survey it is clear that although the identities of crucial regulators defining 
cardiogenesis has been uncovered, it is still unknown which transcription factors are 
involved in the earliest differentiation of cardiac cells from the mesoderm. Moreover, 
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the downstream pathaways regulated by transcription factors responsible for key 
morphogenetic events are still unknown. It also remains to be addressed whether 
protein functions are maintained or inactivated through posttranslational modification 
during development.  
 
1.1.6 The secondary heart field 
Several lines of evidence have led to a surprising shift in the established paradigm 
regarding the origin of cardiac myocytes. It is now recognized that a second 
population of cardiac precursors migrates into the outflow region of the looped heart, 
providing mature cardiomyocytes that contribute to the right ventricle, and probably 
to the atria and left ventricle as well (78-81). Marking experiments in ovo suggest that 
the atrioventricular canal, atria and conotruncus are added secondarily to the straight 
heart tube during looping (81). The heart tube elongates during looping, concomitant 
with accretion of new myocardium. The atria are added progressively from the caudal 
primary heart fields bilaterally, while the myocardium of the conotruncus is elongated 
from a midline secondary heart field of splanchnic mesoderm, beneath the floor of the 
foregut. This population of cells is called secondary heart field or anteroior heart field. 
As the cells in the secondary heart field begin to move into the outflow or inflow 
myocardium, distinguishable later as the outflow and inflow tract of the forming 
heart, they express HNK-1 initially and then MF-20, a marker for myosin heavy 
chain. FGF-8 and BMP-2 are present in the ventral pharynx and secondary heart 
field/outflow myocardium respectively, and appear to effect induction of the cells in a 
manner that mimics induction of the primary myocardium. Neither FGF-8 nor BMP-2 
is present when the inflow myocardium is added from the primary heart fields. 
Precursors of this heart field probably arise close to the cardiac crescent, where 
primary heart field cells also arise, and subsequently migrate to the anterior pharynx, 
contributing later to the heart. Secondary heart field myoblasts express many of the 
same cardiac markers as those previously analyzed in the primary heart field, 
including Nkx2-5 and GATA4, but they remain undifferentiated until later in 
development. The addition of a secondary myocardium to the primary heart tube 
provides a new framework for understanding several null mutations in mice that cause 
defective heart development. 
 
 19 
1.2 EXTRACELLULAR SIGNALING 
1.2.1 Specification of cardiac cell fate by extracellular cues 
Two families of peptide growth factors have been studied most extensively for their 
positive and negative effects on the establishment of cardiac cell identity: Bone 
Morphogenetic Proteins (BMPs) and Wnt proteins. BMPs are a subset of the 
transforming growth factor-β (TGFβ) superfamily, shown to promote cardiogenesis in 
vertebrate embryos (82). Equivalent effects have been shown also in Xenopus and 
avian embryos explants, using soluble inhibitors of the BMP ligand-receptor 
interaction such as noggin (83), and dominant –negative BMP receptors (84). In mice, 
mutations of certain BMPs or of any BMP receptor are lethal at gastrulation, 
obscuring the potential role of BMPs in cardiogenic specification. Notably, epiblast-
specific deletion of the type IA BMP receptor is permissive for gastrulation, but 
markedly impairs the inception of heart development (85).  
 
Wingless in Drosophila and the related Wnt proteins in vertebrates are the second 
class of secreted signal for cardiac specification. The primary mode of Wnt signaling 
is through an intracellular cascade that inhibits the activity of glycogen synthase 
kinase-3 (GSK3). Inhibition of GSK3 leads to β-catenin stabilization and its 
interaction with the transcription factors of T-cell factor (TCF) family (86). It has 
been reported that Wnt signaling can either suppress either activate cardiac 
specification. This feature is present among different species and intra-species. 
Wingless in Drosophila is essential for cardiogenesis, as cells exposed to Dpp, an 
endogenous inhibitor of Wingless signaling, become visceral muscle instead (87). On 
the contrary, Wnt signaling blocks cardiogenesis in heart field explants from the 
chick, and in microinjected Xenopus embryos overexpressing Wnt3A and Wnt8 (88-
90). (88-90). Intriguingly, Wnt11 stimulates cardiogenesis in avian explants, Xenopus, 
and mouse P19 cells (91-93). In this case, the pro-cardiogenic signal is transduced by 
the “non-canonical” Wnt pathway, involving PKC and JNK (91). It is clear that the 
role of Wnts in vertebrate heart formation is very complex, encompassing a game of 
induction or suppression of cardiac specification by expression of different Wnt 
isoforms. 
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1.2.2 Extracellular Signal for Ventricular Growth 
Prior to embryonic day 9.5 in the mouse, the looped heart tube is a thin-walled 
structure with the atrial and molecular chamber already specified, but indistinct. 
Growth of the heart from this stage onwards involves proliferation of myocytes along 
the walls of the heart tube and within the developing interventricular septum. As the 
wall thickens, cardiomyocytes along the inner wall become organized into finger-like 
projections called trabeculae, which are thought to enhance oxygen and nutrient 
exchange, and to increase contractile area.  
 
The epicardium, the thin layer of cells surronding the heart, serves as a source of 
mitogenic signals that are necessary and sufficient to stimulate proliferation of 
cardiomyocytes. Retinoic acid produced by the epicardium is one critical regulator of 
cardiac growth. Knockout mice lacking the retinoic acid receptor RXRα dye during 
embryogenesis from a failure in proliferative expansion of ventricular 
cardiomyocytes, resulting in a thin-walled ventricle (94, 95). This defect is 
recapitulated by epicardium specific deletion of RXRα, but not by cardiomyocytes 
specific deletion of the gene (96, 97). Consistent with the role of epicardium as a 
source of Retinoic Acid for myocardial growth, the epicardium express high levels of 
retinhaldehyde-oxidizing dehydrogenas (RALDH2), which is a Retinoic Acid 
synthetic enzyme. Importantly, Retinoic Acid also is involved in posterior chamber 
specification (98, 99). 
 
Growth signals from the endocardium are also critical. The neuregulin family of 
peptide growth factors and their tyrosine kinase receptors, ErBs, have been shown to 
promote growth of embryonic cardiomyocytes in vivo (100). Knockout mice lacking 
ErbB2, Erb4, and neuregulin-1 die at midgestation from cardiac growth defects, 
characterized by the absence of trabeculae (101, 102). Cardiac specific deletion of 
ErbB2 results in dilated cardiomyopathy with ventricular wall thinning in adult 
animals (103), reminiscent of certain phenotypes observed in breast cancer patients 
receiving anti-ErbB2 antibody therapy.  
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1.3 CARDIOMYOCYTE PROLIFERATION 
Cardiac development involves the robust proliferation of cardiac myocytes during 
embryonic life, culminating in the completion of cycling soon after birth, virtually 
abrogating the potential for further hyperplastic growth. Sevaral lines of evidence 
indicate that cardiac myocyte DNA synthesis occurs in two distinct phases (104). The 
first phase occurs during fetal life and it is maximal at embryonic day (E) 12, when 
karyokinesis and cytokinesis are coupled, resulting in an expansion of the cardiac 
myocyte population. The second phase occurs early in neonatal life and peaks 4-6 
days after birth. During this phase, kariokinesis occurs in the absence of cytokinesis, 
resulting in binucleation of ventricular myocytes (105). 
 
Cyclin D-dependent kinase activity is critical for early G1 phase progression, but 
dispensable in late G1 for S phase-entry in many cultured cell lines (106). Members of 
the cyclin-D family are expressed in distinct tissue-restricted patterns, suggesting 
specialized roles for these proteins in different tissues. All three types of cyclin D are 
detected in embryonic and neonatal ventricles, but are downregulated in adult heart 
(104). Similarly, Cdk4, mediating the early G1 transition, and Cdk2, active later in 
G1, both are expressed in the embryonic ventricle, but not in adult hearts. Transgenic 
mice overexpressing cyclin D1 under the control of the α-MHC promoter showed a 
40% increase in heart weight, ascribed to a two fold increase in cardiac myocyte 
number at 14 days (104). Although the relative amount of proliferation increased 
(0.05%) compared to control (0.0003%), the absolute magnitude of this event was 
small, and there is no evidence that cyclin D1 can suffice for enhancing DNA 
synthesis and cytokinesis. In contrast to skeletal muscle, where forced expression of 
cyclin D1, A or E inhibited myogenic differentiation (107), several markers of cardiac 
differentiation were normal in D1 transgenic hearts, indicating a lineage-specific 
difference in fundamental mechanisms inducing differentiation.  
 
Cyclins D act by hyperphosphorylation and inactivation of “pocket proteins”, for 
which the archetype is Rb. Rb and other pocket proteins exert their function through 
binding and inactivation of E2F family of transcription factors (108). Quiescent cells 
express an active hypophosphorylated form of Rb, whereas cells in S- and M-phase 
contain active/hyperphosphorylated Rb.  
 22 
 
The exact expression pattern for these protein members in cardiac muscle is 
controversial. Some authors reported that Rb is expressed as early as E12 in 
developing ventricles, with Rb messanger remaining constant through development, 
but with protein expression subsequently downregulated (109). Other reports have 
failed to confirm the presence of Rb in fetal heart (110). Interestingly, the pocket 
protein p130 and the factor E2F are the major components of cell cycle present in the 
adult heart, indicating a possible differential role at this time of heart development. 
Pocket proteins act also as cofactors and their importance in myocyte differentiation 
has to be taken in consideration.  
 
The factors that regulate embryonic cardiac myocyte proliferation are largely 
speculative, because loss of function, which is usually the best way to gain insight 
protein function in vivo, can be confounded by premature lethality, systemic defects, 
and maternal rescue of secreted factors. Fibroblast growth factor (FGF) family is an 
exception in this regard. FGF1 and FGF2 are expressed in the developing rat 
myocardium and are produced by cardiac myocytes themselves (111). In cultured rat 
myocytes, FGF1 can induce cell cyle reentry, and in avians, FGF1 and FGF2 can 
trigger proliferation of precardiac mesoderm (112). A kinase defective FGFR1 was 
introduced into the embryonic chick ventricle by inoculation of a recombinant 
retrovirus (113). This truncated receptor forms heterodimers with all known FGFRs, 
preventing their autophosphorylation and activation. Myocytes infected with the 
truncated receptor had a reduced clonal expansion, indicating an important role for 
endogenous FGF as a mitogen for proliferating ventricular muscle cells.  
 
Recent studies have challenged the dogma that cardiac myocytes are permanently 
withdrawn from cell cycle, and have no capacity of regeneration. In rat cardiac 
myocytes after cardiac injury or with hypertrophy, mitotic myocytes have been 
reported, with an increasing proportion of cells in the S and G2/M phases (114, 115). 
However, other studies have failed to confirm these increases in DNA synthesis (104).  
This discordance between models suggests the possibility that cell cycle regulators are 
absent or inactive in the normal adult myocardium and that the basis of a postmitotic 
state resides in this inability. A species-specific difference was also observed, since 
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cyclins E, A and B, as well as Cdk2 and Cdc2, were upregulated after infarction in the 
surviving myocytes of the rat heart, whereas similar upregulation was not observed in 
murine models of cardiac hypertrophy (116).  
 
The clinical outcome of human myocardial infarction is a limited capacity to restore 
cardiac functions due to cardiac fibrosis and hypertrophy (117, 118). Current therapies 
to prevent the extension of hypertrophy are aimed to improve cardiac workload and 
contractility, although increased myocardial mass caused by increase myocyte number 
could provide an alternate strategy to obviate the development of maladaptive growth. 
More detailed studies are needed in order to attempt this task. 
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2. POSTNATAL CARDIAC GROWTH CONTROL (HYPERTROPHY) 
Growth of the heart during embryogenesis occurs primarily through proliferation of 
cardiac myocytes, however soon after birth cardiac myocytes withdraw irreversibly 
from cell cycle, and subsequent growth of the heart occurs through hypertrophy rather 
than myocyte hyperplasia. The hypertrophic growth of cardiomyocytes is initiated by 
mitogenic stimuli, canonical cardiac agonists, and passive mechanical stress or 
haemodinamic burden. All these stimuli induce cardiac remodelling during postnatal 
development to maintain a balance between physiological demands for contractile 
work, and the capability of muscle tissue to meet those demands (119, 120).  
 
The features of hypertrophy are an increase in cardiomyocytes size, enhanced protein 
synthesis, and higher organization of the sarcomeres. Hypertrophic growth involves 
control at multiple molecular levels: transcription initiation, transcription elongation, 
and protein translation (Figure 1.3). As described by Molkentin and Dorn, “no single 
intracellular transduction cascade regulates cardiomyocyte hypertrophy in isolation, 
but each pathway operates as an integrated component of an orchestrated response 
between interdependent and cross-talking networks” (121). These networks culminate 
in the nucleus with the post-translational activation of a set of transcription factors 
that have a role in early heart development. When activated in the adult myocardium, 
these factors reactivate a “fetal cardiac” gene program. Common examples are the re-
expression of atrial natriuretic peptide (ANP), α-skeletal actin, atrial myosin light 
chain-1, and β-myosin heavy chain (β-MHC). Although elements of this program 
might be important adaptation signals to stress, their prolonged expression leads to 
maladaptive changes in cardiac function, associated with myocyte loss through 
apoptosis and replacement with fibrotic tissue (122). These processes lead to a 
transition from hypertrophy to cardiac failure.  
 
There are two forms of cardiac hypertrophy: physiological, as occurs in response to 
exercise, and pathological, as occurs in response to abnormal stress. Stress signals 
inducing hypertrophy include hypertension, pressure overload, endocrine disorders, 
myocardial infarction, and contractile dysfunction from inherited mutations in 
sarcomeric or cytoskeletal proteins. Cardiac hypertrophy eventually normalizes the 
increase in wall tension, thereby abrogating the initial stimulus; where this possibility 
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is impaired, it results in pathological hypertrophy that frequently progresses to dilated 
cardiomyopathy.  
 
Numerous questions remain about the physiological border between the good and the 
bad of hypertrophy. Stress-induced hypertrophy may be initially adaptive and leads to 
cardiac demise only when prolonged. There is general agreement that cardiac 
hypertrophy is triggered by abnormalities in calcium homeostasis (123), although the 
mechanism remain vagues whereby calcium, which fluctuates by orders of magnitude 
during a cycle of contraction, can activate hypertrophic signals. The various pathways 
leading to cardiac hypertrophy are discussed below. 
 
2.1 GROWTH FACTORS AND CYTOKINES 
2.1.1 gp130-Mediated Factors 
Recently, cytokines were recognized to play a critical role in the development and 
homeostasis of many organs. In particular, IL6, IL11, leukemia inhibitory factor 
(LIF), cardiotrophin-1, and oncostatin M, which all share the common signal 
transducer gp130 in their receptor, have been implicated in both normal and 
pathological cardiac growth (124). Recently, gp130 was deleted specifically in 
ventricular cardiac myocytes using the cre/lox technology (125). These mice 
developed normally, however, when they were subjected to hemodynamic stress 
caused by aortic banding, they developed marked abnormalities, including rapid 
development of cardiomyopathy associated with myocyte apoptosis (125). From this 
analysis results it is clear that gp130-mediated signaling is crucial for myocyte 
survival in the development of compensatory hypertrophy.  
 
The physiological ligand for gp130 in the heart is unknown, but one potential 
candidate is cardiotrophin-1, a member of the IL6-cytokine family, known to induce 
cardiac hypertrophy and reduce cardiac myocyte apoptosis (126). Another potential 
candidate is IL6, which is produced by cultures of fetal cardiac myocytes, and is 
upregulated in the adult myocardium in response to many pathological stimuli (127). 
Transgenic mice overexpressing IL6 or IL6 receptor in the heart did not exhibit 
increased cardiac growth, but developed dramatic cardiac hypertrophy when the two 
lines were crossed (128).  
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A schematic representation of gp130-mediated signaling is presented in Figure 1.4. 
Induction of gp130-dependent signaling leads to activation of both MAPKs and 
JAK/STAT pathways (119). Specifically, STAT3 is translocated to the nucleus in 
response to gp130 activation, which results in the induction of genes involved in 
cardiac survival and hypertrophy (120). Overexpression of STAT3 in transgenic mice 
is sufficient to induce cardiomyocyte hypertrophy in vitro (129) and in vivo (130). It 
was shown that adenovirus-mediated gene transfer of either wild-type or dominant 
negative STAT3 stimulates or attenuates respectively LIF-induced cardiomyocytes 
hypertrophy (129). These results clearly establish an important role for IL6 family of 
ligands and gp130-STAT signalling in regulating cardiac hypertrophy and survival. 
 
2.1.2 Fibroblast Growth Factor 2 (FGF2) and Transforming Growth Factor Beta 
(TGFβ) 
FGF2 and TGFβ can induce a fetal-like gene program in cultured rat neonatal 
ventricular myocytes, consistent with induction of the hypertrophic program (131). 
Since this initial observation, a number of additional studies have demonstrated the 
importance of FGF and TGFβ  as mediators of the hypertrophic program. 
Cardiomyocytes and non-myocyte cells within the heart produce both growth factors, 
each of which binds to a separate membrane receptor that has tyrosine (FGF2) or 
serine (TGFβ) kinase activity to elicit further signalling.  
 
TGFβ can induce two different signalling pathways, one leading to activation of Smad 
proteins, and the other to activation of TGFβ-activated kinase (TAK1). It is not yet 
clear whether Smads are involved in hypertrophy, but it is known that TAK1 induces 
JNK and /or p38 activation, known mediators of cardiac hypertrophy, and upregulates 
the α-skeletal actin promoter in cultured neonatal cardiomyocytes (132). In vitro 
studies showed that adenovirus-mediated overexpression of TGFβ1 in cultured 
neonatal cardiomyocytes increased sarcomeric actin, suggesting a growth response 
(119). In addition, angiotensin II-induced neonatal myocyte hypertrophy required 
paracrine TGFβ1 release from non-myocytes in culture (119). 
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2.1.3 Insulin-like Growth Factor 1 (IGF-1)  
Growth of the heart after birth has been shown to involve the IGF-1 signaling 
pathway, through the activation of the PI3K/AKT signaling (133). This same pathway 
controls cells, organs, and body size in Drosophila (134). Although the role of IGF-1 
in the heart is still controversial due to usage of different isoforms in overexpression 
studies (135, 136), it is well established that skeletal muscle growth and hypertrophy 
are mediated by activation of the AKT/mTOR pathway, leading to upregulation of the 
translational machinery (137). Compelling evidence coming from lower organisms 
such as Drosophila Melanogaster, showed that loss or inhibition of either PI3K, 
mTOR or p70S6K resulted in decrease of cell size (134). Conversely, overexpression 
of the insulin receptor substrate IRS-1, or AKT, or p70S6K was sufficient to cause 
hypertrophy of cells in which they were expressed (138, 139).  
 
Consistent with the central role of this pathway in muscle growth (2), it has been 
shown that cardiac hypertrophy, induced by increased pressure overload or various 
agonists, can be attenuated by rapamycin, an inhibitor of mTOR activity (140). This 
growth effect appears to be functionally conserved in mammals, as p70S6K knockout 
mice have reduced body size and cell growth (141). The analysis of IGF-1 signalling 
in the heart is further analyzed as part of this thesis. 
 
2.2 SIGNAL TRANSDUCERS 
2.2.1 Calcineurin and Cardiac Hypertrophy 
The serine-threonine phosphatase calcineurin is expressed in multiple tissues, and 
consists of a catalytic subunit, termed Calcineurin A, and a regulatory subunit known 
as Calcineurin B. Calcineurin B is encoded by a single gene, while Calcineurin A is 
encoded by three genes, calcineurin Aα, calcineurin Aβ and calcineurin Aγ. 
Calcineurin Aα and calcineurin Aβ, but not the third isoform, are detected both in the 
adult human, rat and mouse heart (142). Calcineurin signaling has been well 
established in T cells (143). Activation of the T cell receptor results in elevated 
concentration of intracellular calcium, which binds calmodulin and Calcineurin B, 
resulting in activation of the catalytic subunit of Calcineurin A. Calcineurin directly 
dephosphorylates members of the NFAT transcription factors family in the cytoplasm, 
and induces their nuclear translocation and consequent activation of genes involved in 
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the immune response (Figure 1.5). The immunosuppressive drugs Cyclosporine A 
(CsA) and FK506, as well the endogenous scaffold proteins AKAP79, Cain/Cabin and 
DSCR/MCIP are thought to act by inhibiting calcineurin and preventing NFAT 
nuclear translocation (142, 144, 145). 
 
A conserved role for calcineurin-NFAT signaling was also identified in the heart 
(146). Overexpression of activated calcineurin in the hearts of transgenic mice 
resulted in profound cardiac hypertrophy, progressing to dilated heart failure within 
two months (146). A similar, but less dramatic response was obtained by 
overexpression of a constitutively nuclear NFAT3 mutant, suggesting that NFAT is 
also a principal target of calcineurin-dependent signaling in cardiomyocytes (150). 
Moreover, mice deficient in Calcineurin Aβ display a 12% reduction in basal heart 
size, and are resistant to diverse hypertrophic stimuli, such as pressure overload and 
infusion of isoproterenol or angiotensin II (147). 
 
However, there is still confusion surrounding the role of calcineurin signalling in the 
heart, specifically when the calcineurin function is explored by the usage of 
pharmacological inhibitor, such as CsA and FK506. CsA has been shown to prevent 
hypertrophy of neonatal rat cardiomyocytes in response to stimulation with 
angiotensin or phenylephrine (PE) in vitro (119), and in vivo in three different murine 
models of hypertrophic cardiomyopathy (148). These results are in conflict with other 
studies in which calcineurin inhibitors had no effect in blocking pressure overload 
hypertrophy in rodents (149, 150). Interpretation of these conflicting results is 
difficult for two important reasons: 
a) Calcineurin is expressed in other tissues, not only in the heart, and a systemic 
delivery of calcineurin inhibitors can cause collateral effects on other organs, 
affecting in primis arterial hypertension, and consequently heart maladaptative 
morphology and function.  
b) The immunosuppressant doses used for in vivo heart experiments are 10-fold 
higher than the doses required for immunosuppression, and are associated with 
systemic toxicity, as illustrated by weight loss of CsA-treated animals in some 
studies (119). 
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This source of variability can be resolved by in vivo engineering of endogenous 
calcineurin inhibitors. Although AKAP79 and Cabin/Cain are expressed at very low 
level, the inhibitory proteins of calcineurin termed DSCR/MCIPs (myocyte-enriched 
calcineurin –interacting proteins) are highly expressed in striate muscles and may 
function as endogenous modulator of calcineurin activity in the heart (151-153). 
Interestingly, in MCIP/calcineurin double transgenic mice overexpression of MCIP 
inhibited cardiac hypertrophy and progression to dilated cardiomyopathy, but also 
attenuated isoproterenol-and exercise-induced increase in cardiac mass (154).  
 
A lack of consensus also pervades studies on the role of calcineurin signalling in 
failed human hearts. Either increased calcineurin activity, or decrease in the 
expression as well as in the activity, have been reported in hypertrophied and failed 
human hearts (155). A promising approach in the future to elucidate the role of 
calcineurin signaling during hypertrophy may involve spatial and temporally 
controlled inhibition or activation of calcineurin, as well as by employing tissue-
specific docking molecules for the phosphatase rather than pharmacological 
approaches.  
 
2.2.2 Signaling via G Protein-Coupled Receptors 
G Protein-Coupled Receptors (GPCRs) play an important role in the regulation of 
cardiac function and adaptation to changes induced by haemodynamic burden (156). 
These receptors are coupled to heterodimeric G-proteins consisting of two subunits, 
Gα and Gβγ. Upon receptor activation, GDP is converted in GTP on the Gα subunit, 
with consequent dissociation from the Gβγ subunit, and modulation of the activity of 
downstream signaling effectors. The functional classes of cardiovascular receptors 
correspond to three major classes of G proteins (Figure 1.6): 
a) Beta-adrenergic receptors (βAR) are coupled to Gαs and mediate 
enhancement of heart rate and myocardial contractility in response to 
epinephrine and norepinephrine stimulation (157). The immediate downstream 
mediator of Gαs is adenylate cyclase (AC). Overexpression of β1-receptors in 
hearts of transgenic mice initially increases contractile function and 
responsiveness to isoproterenol, but eventually results in progressive 
deterioration of cardiac performance, cardiomyocytes hypertrophy and fibrosis 
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(158). Similar findings were obtained with overexpression of Gαs, but 
surprisingly were not dependent on AC activation (159). Conversely, 
overexpression of AC type VI does not exert adverse effects on cardiac 
function and has been reported to attenuate cardiomyopathic changes, 
including cardiac hypertrophy in Gαq transgenic mice (160). The principal 
target of AC activity is PKA. Interestingly, mice overexpressing PKA showed 
dilated cardiomyopathy, cardiac hypertrophy and fibrosis, similar to mice 
overexpressing β1-receptors, indicating that β1-receptors mediate their 
responsiveness through PKA activity, and independently from AC (161). In 
contrast to β1-receptor signalling, overexpression of β2-receptors improve 
basal contractile function, and the cardiomyopathic phenotype of Gαq 
transgenic mice (162). 
b) Angiotensin II, endothelin, and α-adrenergic receptors (α-AR) are coupled to 
Gαq/G11 and modulate cardiac hypertrophy in response to pathological 
stimuli. Transgenic overexpression of the above receptors, as well as Gαq, 
leads to cardiac hypertrophy, with consequential depressed contractility and 
cardiomyopathy (163, 164), indicating that signals downstream of Gαq/G11 
are sufficient to cause maladaptative cardiac hypertrophy. Cardiac-specific 
ablation of Gαq/G11 resulted in complete absence of hypertrophy and cardiac 
fetal program reactivation in response to aortic banding (165), indicating the 
necessary requirement of Gαq/G11 for pressure-overload cardiac hypertrophy. 
Indirect evidence for an important role of Gαq/G11 signaling in hypertrophy 
also stems from clinical observations of patients with cardiomyopathy, in 
which Angiotensin II receptor blockers conferred beneficial effects, such as 
inhibition of cardiac remodeling that exceeded their antihypertensive 
properties (166). 
c) Cholinergic receptors are coupled to Gαi and are activated by acetylcholine. 
Receptor-mediated activation of Gαi subunit results in direct attenuation of 
AC in the heart and consequent cardiac hypertrophy and heart failure (119). 
Gαi is upregulated in human heart failure, and patients with Gαi increased 
levels showed impaired responsiveness to isoprenaline (119). Taken together 
these studies indicate that upregulation of Gαi and blunting of AC signaling 
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may represent a primary event in cardiac hypertrophy, which can contribute to 
transition from compensated hypertrophy to decompensated heart failure.  
 
2.2.3 Small GTP-binding proteins and sarcomeric signaling 
The small G protein family consists of multiple members, regulating diverse cellular 
processes such as cell growth, division and survival, organization of the cytoskeleton, 
membrane trafficking, and cellular motility. G proteins have GTPase activity, which 
hydrolyzes GTP to GDP, thus returning the molecules to their inactive state. Five 
families of small G proteins have been described: Rho, Ras, ARFs, Rab, and Ran.  
 
Ras signaling (Figure 1.7) is coupled to multiple downstream effectors, including Raf, 
PI3K, and MAP kinase pathways, all of which participate in the hypertrophic 
response. Activated ras was shown also to promote nuclear localization of NFAT3, 
whereas a dominant-negative ras-mutant was able to abrogate the phenylephrine-
induced increase in NFAT activity (167), suggesting a cross-talk between ras 
signalling and the calcineurin pathway in cardiomyocytes. Overexpression of a 
constitutive active Ras induced hypertrophy (168), whereas dominant negative Ras 
prevented phenylephrine-mediated increase in cell size and protein synthesis (169).  
 
The Rho family of small G proteins, consist of Rho, Rac and Cdc42. Rho A signalling 
stimulates the transcriptional activity of SRF via changes in actin dynamics (170). 
SRF regulates many muscle-specific genes, including ANF and α-skeletal actin. 
Overexpression of SRF induces massive hypertrophy (119). A novel muscle specific 
sarcomeric protein, STARS, which stimulates SRF in Rho-dependent fashion, is 
upregulated in calcineurin-mediated cardiac hypertrophy, leading to speculation that 
this molecule modulates hypertrophy through Rho/SRF (119). Similar effects have 
been observed with a constitutive active Rac in vitro and in vivo (119). 
 
2.2.4 MAPK Pathways 
MAPKs can be divided into three major subfamilies: extracellularly responsive kinase 
(ERKs), c-Jun N-terminal kinases (JNKs), and p38 MAPKs. The latter two groups are 
also categorized as stress-responsive MAPKs, since they cannot only be activated by 
anabolic stimuli and agonists of GPCRs, but also by pathological stress such as 
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ischemia or cytotoxic agents (171). Overexpression of MAPK phosphatase 1 (MKP-
1), which inhibits all three branches of MAPK signaling mentioned above, blocked 
both agonist-induced hypertrophy in vitro, and pressure-overload-associated 
hypertrophy in vivo, demonstrating a significant role for these pathways in 
hypertrophic responses (172).  
 
In vivo experiments supported the notion that ERK1/2-dependent signaling is 
sufficient to evoke a hypertrophic phenotype (173). Transgenic overexpression of 
MEK1, a MAPK kinase that activates ERK1/2, but not JNK and p38 MAPK, resulted 
in considerable cardiac hypertrophy (173). The hypertrophic gene program was 
induced as in pathological hypertrophic models, with systolic function at supernormal 
levels, and impaired diastolic function, resembling phenotypes typical of patients with 
hypertrophic obstructive cardiomyopathy (173). Several other studies showed that 
ERKs were required for sarcomeric organization induced by hypertrophic agonists 
(174). Moreover, transfection of a constitutively active MEK1 augmented ANF 
promoter activity in cultured cardiomyocytes, whereas a dominant negative MEK1-
encoding construct attenuated ANF promoter activity (175). Although these data 
strongly implicate that ERK is implicated in hypertrophic response, it has been shown 
that inhibition of ERK1/2 signalling with the drug PD98059 was not sufficient to 
block ANF promoter activity in cultured cardiomyocytes (176). Furthermore, 
transfection of an activated MEK1-encoding expression plasmid was shown to induce 
c-fos, but not ANF or myosin light chain 2V promoter activity in cardiomyocytes in 
culture (177). These data indicate that ERK1/2 may synergize with other intracellular 
signals to complete the hypertrophic program.  
 
Three distinct JNK genes have been identified in mammalian cells, each of them 
directly phosphorylated and activated by MKK4 or MKK7, which in turn are 
regulated by MEKK1 phosphorylation (Figure 1.8). In cardiomyocytes, mechanical 
stretching (178), or agonist stimulation by Et-1 (179), PE or Angiotensin II (180, 181) 
results in rapid phosphorylation of JNK. Moreover, MKK7 is sufficient to induce all 
features of cardiomyocytes hypertrophy when overexpressed in cultured 
cardiomyocytes (182). Conversely, adenovirus-mediated expression of a dominant 
negative MKK4 mutant attenuates the hypertrophic response to ET-1 in vitro (179). A 
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target disruption of the Mekk1 gene results in selective attenuation of JNK activity 
(183); moreover, adenoviral delivery of dominant negative MKK4 to the hearts of 
aortic banded rats, resulted in reduced cardiac hypertrophy in response to pressure 
overload (184).  
 
Similar to the other branches of MAPKs, p38 activity is induced in pressure overload, 
ET-1/PE stimulation, physical stress, osmolar stress, and GPRC activation (119).  
Four separate p38 MAPK have been described p38α, p38β, p38γ, and p38δ (185). 
The major activators of p38 MAPKs are MKK3 and MKK6 (Figure 1.8), which 
phosphorylate the dual site Thr-Gly-Thr on the p38 MAPKs. Potential activators of 
MKK3 and MKK6 are PAK1, TAK1 and MLK3 (185). Interestingly, p38 
phosphorylates several transcription factors involved in hypertrophic gene expression, 
including MEF2 (186), and NFAT3 (187). p38α and p38β are the most important 
isoform expressed in the human heart, whereas p38γ and p38δ are undetectable (188). 
In vivo, p38 MAPK activity is elevated by pressure overload hypertrophy in aortic-
banded mice (119), and in human hearts with failure secondary to advanced coronary 
artery disease (189). Further evidence for the role of p38 as a mediator of 
hypertrophy, came from the observation that overexpression of an activated MKK3 or 
MKK6 factor in neonatal cardiomyocytes was sufficient to induce hypertrophy, and 
ANF expression (119, 190).  
 
Interestingly, the upstream activator of p38 signalling TAK1 is upregulated after 
aortic banding (191), and transgenic mice overexpressing a constitutively active 
TAK1 mutant resulted in cardiac hypertrophy and subsequent heart failure, 
implicating that this branch of MAPKs play also essential role in pathological growth 
of the myocardium (191). Thus, MAPK signalling is involved in both physiological 
and pathological hypertrophy.  
 
2.2.5 MEF2/HDAC signaling 
HDACs deacetylate nucleosomal deacetylases, promoting chromatin condensation 
and transcriptional repression when recruited to target genes via binding of specific 
transcription factors, such as MEF2. HDACs can be categorized into three classes, of 
which HDACs class II are preferentially expressed at high levels in striated muscle 
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and neurons. HDACs class II contains N-terminal extensions that interact with 
specific cofactors and transcription factors, including MEF2, GATA and NFAT. 
Moreover, phosphorylation of specific sites within the N-terminal regulates these 
associations. 
 
Recently, it has been shown that hypertrophic stimuli, such as pressure overload and 
calcineurin activation, results in activation of a HDAC kinase, which phosphorylates 
HDACs class II in serine residues and regulates the association with MEF2 (192). 
Adenoviral-mediated expression of HDAC5 or HDAC9 that lack the regulatory serine 
residues renders cardiomyocytes resistant to serum- or PE-induced upregulation of 
ANF and β-MHC expression, and cardiomyocytes hypertrophy. Intriguingly, mice 
lacking HDAC9 show normal cardiac size and function at early age, but develop 
spontaneous cardiac hypertrophy at advanced age; moreover, these mice show a 
severe response to thoracic aortic banding and calcineurin activation, underscored by 
superinduction of ANP, BNP, and β-MHC (119, 192). Contrary to these observations, 
expression of signal-resistant HDAC mutants in primary cardiomyocytes is sufficient 
to suppress fetal gene activation in response to hypertrophic signaling (85). 
Paradoxically, HDAC inhibitors, tested in clinical trial as anticancer agents, block 
cardiac hypertrophy and fetal gene expression (85), indicating the existence of certain 
cardiac HDACs that control the growth inhibitory function of class II HDACs (85). 
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3. MYOCARDIAL INFARCTION: ETIOLOGY AND PATHOPHYSIOLOGY 
Myocardial infarction  (MI) is defined as death or necrosis of myocardial cells. It is 
diagnosed as the result of myocardial ischemia or acute coronary syndromes. It occurs 
when myocardial ischemia exceeds a critical threshold, and overwhelms myocardial 
cellular repair mechanisms, designed to maintain tissue homeostasis. Ischemia, at this 
critical level, results in irreversible myocardial cell damage or death. Ischemia occurs 
mainly for increased myocardial metabolic demands, caused by physical exertion, 
severe hypertension, severe aortic valve stenosis, and/or decreased delivery of oxygen 
and nutrients to the myocardium via coronary occlusion (atherosclerotic plaques).  
 
MI is cathegorized in transmural and nontransmural. A transmural MI is characterized 
by ischemic necrosis of the full thickness of the affected muscle segment, extending 
from the endocardium, throughout the myocardium, till the epicardium. In 
nontransmural infarct, the area of necrosis does not extend through the full thickness 
of myocardium, being affected the endocardium and part of the myocardium. 
 
Approximately 800.000 people in U.S are affected by MI, and 250.000 people die 
prior being hospitalized (193). Hospitalized patients survive with a rate of 90%-95%. 
MI can occur at any age, with higher incidence in older individuals. The incidence 
increases with the increase of risk factors, such as high blood cholesterol, 
hypertension, and genetic or acquired components. Different therapies aimed to 
restore the coronary blood flow, and restrict the extension of necrotic area in the 
myocardium have had limited benefits in the case of delayed recognition of MI 
symptoms. Models of regenerative medicine, employed by several groups, and mainly 
based on delivery of Bone Marrow (BM) cells to the area of infarct are still under 
experimental analysis, although a good index of recovery has been found in patients 
with BM transplantation in the infarct area (194). (The ongoing studies on 
regeneration of the infarcted myocardium will be discussed extensively in Chapter 3). 
 
While clinical trials try to find the best way to reduce limited functionality of the 
infarcted heart, numerous experimental analyses have dissected the biochemical 
features of MI.  Following MI, together with loss of necrotic cardiac myocytes, a 
reparative process is quickly initiated to rebuild infarcted myocardium and maintain 
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structural integrity of the ventricle. Initially, myocardium necrosis is associated with 
complement activation and free radical generation, triggering to cytokine cascades 
and chemokine upregulation. Interleukin 8 (IL8), IL6, and C5a are released in the 
ischemic myocardium, and may play a critical role in neutrophil recruitment (Figure 
1.9). Monocyte chemoattractant protein 1 (MCP-1) is upregulated in the infarcted area 
and controls mononuclear cell recruitment. Accumulation of monocyte-derived 
macrophages and mast cells may increase expression of growth factors, inducing 
angiogenesis and fibroblast accumulation in the infarct. In addition, expression of 
cytokines, inhibiting the inflammatory response, such as IL10, may counteract the 
inflammatory response of other cytokines. New blood vessels are formed 
(angiogenesis), and fibroblast-like cells appear and replicate (Figure 1.9).  
 
This initial inflammatory phase of healing, with resultant granulation tissue formation, 
is followed by a fibrogenic phase that terminate in scar tissue, a rebuilding of 
infarcted myocardium (195). Post-infarction healing has been considered complete 6-
8 weeks after MI (195). Matrix metalloproteinases (MMPs), involved in proteolytic 
degradation of fibrillar collagen, are upregulated in these initial phases of post-infarct 
tissue remodeling (196). Tissue inhibitors of MMPs (TIMPs) neutralize this 
collagenolytic ativity and are upregulated at 1 week after myocardial infarction, 
staying at high levels in the following weeks (196). The activity of TIMPs promotes 
progressive collagen accumulation in the infarcted area. The delicate equilibrium 
regulating the activity of MMPs and TIMPs is fundamental in tissue remodelling after 
myocardial infarct. Continuous activation of MMPs could cause lack of remodelling 
and collagen deposition, with immediate failure of the heart.  
 
Collagen deposition, ensured by TIMP activity, avoids an early collapse of heart 
structure and functionality. Interestingly, collagen deposition is continuous in the 
infarcted area and not a transient process (195). Scar tissue is predominantly 
composed of type I and type III collagen. Fibroblast-like cells are the main cells in the 
infarcted area to secrete collagen. These cells express α-smooth muscle actin (α-
SMA) microfilaments, and are generally termed myofibroblasts for their pale and 
asynchronous capacity to contract (195). Myofibroblasts appear to arise from 
interstitial fibroblasts and/or adventitial fibroblasts (195). Signals that induce 
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fibroblasts to transdifferentiate in myofibroblats are unknown, although it has been 
shown in vitro that TGFβ1 contributes to this event (197). Interestingly, the 
continuous release of collagen and the formation of fibrotic tissue is ensured by the 
presence of these cells, which reside in the infarcted area for months in rats, and years 
in humans (198). It is notable that these cells are present also in the site of injury in 
the skin, but they disappear once healing is complete via apoptosis (199). Their 
persistence in the heart is associated with progressive fibrosis and predicts organ 
failure.  
The signals implicated in heart remodelling after myocardial infarction reveal that 
Angiotensin II and TGFβ1 expression remains elevated several months after infarct 
(200). Current pharmacological interventions with ACE inhibitors or AT1 receptor 
antagonists can reduce scar extension and hydroxyproline concentrations, if 
administered soon after MI. 
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Figure 1.1: Mouse heart development. Five major stages of heart 
development are shown. The transcription factors involved or suspected to be 
involved are listed below. Abbreviations: AO, aorta; A, atrium; LA, left 
atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; OT, outflow 
tract; SV, sinus venosa; PA, pulmonary artery. 
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Day 15                  Day 21                   Day 28                             Day 50 
Figure 1.2: Schema of cardiac morphogenesis. The picture shows cardiac development seen 
from a ventral view. The heart is divided in different regions that represent specific segments 
of the linear tube, patterned along the anterior-posterior axis to form various specific parts and 
chambers of the looped and mature heart. Abbreviations: AS, aortic sac; III,IV,VI, aortic 
archarteries; CT, conotruncal; AVV, atrio-ventricular valve; A, atria; Ao, aorta; DA, ductus 
arteriosus; LCC, left common carotid; LSCA, left subclavian artery; PA, pulmonary artery; 
RCC, right common carotid; RSCA, right subclavian artery; RV, right ventricle; LV, left 
ventricle; RA, right atrium; RV, right ventricle; V, ventricle. 
 
Srivastava D. and Olson E.N. Nature, 2000, 407: 221-226 
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Figure 1.3: Hypertrophic signaling. Four signaling modules promote fetal gene program 
transcription and translation in response to diverse agonists and load control, separately or 
by synergistic events. These pathways are a simplification of a more complex program of 
signal transduction.  
 
Olson E.N. and Schneider M.D. Genes & Development, 2003, 17: 1937-1956 
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Figure 1.4: gp130 signal transducer and activator of STAT transcription signaling pathway. 
LIF, cardiotrophin, and other members of the IL6 cytokine family activates gp130 
transmembrane receptor, which associates with the leukemia inhibitor factor receptor, LIFR, 
to signal at different intracellular MAPKs components, to PI3K (phosphatidylinositol 3-
kinase), and to STAT transcription factors. Abbreviations: MEK, mitogen-activated protein 
kinase kinase; ERK, extracellular-signal regulated kinase. 
 
Molkentin J.F. and Dorn G.W. Annu. Rev. Physiol. 2001, 63: 391-426 
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Figure 1.5: Calcineurin signaling pathway in cardiomyocytes. Calcineurin activation by 
calcium bound to calmodulin results in nuclear factor activated T cells, NFAT, 
dephosphorylation and nuclear translocation. Activated calcineurin has also been shown 
to promote c-jun NH2 terminal kinase (JNK) activity, as well as activation of certain 
protein kinase C, PKC, isoforms. Abbreviations: CsA, cyclosporine A; PLC, 
phospholipase C; FKBP12 FK binding protein 12; MAPKK, mitogen-activated protein 
kinase kinase. 
 
Molkentin J.F. and Dorn G.W. Annu. Rev. Physiol. 2001, 63: 391-426 
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Figure 1.6: G protein-mediated signaling pathway. Multiple transmembrane 
spanning receptors are directly coupled to G proteins to mediate GDP-GTP 
exchange, dissociation of Gα and Gβγ subunits, and activation of specific signal 
transduction, directly involved in heart hypertrophy. Abbreviations: Et, endothelin 
receptor; AT1 and AT2, angiotensin receptors; AR, adrenergic receptor; MusAcR, 
muscarinic acetylcholine receptor; AC, adenylyl cyclase; βARK, beta adrenergic 
receptor kinase; IP3, inositol 3 phosphate; DAG, diacylglycerol; PLC, phospho-
lipase C. 
 
Molkentin J.F. and Dorn G.W. Annu. Rev. Physiol. 2001, 63: 391-426 
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Figure 1.7: Ras signaling pathway. Ras is activated by receptor tyrosin kinases (RTKs), by G  
protein coupled receptors (GPCR), and Janus kinase 1 (Jak). Ras activation results in GDP 
GTP exchange and activation of numerous effector proteins. Abbreviations: GAP, GTPase  
activating protein. 
 
Molkentin J.F. and Dorn G.W. Annu. Rev. Physiol. 2001, 63: 391-426 
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Figure 1.8: Mitogen-activated protein kinase signaling pathways. MAPK signaling  
is activated in cardiomyocytes by G protein-coupled receptors (GPCRs), receptor tyrosine 
kinases (RTKs), transforming growth factor β receptor (TGFR), protein kinase C (PKC), 
and stress stimuli. These upstream events result in the activation of mitogen-activated 
kinase kinase kinase (MEKK) signaling pathway, terminating with the activity of three 
canonical MAPK effectors, c-Jun NH2 terminal kinases (JNK1/2/3), extracellular-signal 
regulated kinases (ERK1/2) and p38. Abbreviations: TAK1, TGFβ activated kinase. 
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Figure 1.9: Myocardial inflammatory pathway. A general inflammatory cascade is 
activated in infarcted heart. The remodeling of myocardial tissue after necrosis of cells 
involves persistent release of collagen type I and III by myofibroblasts and formation of 
fibrotic tissue, which replaces the myocardium. Scar formation ultimately leads to 
impairment of heart functionality. Abbreviations: IL8, Interleukin 8; IL6, Interleukin 6; 
IL10 and 4, Interleukin 10, 4; C5A, complement 5A; TGFβ, transforming growth factor β; 
INFγ, interferon γ 
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1. BYOSYNTHESIS, STRUCTURE AND ACTION OF IGF-1 
The expression of various components of the insulin-like growth factor system of 
ligands (IGF-1 and IGF-II), receptors (IGF-1R and IGF-IIR) and soluble binding 
proteins (IGFBP1-6) is ubiquitous throughout intrauterine and postnatal development 
(201). The IGF family of ligands and receptors is homologous to the insulin/insulin 
receptor (IR) combination, suggesting a common evolutionary heritage. The IGF-1R 
is activated by IGF-1 and IGF-II, and like the IR has an α2β2 heterotetrameric 
structure (201). The receptors are coupled to several common intracellular second 
messenger pathways, although there are increasing evidence for more specific 
interaction with second messenger (202).  
 
Several analyses showed that IGF signaling is essential to promote growth in and ex 
utero (203, 204). Gene-targeting disruption of Igf-II or Igf-IIR revealed clearly that 
IGF-II acts primarily during embryonic development, stimulating fetal growth 
throughout its interaction with IGF-1R and IR (205). Igf-1 gene disruption showed 
that IGF-1 is critical in both embryonic and postnatal development (206, 207), 
indicating a broad temporally regulated spectrum of action of this gene. Interestingly, 
IGF-1 is involved in a plethora of different biological functions, including the control 
of growth and metabolism, as well as survival and proliferation in several organs and 
tissues during embryonic and postnatal development. The pleiotropic functions of 
IGF-1 reflect the complicated structure and regulation of Igf-1 gene, as well as the 
post-translational modifications that remodel IGF-1 structure during protein 
biogenesis. This intriguing peculiarity will be discussed in the following paragraphs. 
 
1.1 STRUCTURE AND TRANSCRIPTS OF THE Igf-1 GENE 
The complete structure of the Igf-1 gene has been elucidated in rats (208-210). The 
gene is large, spanning more than 90kb of genomic DNA, and contains six exons 
separated by five introns (Figure 2.1). Exon 3 and exon 4 encode for the identical 
sequence found in all rat IGF-1 cDNAs, including the IGF-1 coding sequence. Exon 3 
encodes 27 amino acids that are part of the signal peptide, as well as part of the 
mature peptide. Exon 4 encodes the rest of the mature peptide, and 16 amino acids of 
the amino-terminal region of the E-peptide. Exon 1 and exon 2 are termed 5’ leader 
exons and encode part of the signal peptide and for different 5’ UTRs, determined by 
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different transcription starting sites and splicing variants with the other exons. Exons 
5 and 6 encode two distinct carboxy-terminal peptides, termed Ea peptide and Eb 
peptide, as well as the 3’UTR. Rat IGF-1 transcripts encoding the 35 amino acid Ea 
domain, derive from splicing of exons 4 and 6 together, and exclusion of exon 5 
(Figure 2.1). Rat IGF-1 transcripts encoding the 41-amino acid Eb domain derive 
from splicing of exons 4, 5, and 6 together (Figure 2.1). Exon 6 is a large exon of 
more than 6kb, specifies for a small amount of coding sequence, and is composed 
primarily of 3’UTR. This exon contains multiple polyadenylation sites (209, 210), 
which account for the size heterogeneity of IGF-1 transcripts observed on Northern 
blots. The large molecular weight (7.5 kb) IGF-1 transcript contains all of the exon 6 
sequence and an unusually long 3’UT, whereas smaller IGF-1 transcripts use 
upstream polyadenylation signals and contain shorter 3’UTs (211). Available 
evidence suggests that the Igf-1 genes of all mammals studied, including humans, are 
similar to the rat genes in terms of size and complexity (211). 
 
1.2 EXPRESSION OF IGF-1 TRANSCRIPTS AND ENCODED PRECURSORS 
The first IGF-1 cDNA to be characterised was isolated from a human liver cDNA 
library by Jansen (212). In both rats and humans, the structure of the initially 
characterised IGF-1 cDNAs predicted an IGF-1 precursor with 70 amino acids, 
representing the mature peptide (B,C,A,D domains) in the midregion, and flanked by 
precursor peptide sequences at both amino- and carboxy-termini (Figure 2.1).  The 
amino-terminal part is characterised by two different 5’ sequences designated class 1 
and class 2 sequences (Figure 2.1). In rat, class 1 IGF-1 transcripts are expressed in 
liver and all non-hepatic tissues analyzed at all stages of development from fetus to 
adult (213, 214). In contrast to class 1 IGF-1 transcripts, the expression of class 2 
transcripts is more restricted. Class 2 IGF-1 transcripts are expressed primarily in the 
liver, and within the liver significant levels of class 2 mRNAs are detected only in the 
postnatal period (213, 214). These data argue for a tissue-specific transcriptional 
control of class 1 and class 2 transcripts. In many genes the promoters and regulatory 
elements that dictate tissue and cell-specific transcription and transcriptional 
regulation by physiological stimuli reside in the 5’ sequences, flanking the 
transcription start sites. There is little information about the promoters or regulatory 
elements in the rat Igf-1 gene that could determine the distinct patterns of expression 
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of class 1 and 2 transcripts. Interestingly, non-consensus TATAA or CCAAT 
sequences associated with transcription initiation have been found upstream the 
transcription start sites in exon 1 and 2 of the rat IGF-1 gene.  
 
Cell-free translation studies suggests that class 1 and 2 transcripts initiate translation 
at different AUG codons (208). Rat class 1 transcripts initiate translation primarily at 
the -48 AUG to result in an IGF-1 precursor with a 48-residue amino-terminal 
precursor peptide (208). A major level of complexity is due to the fact that in some 
class 1 transcripts a 186 bp region can be spliced out (210) (Figure 2.1). Rat class 2 
transcripts initiate translation primarily at the –32 AUG to result in an IGF-1 
precursor with a different 32-residue amino-terminal precursor peptide (208). Class 2 
transcripts also contain an in frame AUG at codon –44 relative to the IGF-1 coding 
sequence.  
 
Within the sequence common to class 1 and class 2 there is an in-frame AUG codon 
at position –22 relative to the IGF-1 coding sequence. If the –22 AUG is used for 
translation initiation class 1 and class 2 could encode the same amino-terminal 
precursor, and differ only in the 5’UT (figure 2.1). Other start sites (1-4) have been 
found in the early 1990s, and their usage increased the possibility of different variants 
of IGF-1, suggesting a complicate tissue- and development-specific IGF-1 
transcription (215), as discussed below (Figure 2.1).  The function of the different 
amino-terminal precursors is still a matter of speculation. The amino-terminal 
precursors usually function as signal peptides that lead translocation of a nascent 
precursor into the endoplasmic reticulum, or signal peptide cleavage and 
glycosylation. It is possible that the different classes of IGF-1 transcripts may 
influence these events determining subsequent compartmentalization, binding to 
IGFBPs, and biological function.  
 
The IGF-1 carboxy-terminal encodes the E domains, Ea and Eb. The 35 amino acid 
domain encodes the Ea domain as shown in figure 2.1. The Ea precursor peptide is 
highly conserved across mammalian species (216). An alternate 41 amino acid Eb 
domain results from insertion of a 52 bp mini exon at the point of sequence 
divergence, shifting the translational reading frame in Eb-type transcripts. 
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Downstream the 52-base pair mini-exon, 3’ sequences in rat Eb-type IGF-1 transcripts 
are identical to those found in Ea type transcripts. The rat Eb precursor peptide is 
highly basic, and lacks the motifs associated with N-glycosilation that are found in the 
Ea precursor peptide (210). In humans, there are also IGF-1 transcripts encoding two 
different Ea and Eb domains, but they result from a slightly different exon-splicing 
pattern. Downstream from the point of divergence, human Ea and Eb type transcripts 
contain entirely different 3’sequences, which specify different 3’ UTRs, as well as 
different E domain coding sequences, due to splicing in different 3’ exons (217). 
Conversely to Ea, the Eb sequence is less conserved between rodents and humans 
(216).  
 
In rats, IGF-1 transcripts encoding the Ea-type precursors are expressed in most, if not 
all tissues (213). It is not clear whether the Ea domain is processed from the pro-IGF-
1 prior to secretion or after secretion, and little is known about the mechanisms 
involved in the processing of IGF-1/Ea precursors to mature IGF-1. Overexpression 
of a human transgene IGF-1/Ea precursor in transgenic mice leads to preferential 
overgrowth of specific organs, including brain, spleen and pancreas (218).  
 
The Eb-type precursors are expressed primarily in the liver, and at much higher levels 
postnatally (213), suggesting a liver-specific role of the IGF-1/Eb precursors. 
Interestingly, the liver is the major source of circulating IGF-1, and the increase of 
IGF-1/Eb transcripts in the liver is parallel to the increase in circulating IGF-1 (213). 
The data reported suggest that the Eb domain could play a role in targeting mature 
IGF-1 to the circulation, whereas the Ea precursor peptide may play an important role 
in the local action of IGF-1. Further analyses will elucidate the role of the variable 
amino-and carboxy-termini. 
 
1.3 DIFFERENTIAL ACTION OF IGF-1 SPLICED VARIANTS 
IGF-1 was originally discovered as a circulating factor, termed somatomedin C, which 
mediates the growth-promoting actions of pituitary-derived Growth Hormone (GH) 
on cartilage (219). Subsequent studies have established that in the period from birth to 
puberty, GH and IGF-1 act together in an endocrine manner to regulate the linear 
growth of the skeleton and coordinate the growth of other organs (220). Liver was 
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then considered the major source of IGF-1, since the rates of hepatic secretion of IGF-
1 were sufficient to account for levels of IGF-1 found in plasma. Studies in the early 
1980s provided some evidence for the synthesis of IGF-1 in non-hepatic tissues (221). 
The production of IGF-1 in extra-hepatic tissues supports both autocrine and paracrine 
functions, and a different regulation from that in liver, which supports endocrine 
functions (215). Collectively, the data presented so far led to the hypothesis that class 
1 transcripts, together with the Ea peptide, might encode the local IGF-1 isoform, 
functioning in an autocrine/paracrine manner. On the contrary, class 2 transcripts, 
together with Eb peptide, are regulated by GH release, and are mostly express in liver, 
functioning in endocrine manner.  
 
Interestingly, the start sites present within exon 1 and exon 2 (Figure 2.1) are 
differentially used, corresponding to developmental stage- and tissue-specific 
expression (215). Most extra-hepatic tissues (stomach, heart, muscle, as well as testes 
and lung) use the start site 3, while liver, brain, and kidney use the start site 2 and 3 
equivalently. Start sites 1 and 4 are used in all tissues at very low level (215). Exon 2 
transcripts are expressed mostly in testes, lung, stomach, kidney and liver, and 
transcription initiation was equivalent in all the tissues (215). Developmental 
specification was also observed, since within exon 1 start site 3 was used perinatally 
and postnatally, whereas start site 2 was detected only at stage of weaning. Moreover, 
exon 2 transcripts appear only at the postnatal period (215).  These data highlight the 
difficulty in mapping a common action of the IGF-1 isoforms, because of very tight 
and tissue-specific regulation.  
 
1.4 IGF-1 FUNCTIONS 
In general, IGF-1 shares many anabolic functions with insulin, such as stimulation of 
nutrients and amino acid uptake, as well as DNA and RNA synthesis. IGF-1 differs 
from insulin for its metabolic functions, which include stimulation of whole-body 
protein metabolism by increasing protein synthesis and inhibiting protein proteolysis. 
In contrast to other growth factors (FGF, EGF, or PDGF), which act as potent 
mitogens inhibiting differentiation, IGF-1 can induce both proliferation and 
differentiation, as shown most unequivocally in skeletal muscles (1, 2). 
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Studies on gene disruption of Igf-1 or Igf-II, as well as the respective receptors, Igf-1r 
and Igf-IIr, have led to important considerations about the functions of IGF-1. Mice 
lacking either Igf-1 or Igf-II genes exhibit intrauterine growth retardation, with 
weights approximately 60% that of wild-type littermates (204). Interestingly, while 
exhibiting intra-uterine growth retardation, the Igf-II-/- mice have essentially normal 
postnatal growth. On the contrary, Igf-1 null mice die shortly after birth, and only a 
small percentage survives and reaches adulthood, with severe under-developmental 
growth of the entire organism (204). More severe is the phenotype of mice lacking a 
functional Igf-1r (204). These mice are born weighing only 45% of normal, and die 
soon after birth from respiratory failure (204). Skin and all skeletal muscles present a 
generalized hypoplasia (204). Delays in ossification were observed in these animals, 
and changes in architecture of the spinal cord and brain, due to diminished number of 
non-neuronal cells (204). Igf-IIr null mice exhibit a completely opposite phenotype, 
characterised by fetal overgrowth syndrome, which results in lethality (222). The 70% 
weight reduction in pups null for Igf-1/Igf-II genes results in a dwarf phenotype. The 
phenotype of the double knockout (KO) Igf-1/Igf-1r is identical to that of Igf-1r null 
mice, indicating that IGF-1 is acting predominately through the IGF-1R (202). 
Interestingly, the Igf-II/Igf-1r double KO have a growth retardation more severe than 
that of the Igf-1r single KO, indicating that IGF-II acts through another receptor 
different form IGF-1R, identified as the Insulin Receptor (IR) (223). Thus, the IGFs 
stimulate fetal growth through IGF-1R and IR, whereas IGF-IIR appears to inhibit the 
effects of IGF-II on fetal growth. 
 
Most of the phenotypes so far described exhibit a clear growth deficit, and the severe 
rate of mortality has led to an underestimation the function of IGF factors in different 
adult organs. More sophisticated studies employing the Cre/lox technology have 
addressed questions regarding the function of IGF-1 in different and specialized 
tissues during development. The most long-standing question concerns the function of 
IGF-1 produced in the liver.  IGF-1 transcripts are expressed in the liver at a level 10- 
to 100-fold greater than in the majority of other tissues. Hepatic IGF-1 increases 
dramatically postnatally, accompanied by increased IGF-1 levels in serum, indicating 
that the function of hepatic IGF-1 becomes important with age (202). Since 
hepatocytes do not express IGF-1R, production of IGF-1 has been hypothesized to 
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affect growth of organs. By crossing the Igf-1/lox mice with a transgenic line 
overexpressing Cre under the albumin promoter, it was possible to generate mice with 
specific deletion of the Igf-1 gene in the liver (224). Interestingly, these mice did not 
present any deficit in pre and postnatal growth, despite a marked reduction (75%) in 
the concentration of total IGF-1 in serum (224). Moreover, it has been found that GH 
levels increase in serum (224). These data reveal clearly that circulating IGF-1 does 
not affect growth of different organs, and that one possible function of circulating 
IGF-1 is the control of GH levels. IGF-1 in serum could function as feedback in the 
somatotropic axis, reducing GH release from the pituitary gland. Importantly, the 
control of GH levels in the circulation could account for a non-detrimental effect on 
growth, and for normal levels of IGF-1 in extra-hepatic tissues (202). However, it has 
been found that in Ghr-/- mice IGF-1 expression in heart, lung, testis, spleen and brain, 
with the only exception of liver, is not affected, indicating a GH-independent circuit 
of IGF-1 regulation (225). Notably, liver-specific Igf-1 null mice develop insulin 
resistance, specifically in muscles, but not in liver, arguing that circulating IGF-1 
could regulate glucose homeostasis and metabolic reactions in extrahepatic tissues 
(224).  
 
In the next paragraphs the functions of IGF-1 will be described in details in several 
organs with more attention on heart. 
 
1.4.1 Role of IGF-1 in the Nervous System 
It is known that IGF-1 can be transported in brain across the blood-brain barrier, but is 
also produced locally in the nervous system. Several lines of evidence show that IGF-
1R modulates neuronal activity, resulting in the regulation of food intake, energy 
metabolism, reproduction, and possibly cognitive functions. Studies in the early 1990s 
showed that IGF-1 stimulates proliferation of neuron progenitors, induces 
differentiation of oligodendrocytes, and increases the survival of neurons and 
oligodendrocytes in vitro (226, 227). In homozygous mice, disruption of Igf-1 or Igf-
1R genes produces pathological abnormalities and brain growth retardation (204). 
Interestingly, brain growth retardation occurs also in transgenic mice overexpressing 
IGFBP1 in the brain, probably because of an inhibition of IGF-1-stimulated growth 
(228). In transgenic mice overexpressing IGF-1 in the brain, the size and the weight of 
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the brain increases markedly (218). Different studies showed that the brain of these 
mice contains an increased number of neurons, and of total brain myelin, as well as of 
regional density of myelinated axons (229). A transgenic model with IGF-1 
overexpression in the brain mainly during postnatal development showed that IGF-1 
is implicated in neurogenesis and synaptogenesis in the hippocampal dentate gyrus 
(230).  
 
Notably, IGF-1 also has an important role in the case of nerve injury. In crash-injured 
and freeze-injured rat sciatic nerve, local administration of IGF-1 increases axon 
regeneration. An interesting study, where the left musculo-cutaneous nerve of adult 
rats was fully transected to induce biceps-muscle paralysis, and the distal part of this 
nerve was co-opted to a different nerve, showed that IGF-1 infusion promoted 
increased myelin thickness/axon diameter ratio (231). Moreover, functional recovery 
of the paralyzed muscle was expedited in these animals, indicating that IGF-1 may 
have a potential role in therapeutic trials in case of exogenously- and/or 
endogenously-induced damage (231). 
 
1.4.2 Role of IGF-1 in Bone Formation 
The skeleton is a highly organized and physiologically active organ, continuously 
remodeling itself to preserve skeletal integrity (232). The mammalian skeleton is 
organized in an outer surface of cortical bone that surrounds the inner trabeculae 
elements. Both cortical and trabeculae bones undergo to a constant remodeling, which 
is orchestrated by different growth factors and cytokines. IGF-1 is known to be 
implicated, together with TGFs, in the recruitment of osteoblasts to the bone surface, 
for collagen synthesis, and for matrix deposition and mineralization (233). Although 
there are several genetic analyses on IGF-1 functions in bone morphogenesis and 
remodeling, the effective role of this growth factor is still unclear. Some studies have 
reported that IGF-1 induces increased uptake of thymidine incorporation in most of 
the cells, but its role as a mitogen in pre-osteoblasts proliferation is limited. Moreover, 
its action on osteoclast differentiation is still elusive (232). However, Rubin and 
collegues have demonstrated that IGF-1 stimulates the secretion of Receptor Activator 
of nuclear factor kappa B ligand (RANKL), important for recruitment of osteoclasts 
(234).  
 56 
 
Although mice lacking Igf-II gene do not show any phenotype related to bone growth 
and remodeling, genetic disruption of the Igf-1 gene leads to short bone phenotype 
and low bone mineral density (235). A more striking phenotype was observed in mice 
with targeted deletion of the Igf-1 gene in osteoblasts (236). These mice show a 
significant defect in bone formation with reduced osteoblastogenesis; overall the mice 
present a dramatic reduction in bone mineralization occurring by three weeks of age, 
indicating that IGF-1 signaling is fundamental in the process of bone mineralization 
(236). 
 
1.4.3 IGF-1 functions in Skeletal Muscles 
The role of IGF-1 in striated muscles has been studied in transgenic models 
overexpressing various IGF-1 isoforms. Whereas mice lacking Igf-1 and Igf-1R genes 
exhibit marked muscle hypoplasia, mice overexpressing Igf-1 transgenes showed 
enlarged myofibers and hypertrophy (2). Increased fiber size, protein content, and 
nuclei within myofibers has been found in mice overexpressing the class 1/Ea IGF-1 
isoform in skeletal muscles (2). These features were accompanied by activation of 
GATA2, a novel marker of myocytes hypertrophy (237). Moreover, this isoform of 
IGF-1 confers muscle mass and strength during aging, in neuromuscular disease, and 
after injury (2). In contrast, a class 2/Eb transgene increased the numbers of 
dihydropyridine receptors, preventing their age-related decline (238), and extended 
the replicative life span of skeletal muscle satellite cells in vitro, although no 
beneficial effect on enhancing satellite cells proliferation ability was found in vivo 
(239). 
 
In aging studies, it has been found that IGF-1R levels decrease in rat skeletal muscles 
by 80% between infancy and young adulthood, with a subsequent decrease of 10-60% 
during senescence (240). In conjunction with this decline, the ability of IGF-1 to 
stimulate protein synthesis is lost in adult and aged rats, together with the capacity to 
stimulate glucose uptake (240). Disuse or unweighting also induces muscle atrophy. 
In rat soleus, unweighting produces DNA cleavage typical of apoptosis. Whereas a 
combination of intramuscular IGF-1 administration and exercise reduces apoptosis, 
brief intense exercise alone, or prolonged intermittent exercise, partially restores 
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muscle responsiveness to IGF-1, indicating that plasticity for IGF-1 anabolic effects is 
retained in aging muscles (241). An interesting study conducted by De Luca in 1997 
showed that, in aging rat muscle, conductance to chloride is reduced, with subsequent 
decrease in muscle contractility.  Administration of IGF-1 or GH increased muscle 
conductance to chloride, and restore muscle contractility, suggesting a shift to the 
young adult chloride channel expression (242).  
 
In general, a variety of conditions leading to inhibition of GH-IGF-1 axis are 
associated with muscle catabolism. Recently, a single patient with homozygous partial 
deletion of the IGF-1 gene has been reported (243). This patient presents short stature, 
sensorineural hearing loss, and mental retardation (243). Specific evaluation of 
muscle physiology was not reported, but recombinant IGF-1 therapy resulted in 
accelerated growth and increased lean body mass. Myopathies and dystrophies, 
regardless of pathogenesis, are also associated with increased muscle catabolism, and 
IGF-1 has been proposed as an empiric therapy for muscle loss associated with 
Duchenne muscular dystrophies, and with inflammatory myopathies. A rationale for 
IGF-1 therapy in structural dystrophies is supported by the fact that degeneration of 
muscle following denervation or structural injury induces upregulation of IGF-1 and 
IGF-1R in satellite cells localized in the area of regeneration (244). Muscles, damaged 
by inflammatory myopathies, show a similar upregulation (244). Despite its beneficial 
effects in skeletal muscle injury, systemic delivery of IGF-1 remains formidable due 
to cost, doses and administration. Numerous side effects have been found related to 
edema, athralgias, temporomandibular joint pain, and headaches (245). Recently, it 
has been shown that co-administration of IGF-1 with IGFBP-3 minimizes side effects 
over the course of a short trial (246).  
 
In summary, IGF-1 plays a critical anabolic and trophic role throughout the life of 
myocytes. Proliferation of satellite cells in response to injury and/or myopathies 
seems to be mediated by IGF-1 signaling, which provides a clear benefit to the total 
architecture of the muscle, as well in muscle functionality. For these reasons, IGF-1 
may offer effective myotherapy for a spectrum of metaboloic and structural 
myopathies. 
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1.4.4 IGF Family of Binding Proteins (IGFBPs) 
IGFs are normally bound in serum to a family of six structurally and evolutionary 
related binding proteins, termed IGF-binding proteins (IGFBPs). IGFBPs act as 
carrier of IGFs, and function as modulator of IGFs availability and activity (247). 
IGFBPs1-5 bind the two IGFs with similar affinities, whereas IGFBP6 has a higher 
affinity for IGF-II. Notably, in the last few years it has been reported that IGFBPs, 
precisely IGFBP3 and IGFBP5, have important biological functions independent of 
their ability to bind IGFs (248), and that both binding proteins translocate from the 
extracellular compartment to the nucleus of rapidly dividing human lung and breast 
cancer cells (249). Although IGFs can translocate to the nucleus with IGFBP3, it is 
believed that the function of IGFBP3 in the nucleus is independent of IGFs (249). 
Other in vivo and in vitro data support the importance of IGFBPs for cell growth by 
IGF-dependent and -independent mechanisms.  
 
All six IGFBP members share a common structure, which is characterised by an N-
terminal domain and a C-terminal domain, with conserved amino acidic sequence 
among all IGFBPs, and the midregion, which shares similarity less than 15%. The N-
terminal domain contains 80-93 amino acid residues after the signal peptide, and 
shares approximately 58% similarity. IGFBPs1-5 contain 12 cysteines in this domain, 
whereas IGFBP6 contains only 10 cysteines. The high number of these residues argue 
for the formation of disulfide linkages in the primary structure. Indeed, these cysteines 
form intra-domain bindings, which do not affect the C-terminal domain (250). As is 
the case for the N-terminal domain, the C-terminal domain is highly conserved, and 
shares a similarity of approximately 34%. Other 6 cysteines are found in this domain 
and are strictly conserved. They are involved, as described for the N-terminal domain, 
in intra-domain disulfide bond formation (250).  
 
N- and C-terminal domains bind IGF-1 with strong affinity (kd 10-10 M). Spencer and 
Chan (251) generated IGFBP3 fragments that essentially correspond to the N-terminal 
half (residues 1-147), and the C-terminal half (residues 151-263) of the IGFBP, and 
showed that each of these fragments bind IGFs, but with less affinity than intact 
IGFBPs. Sequential C-terminal deletion studies with recombinant bovine IGFBP2 
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suggested that loss of the region spanning the last four cysteines reduced IGF binding 
(252). Interestingly, the C-terminal domain, besides its capacity to bind IGFs,  
participates in binding the cell surface and the extracellular matrix (ECM) proteins, 
via its heparin-binding sites (XBBBXXB), where X is any amino acid and B is a basic 
residue such Arg, His, or Lys, (253). It is hypothesized that the IGFBPs interaction 
with ECM may provide a local reservoir of IGFs (254).  
 
The IGFBP variable midregion segment, ranging in size from 55 amino acid residues 
to 95 amino acids, functions as a hinge between the N-terminal and the C-terminal 
domains. Intriguingly, all the posttranslational modifications occurring in the IGFBPS 
have been found so far in this region. Among the posttranslational modifications 
analyzed, the most well characterised are glycosylation, phosphorylation, and 
proteolysis. No evidence of glycosylation has been found for IGFBP1 and 2, but 
IGFBP3 and 4 are N-glycosylated, whereas IGFBP5 and 6 are O-glycosylated (250). 
The ability to bind IGFs seems not to be affected by glycosylation, although other 
functions may be regulated, such as resistance to proteolysis (250).  
 
Three of the six IGFBPs, IGFBP1, 3, and 5 are phosphorylated (250). The purpose of 
phosphorylating secreted proteins is still unclear, but some evidence suggests that 
phosphorylation enhances the affinity of hIGFBP1 for IGFs by 5 fold (250). 
Interestingly, phosphorylation of IGFBP3 can be upregulated by IGFs, and this event 
can affect the interaction of IGFBP3 with the cell surface or with the acid-labile 
subunit (ALS), typically complexed with IGFBP3 (250).  
 
Proteolysis is a mechanism that ensures IGFBP availability and activity. It has been 
shown that cleavage by endoproteases generates fragments that have greatly reduced 
IGF-binding affinity (250). Usually IGFBP-degrading proteases are considered as 
growth stimulators, since they increase local IGF availability. This phenomenon is 
well illustrated in ovarian follicular development, where IGF actions are blocked by 
IGFBP4 during follicle atresia, and restored by the action of a IGFBP4 proteases, 
induced during follicular development (250).  
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No relevant insights have come as yet from genetic deletion of the igfbp genes. 
Transgenic analysis (255) showed more relevant inputs regarding the function of 
several binding proteins during postnatal development. IGFBP1-4 transgenic mice 
showed impaired brain development, altered glucose homeostasis, reduced body 
weight gain, hypoplasia of smooth muscle cells, and impaired fecundity. More 
analyses supported by tissue-specific gene deletion and overexpression will hopefully 
provide further insights of IGFBPs function. 
 
1.5 IGF-1 SIGNALING 
As described previously, the pleiotropic functions of IGF-1 reside mainly in its 
complicated genetic structure, in different post-translational modifications, and in 
tissue- and developmental-specific transcription and transcriptional regulation. 
Further complexity is provided by a tight regulation of the IGFBPs that bind IGF-1, 
inhibiting or activating its functions. 
 
The IGF-1 signaling pathway arose early in the evolution, possibly as regulator of 
cellular proliferation in relation to nutrient availability (256). This signaling is 
conserved among invertebrates and vertebrates, and probably, in the first unicellular 
organisms (Yeast) was to regulate the capacity to survive during states of reduced 
metabolism (Figure 2.2). In all organisms, homologous players characterise IGF-1 
signaling (Figure 2.2).  
 
IGF-1 signals into the cells via activation of the IGF-1R, which, upon ligand binding, 
autophosphorylates 8 of the 15 tyrosine residues present in the cytoplasmic domain 
(257). Like IR, IGF-1R exists as covalent dimers of two αβ monomers in the 
unliganded state. Ligand binding favors receptors dimerization and activation. The 
immediate downstream mediators of IGF-1R activation are the members of IRS 
family. Interestingly, IGF-1R phosphorylates and activates preferentially IRS1, 
whereas IR preferentially interacts with IRS2 (258). This phenotype is reminiscent of 
the phenotype of Irs1 and Irs2 KO, which show diabetic phenotype and growth 
retardation respectively (259). In Drosophila the homologs of IGF-1R  (Inr) and IRS 
(Chico) are structurally and functionally related to their mammalian counterparts. 
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Partial loss of Inr and complete loss of chico function result in dramatically reduced 
cell, organ and body size (260).  
 
IRS activation can lead either to Ras-MAPK pathway through the adaptors Grb2 and 
SOS to stimulate cell proliferation (261), or to induction of the PI3K/AKT pathway, 
which is implicated in metabolism, growth and cell survival. Both signaling pathways 
are conserved in mammals and in Drosophila (Figure 2.2). Interestingly, mutations of 
the Drk- (Grb2 homolog) binding site in Chico is not required for Chico-mediated 
growth effects, in contrast to mutations on the PI3K binding site (262). The fact that 
an activated version of PI3K dramatically affects heart growth and cardiomyocyte size 
in mice shows that the biological growth function of this downstream mediator of 
IGF-1 signaling has been functionally conserved during evolution (263).  
 
Mediators of PI3K downstream signaling are AKT, phosphoinositide-dependent 
kinase 1 (PDK1), and Target of Rapamycin (TOR),  (Figure 2.2). AKT, also termed 
protein kinase B, is fully activated by binding of PIP3 in its PH domain, and by 
additional serine/threonine phosphorylation events mediated by PDK1 (264). 
Mutations analysis of AKT in Drosophila clearly showed that at least in flies, PI3K-
induced growth is mediated by AKT, since loss of AKT function generates flies with 
severe impairment in cellular growth and decreased body size (265). Conversely, 
overexpression of AKT can cause overgrowth in the eye and wing tissues (265).  
 
TOR was first discovered in budding yeast as a regulator of growth in response to 
nutritional alterations (266). Rapamycin inhibits the function of TOR by forming a 
complex with FK506 binding protein–12, which then binds a conserved region 
immediately upstream of TOR’s kinase domain (266).  TOR is known to respond 
positively to the presence of amino acids, and induces upregulation of translation 
through activation of ribosomal S6 kinase (p70S6K or S6K) (267). Exciting work in 
Drosophila has shown that TOR and S6K regulate growth. Loss of function of dTOR 
decreases cell size and growth in part through downregulation of S6K activity (268).  
 
Interestingly, the same signaling is preserved in mammalian cells. In skeletal muscle, 
it has been reported that growth and hypertrophy are mediated by activation of the 
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AKT/mTOR pathway, leading to upregulation of the translational machinery (137), 
and that IGF-1 induces skeletal myotube hypertrophy by the PI3K/AKT/mTOR 
pathway. Moreover, the inhibition of mTOR activity by rapamicyn blocks 
compensatory hypertrophy in vivo (137). However, in mammalian cells the precise 
pathway connecting PI3K to the activation of p70S6K and consequently of the 
translational machinery is a matter of some dispute (134). It is interesting to note that, 
independently from AKT, PDK1 has been found to directly phosphorylate p70S6K 
(134), indicating that AKT has a dispensable role for signaling to p70S6K. It is 
noteworthy that mutational inactivation of PI3K and AKT in Drosophila still leaves 
S6K and, presumably, TOR activity intact, suggesting that TOR and S6K can reside 
in another pathway independent from PI3K (268). In the worm Caenorabditis Elegans 
inactivation of TOR produces a phenotype that partially resembles amino acid 
starvation (269), but not the developmentally delayed phenotypes caused by 
IGF/insulin pathway mutations. 
 
Lately, another player in IGF-1 signaling has been discovered. Studies on 
Caenorabditis Elegans showed that the serum- and glucocorticoid-inducible kinase 
(SGK) forms a kinase complex with AKT1 and AKT2, upon activation of DAF2 
(homologous of IGF-1R in mammals) and PDK1, to phosphorylate and inactivate 
DAF16 (homologous of forkhead-transcription factor FKHRL1). This mechanism 
accounts for dauer formation, development and stress tolerance (270). The authors 
showed that whereas AKT1 and AKT2 activation are important for regulating dauer 
formation, SGK activation is crucial for the control of development, stress response 
and longevity (270). In mammals, recent studies revealed that SGK plays an 
important role in cell survival signaling (271) (Figure 2.3), although the mechanisms 
distinguishing stress resistance, survival, and growth have not yet elucidated in higher 
organisms as it has been done in the worm.  
 
In mammals, other signaling pathways are regulated by IGF-1 (Figure 2.3). The 
expression of the class 1/Ea IGF-1 isoform, termed mIGF-1, in post-mitotic myoblasts 
induced transcription of calcineurin (2). In this study, a cross-talk between calcineurin 
signaling and GATA activity has been observed. The calcineurin-activated 
transcription factor NFATc1 interacts with GATA2 in muscle overexpressing the 
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class 1/Ea IGF-1 isoform, and could account for the strong hypertrophic phenotype 
observed in mIGF-1 transgenic mice (2).  
Finally, the survival signaling attributed to IGF-1 is mediated by AKT-induced 
inhibition of the pro-apoptotic factor Bad, inactivation of caspase 9 (272), and of 
forkhead family of transcription factors, FOXO (273). Interstingly, IGF-1/ 
PI3K/AKT-mediated inhibition of FOXO1 prevents expression of muscle atrophy- 
induced ubiquitin ligase, indicating that the signaling through inhibition of FOXO 
rescues, to some extent, deterioration of muscle fibers (274) (Figure 2.2). 
 
2. IGF-1 SIGNALING AND FUNCTION IN THE HEART 
The functions of IGF-1 in the heart have been extensively analyzed, although several 
groups reported different and contradictory roles of the growth factor in vivo and in 
vitro. The first demonstration that IGF-1 induces cardiac hypertrophy came from Ito 
and coworkers (275), who showed that fully processed IGF-1, which does not contain 
class 1 or 2/E peptides, increases the transcription of muscle specific genes, induced a 
two fold increase of cell size in neonatal rat cardiomyocytes, and promotes protein 
synthesis, indicating its functional role in regulating cardiac cell hypertrophy. These 
effects could be inhibited by addition of IGFBP3 to cultured cardiomyocytes, 
indicating that this binding protein could bind and inhibit IGF-1 (275). The signals 
leading to IGF-1-induced hypetrophy involves activation of IRS1, PI3K, ERK, and 
p90-S6 kinase (276). Supporting these data, the phenotype of transgenic mice 
overexpressing a constitutive active form of PI3K in the heart (263), displays evident 
cardiac hypertrophy and increased cardiomyocyte size. Contrasting with this 
phenotype, transgenic mice overexpressing dominant-negative PI3K have smaller 
hearts and individual fibers compared to wild-type littermates (263). More insights 
into IGF-1-induced hypetrophy come from transgenic overexpression of intermediary 
molecules in IGF-1 signaling. Overexpression of AKT is sufficient to induce cardiac 
hypertrophy without affecting systolic function (277). Cardiac hypertrophy induced 
by AKT overexpression is attenuated by rapamicin, indicating that hypetrophic 
signaling occurs through mTOR (133). Interestingly, rapamacin blocks the increase in 
cardiomyocyte size, resulting from oxidative stress (278), treatment with PE (279), or 
Angiotensin II (280).   
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In vivo, intravenous infusion of fully processed IGF-1, lacking class 1 or 2/E peptides, 
induced increased protein synthesis particularly in the heart, which was not 
accompanied by significant changes in blood glucose (281). Interestingly, 
administration of IGF-1 alone or in combination with Growth Hormone (GH) in 
normal adult rats increased the left ventricular weight compared with placebo-treated 
rats (282). It is important to stress that in all these animal models, IGF-1 significantly 
increases systolic and diastolic left ventricular function, without affecting collagen 
deposition, which usually accompanies cardiac overload-induced hypertrophy (282-
284). These effects were evident in experimental postinfarction models, in which IGF-
1, given early after myocardial infarction, improved left ventricular function, 
enhanced cardiomyocyte hypertrophy, and reduced adaptive fibrosis in non-infarcted 
myocardium (283, 284). In contrast to these studies, mice overexpressing a truncated 
form of human IGF-1 (IGF-1A, which does not encode class 1 or 2 signal peptides) 
under the control of an α-skeletal actin promoter induced physiological and then 
pathological cardiac hypertrophy, associated with decreased systolic performance and 
increased fibrosis (135). 
 
In contrast to these studies, in which IGF-1 induced hypertrophy in a mechanism 
dependent from PI3K/AKT/mTOR signaling, different in vivo analyses emphasized 
the role of IGF-1 in inducing proliferation of cardiomyocytes. Transgenic mice 
generated with the human IGF-1B cDNA expressed in the heart showed no striking 
differences in heart size and cell volume when compared to control mice, but the 
number of myocytes in the heart was 55% higher in transgenic animals, indicating 
that overexpression of this IGF-1 isoform is coupled with myocyte proliferation (136). 
Supporting these data that argue for a proliferative function of IGF-1, a recent report 
showed that in vivo administration of IGF-1 in sheep did not stimulate cardiomyocyte 
hypertrophy but, on the contrary, led to a decreased percentage of binucleated cells 
(285). In culture, IGF-1 induces increased myocyte bromodeoxyuridine (BrdU) 
uptake dependently from PI3K and ERK activation (285). In another set of studies in 
vitro, cultured neonatal cardiomyocytes treated with an antisense probe to IGF-1 
receptor, showed suppressed DNA replication, mitosis and cell proliferation (286). 
Moreover, the antisense treatment did not alter the expression of ANF in myocytes or 
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cellular hypertrophy (286), suggesting that IGF-1 controls cell division rather than 
cell growth. 
 
IGF-1 has been shown to protect myocardium against death in animal models of 
infarct and ischemia-reperfusion injury. Qiong Li and co-workers (287) showed that 
mice overexpressing the human IGF-1B under the control of the rat α-myosin heavy 
chain (α-MHC) promoter respond to coronary ligation with attenuated increase in 
diastolic wall stress, cardiac weight, ventricular dilatation, and hypertrophy, due 
mainly to a prevention of cardiac cell death. In a model of ischemia-reperfusion, rats 
treated with IGF-1 presented reduced myocardial apoptosis and injury (288). In other 
reports, IGF-1 was shown to protect against apoptosis in cultured (289) and primary 
cardiomyocytes (182).  
 
The beneficial effects of IGF-1 in animal models match well the results from human 
clinical trials. IGF-1 has been used to improve cardiac performance in human patients 
suffering from cardiac failure (290, 291). Growth hormone (GH) deficiency in 
humans causes numerous defects, and the heart and the cardiovascular system are also 
affected. Patients with GH-deficiency show decreased left ventricular mass (292), and 
replacement treatment with both GH and IGF improved notably cardiac performance 
and morphology (293).  Despite these promising indications, further studies need to 
be employed to verify the clinical importance of IGF-1 and to understand whether a 
coadjuvant therapy with IGFBPs and GH can be salutory in certain cardiac diseases.  
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represents the mature IGF-1 peptide. The different splicing sites generate Class 1 and Class 2  
peptides. The arrows indicate different starting sites on exon 1 and 2.  
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1. REGENERATION: EVOLUTIONARY MECHANISMS 
Wound repair in most vertebrate organs is dominated by a fibro-proliferative response 
leading to scar formation. The injured organ is not restored at its original 
physiological state, but it is rather patched (294). The only adult vertebrates that have 
the incredible capacity to restore the complete structure, the morphogenesis and 
functionality of an entire organ are the urodele amphibians, newt and axolotl. The 
adult newt can regenerate its limbs upon distal amputation (at level of radius and 
ulna), or mid-proximal amputation (at level of mid-humerus) (295) (Figure 3.1). 
Interestingly, newt can regenerate jaws, lens, retina, and large sections of the heart in 
response to molecular events that signal tissue removal or damage (296, 297), (Figure 
3.1).  
 
Urodele amphibian limb regeneration proceeds through a series of cellular events that 
are elusive in mammalian cells. After amputation epithelial cells cover the stump area 
and form the wound epidermis; the mesenchymal cells underlying the wound 
epidermis enter to cell cycle, and the cartilage, the connective tissue and muscle cells 
lose their differentiated features, re-enter cell cycle, and form the blastema with the 
mesenchymal cells (Figure 3.1) (296). Transplantation experiments showed that the 
urodele strategy of regeneration of most structures is due to the re-specification of 
differentiated cells to give rise to local progenitor cells, since limb blastema cells 
produce an ectopic limb after relocation to the anterior chamber of the eye (298). De-
differentiation, as it occurs in newt limb regeneration, is a very well defined process 
involving two main cellular tasks: loss of a differentiated phenotype to acquire a 
proliferative capacity. It has been found that a thrombin-activated serum factor can 
drive differentiated salamander myotubes back into the cell cycle, but does not cause 
loss of proteins normally expressed in differentiated cells, such as muscle myosin 
expression (299). This serum factor appears to be important also for trans-
differentiation of retinal PECs to lens, and, although not tested, it is likely that it is 
also required for heart and lens regeneration (300, 301). 
 
In mammals, there are few examples of regeneration in vivo, other than liver 
regeneration and deer antler seasonal regeneration (295, 302). Although these 
impressive capacities suggest that higher vertebrates can to some extent regenerate, 
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most organs lose this capacity, when the damages overwhelm the homeostatic ability 
of single tissues to restore missing structures. 
 
Why are some animals able to regenerate complex organs and structure, after tissue 
removal or amputation, and others apparently not? Interestingly, regeneration is a 
conditions that can vary among the individuals belonging to the same species (296). 
In 24 urodele species, 4 to 6 species showed little or not regenerative capacity (296). 
It has been argued that regeneration is an evolutionary variable (303), lost in some 
species for secondary reasons, not yet understood, but representing a basic, primordial 
attribute of metazoans.  
 
Interestingly, Harty and collegues (304) hypothesized that the regenerative capacity of 
lower vertebrates resides in their unspecialized immunological systems. Regenerating 
urodeles appear to be immunodeficient compared to anurans, which have lost the 
capacity to regenerate. Although urodeles possess T and B lymphocytes and a diverse 
repertoire of Ig and T-cell antigen receptor genes, humoral immunity is mediated only 
by IgM and is apparently amnestic (304). A correlation between the changes in 
regenerative capacity, immune system, and scarless wound healing in Xenopus 
development also supports this view (304). So far it has been concluded that the 
components of adaptive immunity that emerge during vertebrate development are 
likely to account for scar formation and missing regenerative processes after injury 
(304). Although not sufficient to explain the signaling and cellular properties acquired 
during regenerative processes, the importance of immunodeficiency in urodeles is a 
tempting hypothesis to be experimentally analyzed in higher vertebrates. 
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2. CARDIAC REGENERATION 
The traditional concept that cardiomyocytes are terminally differentiated cells (120, 
305, 306) has changed in the last years, and recent studies have shown that adult 
hearts in physiological and pathological conditions contain a certain number of 
mitotic figures (307-309). Precisely, mitotic indexes between 0.03% (zone distant 
from infarct) and 0.08% (zone adjacent to infarct) were measured post mortem in 
patients who died after myocardium infarction (307). A mitotic index of 0.9% was 
reported in cardiomyocytes of female hearts transplanted into male recipients (309). 
However, the observed mitotic indices indicate that the process would need to be 
manipulated and enhanced to achieve clinical relevance in cases of post-infarct repair.  
So far clinical investigation accompanies and sometimes precedes the biological 
studies, in order to find the relevant cells that can heal a damaged heart.  
 
Stem cell research has opened a new propelling field of analysis. Stem cells are 
defined by their ability to self-renew and to form one or more differentiated cell types 
(310). A clear division of the stem cell family can be drawn between those isolated 
from the embryo, and termed embryonic stem cells, and those in adult somatic tissues, 
known as adult stem cells. Embryonic stem (ES) cells have the greatest potential for 
organ regeneration, because of the diversity and number of cell types that they can 
produce. The versatility of ES cells is counterbalanced by their side-effects, and by 
ethical problematics that limit the studies and the applications of these cells.  
 
Adult stem cells retain far more plasticity than was originally thought. Bone marrow 
derived progenitor cells were able to repair the heart of animals that underwent 
myocardial injury (311, 312). Improved cardiac function was observed when bone 
marrow progenitor cells expressing the receptor for stem cell factor (c-kit) but not 
differentiation markers (lin-) were injected directly into the infarcted hearts of mice, 
(311). Interestingly, recent studies showed that while bone marrow derived progenitor 
cells trans-differentiated into nearly all the haemopoietic and endothelial lineages, 
very few were fated to cardiomyocytes, suggesting that new blood vessel formation 
and increase in blood supply could account for the observed cardiac improvement 
(313).  
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Skeletal muscles maintain a resident population of stem cells, termed satellite cells, 
which are normally quiescent, but can be activated by conditions where muscle repair 
or hypertrophy are required (314). These cells were transplanted successfully in the 
infarcted heart, but in several studies no trans-differentiation into cardiomyocytes was 
observed, and even in cases of rare trans-differentiation, the cells were not 
electromechanically coupled with the recipient myocardium (315).  
 
The existence of putative cardiac stem cells in the myocardium itself has generated 
much excitement. Cells expressing a progenitor phenotype (Lin-ckit+ and Sca1+ 
markers) were isolated from animal heart tissue. These cells were considered a cardiac 
stem cell pool, or a cardiac stem cell-like pool, because they expressed cardiac 
markers like GATA4 or myosin, and lack of markers of haematopoietic or endothelial 
lineage, and for their capacity to self-renew, for their clonogenicity and 
multipotentiality. When transplanted into the infarcted area they seemed to improve 
cardiac function (316, 317).  
 
Whatever the nature of the stem cells, three basic steps of clinical importance have to 
be considered: mobilization, homing and differentiation. Several factors seem to 
regulate mobilization and homing, such as stem cell factor (SCF) and stromal cell 
derived factor (SDF-1) respectively (318). Differentiation is so far precluded by the 
usage of non-committed cells that are potentially unable to differentiate in functional 
cardiomyocytes. A number of clinical trials are currently testing the efficacy and 
safety of using autologous bone marrow-derived or circulating stem cells to promote 
myocardial repair. Transplantation of skeletal myoblasts has resulted in ventricular 
arrhythmias, while stem cells trials have not indicated heart beat dysfunctions (319). 
Preliminary results of some trials injecting bone marrow or circulating stem cells 
directly into the heart have suggested beneficial therapeutic effects (end-systolic 
volume, stroke volume, regional contractility), without apparent adverse side-effects 
(320). Although it is difficult to draw landmark conclusions, these improvements 
encourage further research. However it must be emphasized that preliminary results 
have been generated from short-term, non-randomised trials, with low patient 
numbers. Moreover, the question of whether the applied stem cells act by improving 
tissue perfusion, or regenerate cardiac myocytes remain unresolved.  
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Figure 3.1: Newt limb regeneration. The newt is the only adult vertebrate that can regenerate. 
Regeneration occurs with the formation of a blastema enriched of proliferating mesenchimal 
cells and de-differentiated cartilage, muscle and bone cells. The last step includes re-
programming of the proliferating cells in all the components of the limb. 1 Dorsal crest; 2 
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1. GENERATION OF α-MHC/mIGF-1 TRANSGENIC MICE 
We generated transgenic mice (FVB) with a rat mIGF-1 cDNA driven by the mouse 
α-MHC promoter (321). mIgf-1 insert was excised and purified to avoid introduction 
of vector sequences into the transgene. Transgenic mice were generated by standard 
methods. Transgenic mice were selected by PCR using tail digests. The animals were 
housed in a temperature-controlled (22°C) room with a 12:12 hour light-dark cycle. 
All the analyses were performed on male mice. 
 
2.  RNA PREPARATION AND NORTHERN BLOT ANALYISIS 
We obtained total RNA from wild-type and αMHC/mIGF-1 transgenic hearts by 
RNA-TRIZOL extraction (Gibco-BRL). Total RNA (10µg) was analyzed on 1.3% 
agarose gels and hybridized as described (322).  
 
 3.  HISTOLOGICAL ANALYSIS  
Mice at different ages were anesthetized before cervical dislocation, and hearts were 
perfused with 4% paraformaldehyde (PFA) as previously described (311), then 
excised and embedded in paraffin. Paraffin sections (10µm) were stained with 
hematoxylin and eosin to analyze morphological features of the hearts. Connective 
tissue was visualized by using Masson’s Tricrome stain as described by Manufacture 
(Sigma). Cell size was analyzed by measuring the apparent size of single nuclear cells 
in a 40X magnification. 10 sections (10µm) from wild-type and transgenic hearts 
were used for cell measurement. Cells were measured in the left ventricle. Statistic 
analysis was performed as described below. 
 
4.  CARDIAC INJURY 
3-4 months old wild-type and transgenic mice were anesthetized by Avertin injection 
(0.1ml/10g of a 2.5% solution). The tongue was retracted and a tracheal cannula (1.3 
x 1 mm, OD x ID, Harvard Apparatus) was inserted into the trachea. The cannula was 
attached to the mouse ventilator (Model 687, Harvard Apparatus) via the Y-shaped 
connector. Ventilation was performed with a tidal volume of 200 µl and a respiratory 
rate of 120/min. The chest cavity was opened in the left fourth intercostal space. The 
heart was exposed and 25 µl of 10µM cardiotoxin (Latoxan) were injected in the heart 
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wall of the left ventricle. The chest cavity, the muscle, and the skin were then closed 
by a 6-0 silk suture.    
 
5.  ECHOCARDIOGRAPHY 
Eight 13 week-old males from both strains were weighed and slightly anaesthetized 
with pentobarbital (30mg/kg i.p.) to allow an analysis for cardiac anatomy and 
function on a Sonos 5500 (Hewlett Packard) with a 15MHz linear transducer (15L6) 
(Philips Ultrasound, USA). The images were stored in a digital format on a magnetic 
optical disk for review and analysis. The left hemithorax was shaved and an 
ultrasound transmission gel was applied to the precordium. The heart was first imaged 
in the two-dimensional mode (2D) in the parasternal long-axis view to obtain the 
aortic root dimensions. The aortic flow velocity and the heart rate (HR) were 
measured with pulsed-wave Doppler on the same section. The sample volume cursor 
was placed in the aortic root and the transducer angled slightly, which allowed aortic 
flow parallel to the interrogation beam so that maximum aortic flow velocity was 
obtained easily. The cardiac output (CO) was calculated from the following equation: 
CO=0.785xD2xVTIxHR where D is the internal diameter of the aortic root and VTI is 
the velocity-time integral of the Doppler aortic spectrum. Then the pulsed Doppler 
window was placed between the tip of the mitral valve leaflets to record the mitral 
inflow velocities. The maximal speed of the early (E) and late (A) mitral filling were 
measured as well as the mean deceleration time of the E wave (DT) and the duration 
of the A wave (Adur). By placing the Doppler between aortic flow and mitral valve, 
the isovolumetric relaxation (IVRT) time was measured. Left ventricular cross 
sectional internal diameters in end-diastole (LVEDD) and in end-systole (LVESD) 
were obtained by an M-mode analysis of a 2D-short axis view at the papillary muscle 
level. The ejection and shortening fractions were calculated. From this view, the 
diastolic septum (S) and posterior wall (PW) thicknesses were measured. The left 
ventricular mass (LVM) was calculated with the following formula: 
LVM=1.055x[(S+PW+LVEDD)3-(LVEDD)3]. All the measurements were performed 
on, at least three beats, according to the guidelines of the American Society of 
Echocardiography. 
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6.  NON INVASIVE BLOOD PRESSURE AND HEART RATE 
All measurements were performed in eight 16 week-old conscious male animals of 
both strains on a BP-2000 blood pressure analysis system (Visitech Systems, USA) 
during 5 consecutive days. 
 
7.  ELECTROCARDIOGRAM 
Eight 17 week-old male mice of both strains were anaesthetized with tribromoethanol 
(2.5% solution, 13µL/g body wt SC) and were recorded with the 4 arms of the ECG 
leads attached at the origin of each paw by unipolar and bipolar lead derivations. The 
signal was recorded by an electrocardiograph (EKG-Burdick, Siemens) connected to a 
data acquisition system (MP100 and Acknowledge Software, Biopac Systems Inc). 
 
8.  IMMUNOHISTOCHEMISTRY AND BrdU ANALYSIS 
BrdU (Sigma) was administered ad libitum at 0.1% in the drinking water or injected 
intraperitoneally once a day at 100µg/g. Hearts were perfused with 4% PFA and 
embedded in paraffin. Sections were stained with anti-BrdU (BD-Pharmingen) as 
prescribed by the manufacture. The amount of positive nuclei was measured by 
counting all nuclei and BrdU positive nuclei in 10 sections (10µm) of wild-type and 
transgenic hearts, bordering and covering the cardiotoxin injured side. We used a 40X 
magnification as field of analysis. An average of 200 nuclei was found in each field 
assayed in both wild type and transgenic hearts. The percentage of BrdU positive 
nuclei was calculated based on total nuclei amount. Statistical analysis was performed 
as described below.  
Immunofluorescent analysis was performed on paraformaldehyde (4%) fixed-frozen 
sections (10 µm) with BrdU antibody purchased from Amersham. Myosin antibody 
(Sigma) was used at 1:250 to stain cardiac myocytes, and nuclei were visualized with 
Hoechst at a concentrtion of 1:1000. 
 
9.  WESTERN BLOT 
Hearts from wild-type and transgenic mice were excised and the excess of blood was 
removed by washes in PBS 1X. Hearts were lysated in buffer containing 20mM Tris-
HCl (pH 8.0), 150 mM NaCl, 5mM MgCl2, 10% glycerol, 1% Triton, 0.5% NP40, 
supplemented with 1mM proteases and phosphatases inhibitor cocktail. 50 µg of 
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proteins were loaded onto SDS-PAGE gel and blotted on PVDF membrane. Phospho-
AKT (Pharmingen), Phospho-S6 (Cell Signaling), phospho-JNK (Santa Cruz), and 
phospho-ERK (Santa Cruz) were used at a concentration of 1:500 in 5% BSA. The 
blots were normalized for AKT (Transduction Laboratories), S6 ribosomal protein 
(Cell Signaling), JNK (cell Signaling) and ERK (Cell Signaling). MEF2C, GATA4 
and Nkx2-5 were purchased form Santa Cruz and used at 1:250. Phospho-histone H3 
and histone H3 (Cell Signaling) were used at 1:500 in 5% BSA.  
 
10.  REAL TIME PCR AND REVERSE TRANSCRIPTASE PCR 
1µg of RNA was used to set up the reaction of reverse transcription as prescribed by 
Manufacture (Promega). Real time PCR was performed using 10 µl of the Syber 
Green DynamoTM Master Mix (Finnzymes, Espoo, Finland), along with 1µl of 
cDNA and 0.75 µM of each primer in a total reaction volume of 20 µl. Duplicated 
samples were incubated at 95º for 3 min, followed by 45 cycles of amplification (95º, 
10 sec; 56º, 20 sec; 72º, 30 sec). Results for each cytokine were normalized to 
ubiquitin ligase expression. 
 
11.  PRIMERS 
IL1β, forward 5’-acatcaacaagagcttgacccaggc-3’ reverse 5’-agctcatatggtccgacagcacga-
3’; IL6, forward 5’-aggataccactcccaacagacgtg-3’ reverse 5’-gtagctatggtactccagaagacc-
3’; IL10 forward 5’-ccaagccttatcggaaatg-3’ reverse 5’-tggccttgtagacacc-3’; IL4 
forward 5’-catcggcattttgaa-3’ reverse 5’-cgtttggcacatccatctcc-3’; GAPDH forward 5’-
tgggtgtgaaccacgaa-3’ reverse 5’-acagctttccagaggg-3’; ANP forward 5’-
atgggctccttctccatcaccctg-3’ reverse 5’-tcggtaccggaagctgttgcagcc-3’; BNP forward 5’-
atggatctcctgaaggtgctgtcc-3’ reverse 5’-gcgttacagcccaaacgactgacg-3’; β-myosin heavy 
chain forward 5’-ctgagcagaagcgcaatgcagagtcgg-3’ reverse 5’-
ctcctcattcaggcccttggcaccaatg-3’; α-skeletal actin 5’- atgtgcgacgaagacgagaccacc-3’ 
reverse 5’-gccacatacatggcaggcacgttg-3’; Glucose transporter 1 (Glut1) forward 5’-
gatcccagcagcaagaaggtgacg-3’ reverse 5’-tggagaagcccataagcacagcag-3’; β-actin 
forward 5’-taaaacgcagctcagtaacagtccg-3’ reverse 5’-tggaatcctgtggcatccatgaaac-3’. 
 
 
 
 81 
12.  PHOSPHOPROTEIN SCREEN 
Hearts were excised and washed in PBS 1X to remove the excess of blood. Each one 
gram of chopped tissue was lysated in 4 ml of lysis buffer as described by 
Manufacture (Kinexus, www.kinexus.ca/pdf/informationpackage.pdf). 500µg of total 
protein amount was used to perform the KPSS-4.1 phopshoprotein screen. The 
Kinetworks analysis involves resolution of a single lysate sample by SDS-PAGE and 
subsequent immunoblotting with panels of up to three primary antibodies per channel 
in a 20-lane Immunetics multiblotter. The antibody mixtures were carefully selected 
to avoid overlapping cross-reactivity with target proteins. The comparison report 
compared the trace quantity of the known protein from each screen type against all 
relevant samples. The Corrected data were obtained by trace quantity standardization 
for all samples. 
 
13. ECHOCARDIOGRAPHY IN REGENERATING HEARTS 
Eight 13 week-old males from both strains were analyzed for echocardiography one 
month after CTX injection in the left ventricle wall. The mice were weighed and 
slightly anaesthetized by Avertin injection (0.1ml/10g of a 2.5% solution). Cardiac 
anatomy and function were measured with a Vevo 660 (VisualSonic) Ultrasound, and 
by the use of a 630 RMV (real-time-micro-visualization) scanhead (Visualsonic). The 
analysis performed resulted very sensitive due to the high-resolution images that the 
VisualSonic Ultrasound can acquire. The left hemithorax was shaved and an 
ultrasound transmission gel (Parkers Laboratories Inc.) was applied to the precordium. 
The heart was imaged in the two-dimensional mode (2D) in the parasternal short-axis 
view to obtain left ventricular cross sectional internal diameters in end-diastole 
(LVEDD) and in end-systole (LVESD) dimension by an M-mode analysis. The 
ejection and shortening fractions were calculated. From this view, the diastolic and 
systolic posterior wall (PW) thicknesses was also measured.  
 
14.  STATISTICS 
All comparisons between wild-type and transgenic mice were performed by means of 
paired Student’s t tests. A significant difference was considered when p<0.05. 
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1. Cardiac-restricted expression of mIGF-1 transgene 
We generated transgenic mice with a rat mIGF-1 cDNA driven by the mouse α-MHC 
promoter (Figure 5.1A) (321). Transgenic mice developed normally with no 
perturbation in reproduction and breading. Initial characterisation of three α-
MHC/mIGF-1 transgenic lines with variable transgene expression levels revealed 
similar cardiac phenotypes. Cardiac-restricted mIGF-1 transcript expression levels 
increased with age in all founders tested and reached a steady-level at two months 
(Figure 5.1B). Expression of the transgene in adult mice was restricted to the heart  
(Figure 5.1C), and endogenous levels of IGF-1 were undetectable in other tissues 
using the rat probe. A single transgenic line was selected for further analysis (F018).  
 
2. mIGF-1 overexpression is associated with increased ventricular mass and 
heart size  
Postnatal transgenic mIGF-1 hearts displayed accelerated cardiomyocyte hypertrophy, 
precociously attaining wild-type adult heart size (Figure 5.2A). The morphological 
effects of mIGF-1 overexpression were analyzed in hearts from wild-type and 
transgenic mice at different time points of development (from E18 up to six months). 
Whereas wild-type and transgenic hearts were comparable in morphology and size at 
E18 and two days after birth (data not shown), the mIGF-1 transgenic hearts showed 
an increase in size at an age of one week (Figure 5.2A), that persisted at one and two 
months. In contrast to other transgenic models of cardiac IGF-1 over-expression, the 
transgenic hearts showed a comparative size with wild-type hearts at six months 
(Figure 5.2A). The ratio heart weight/body weight significantly (p>0.05) increased in 
mIGF-1 overexpressing hearts at 1W, 1M and 2M, but it was comparable at six 
months, indicating that mIGF-1 overexpression induces accelerated growth in the 
heart, with unknown compensatory mechanisms at adult age (Figure 5.2A). A 
comparison of cellular components showed a clear increase of cell size in transgenic 
hearts compared to wild-type hearts (20%+/-1.8%; p-value 0.0002), (Figure 5.2B). 
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3. mIGF-1-induced hypertrophic response is associated with a moderate diastolic 
and systolic dysfunction  
Comparable to the histological analysis previously described, echocardiography 
performed on eight wild-type and transgenic mice showed that mIGF-1 mice exhibit a 
20% concentric left ventricular hypertrophy (p<0.05 vs controls), all walls being 
involved in the same extent (Table 2). This increase in the cardiac mass is associated 
with a prolongation of the rate of ventricular repolarization, as attested by 
augmentation of the QT interval on the electrocardiogram (Table 2). In transgenic 
male mice, echocardiography identified a small but significant decrease of cardiac 
contractility, demonstrated by the 13% decrease of the ejection fraction and fractional 
shortening (p<0.05). Nevertheless, this level of contractility preserved the resting 
cardiac output (p>0.05 vs controls) and arterial blood pressure (p>0.05 vs controls), 
despite the trouble of the diastolic function. This dysfunction was identified by the 
21% decrease of the E/A ratio (p<0.05), and the prolongation of the A wave duration 
(+14%). These two abnormalities were not linked to any prolongation either of the 
isovolumetric relaxation time, or of the mean deceleration time of the E wave 
(p>0.05). In most of the transgenic mice, an increase in the P wave amplitude was 
observed on electrocardiograms (Table 2) attesting to an atrial dilatation. 
 
4. mIGF-1 signals through time-dependent regulation of MAPKs and sustained 
activation of S6 ribosomal protein  
To better dissect the signaling activated in response to mIGF-1 overexpression, 
specific markers of heart hypertrophy were analyzed by reverse transcriptase PCR. 
Cardiac hypertrophy was related to higher expression levels of ANP at 1 and 2 
months, without any further significant change (Figure 5.2C). Other markers 
underlining cardiac hypertrophy, such as BNP, α-skeletal actin, β-myosin heavy 
chain, and glutamate transporter 1 were not affected (Figure 5.2C). These results 
suggest that IGF-1 induces a time-dependent increase of specific hypertrophic 
markers when locally overexpressed. 
 
It has been shown that heart remodeling and hypertrophy are correlated with MAPK 
activation in cardiac and skeletal muscle (173), and that cell growth mediated by IGF-
1 overexpression in skeletal muscle cell lines induces S6 ribosomal protein 
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phosphorylation in a mechanism dependent upon activation of mTOR (323). To 
elucidate the signaling regulated by local mIGF-1 overexpression in the heart, total 
tissue protein extracts were analyzed by Western blot to detect the phosphorylation 
levels of the MAPKs, ERK1/2 and JNK. We detected a strong increase in ERK1/2 
and JNK phosphorylation at one week in the mIGF-1 transgenic hearts. At the same 
age, JNK activation mirrored the increased phosphorylation of c-Jun, a downstream 
target of activated JNK. Both kinases returned to activation levels comparable to wild-
type hearts at two weeks (Figure 5.3A). By one month, kinase activation was 
undetectable in both wild-type and mIGF-1 transgenic hearts (Figure 5.3A). 
Interestingly, the phosphorylation level of the proliferation marker histone H3, 
showed a marked decrease at one week of age in transgenic hearts (Figure 5.3A), 
indicating that mitotic activity is downregulated earlier during postnatal development 
of mIGF-1 transgenic hearts compared to wild-type hearts.  
 
Cardiac-specific genes are regulated early during the first phases of heart development 
by the activation of specific transcription factors, such as MEF2C, GATA4 and Nkx2-
5 (7, 42). We analyzed the expression levels of these transcription factors to trace a 
possible involvement of mIGF-1 in their regulation. None of these specific proteins 
were observed to be differentially expressed between wild-type and transgenic hearts, 
beside a slight increase of MEF2C levels in transgenic hearts at two days after birth 
(Figure 5.3B). By contrast, mIGF-1 transgenic hearts maintained sustained S6 
ribosomal protein phosphorylation during all ages analyzed, whereas the activity of 
the protein in wild-type hearts displayed a more modulated regulation, with a strong 
activation at two months and decreased phosphorylation at four and six months 
(Figure 5.3D). Phosphorylation levels of AKT remained unchanged in mIGF-1 
transgenic hearts (Figure 5.3C), indicating that mIGF-1-mediated regulation of the 
translational machinery is independent of AKT activity in cardiac tissue.  
 
To analyze in detail the signaling regulated by mIGF-1 overexpression in the heart, a 
phosphoprotein screen has been performed on wild-type and mIGF-1 transgenic heart 
lysates by Kinetworks analysis (Kinexus Bioinformatic Corp.). The analysis showed 
that AKT pathway leading to S6 phosphorylation is not affected (Table 1). mTOR and 
p70S6 kinase phosphorylation levels were also not changed (33 CPM for control 
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wild-type vs 26 CPM for transgenic hearts) or detected respectively in mIGF-1 
transgenic mice compared to wild-type littermates (Table 1). It is interesting to note 
that, independently from AKT, PDK1, an alternate downstream mediator of PI3K, has 
been found to directly phosphorylate p70S6K (324), indicating that AKT has a 
dispensable role for signaling to p70S6K. Interestingly, our data showed a strong 
activation of PDK1 (241CPM in wild-type hearts vs 507 in mIGF-1 transgenic hearts; 
Table 1). Our studies uncover new physiological activated targets of the mIGF-1 
signaling, which are still under investigation.  
 
Taken together these results showed that remodeling of the hearts overexpressing the 
local IGF-1 isoform was related to the activation of MAPKs signaling in an early 
precise time-window of postnatal heart development, and to a sustained regulation of 
the translational machinery. Both mechanisms were independent of AKT activation, 
but dependent on PDK1 activation, pointing out an unexpected role for a different 
kinase downstream the IGF-1 signaling. 
 
5. mIGF-1 overexpression induces heart regeneration upon cardiotoxin (CTX) 
injury 
We previously reported that mIGF-1 increases regeneration of skeletal muscles in 
response to pathological stimuli (2). To elucidate its role in heart regeneration, heart 
injury was induced by injection of CTX venom in the wall of the left ventricle. This 
snake venom acts on skeletal and cardiac muscle cells, blocking their contractile 
capacity and inducing cell death.  Infarction by CTX injection presented several 
advantages compared to the more widely used technique LAD ligation – mediated 
infarction. First damage caused by injection of this venom is localized and controlled 
better among the different animals tested. Second, the mortality percentage is lower 
with respect the LAD ligation, allowing the analysis of a higher number of animals in 
each independent experiment. 
 
The effects of CTX were analyzed at different time-points (48 hours, 1 week, and 1 
month) after injection of wild-type and mIGF-1 transgenic hearts. At 48 hours and 
one week after injury, both wild-type and mIGF-1 transgenic hearts presented a 
localized and defined area of cell death and massive inflammation in both ventricles 
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(Figure 5.4A). Notably, mIGF-1 transgenic mice sustained a higher dosage of CTX 
injection, performed by a double injection of 10 µM of venom, compared to a higher 
mortality in wild-type animals undergoing the same regimen (data not shown). One 
month after injury the mIGF-1 transgenic hearts showed a well defined repair of the 
injured tissue compared to wild-type hearts, where massive scar formation was 
observed (Figure 5.4B and 5.4C).  
 
6. mIGF-1 induces heart regeneration by lowering the inflammatory response 
Myocardial infarction is associated with an inflammatory response, ultimately leading 
to scar formation (Figure 1.9) (325). To dissect the possible mechanisms leading to 
scarless transgenic heart healing, we performed real time PCR and reverse 
transcriptase PCR in wild-type and mIGF-1 transgenic hearts after 24 hours and one 
week from injury, using primers specific for cytokines involved in pro-inflammatory 
(IL6 and IL1β) and anti-inflammatory response (IL10 and IL4). The pro-
inflammatory IL6 was down-regulated after 24 hours from CTX injection in mIGF-1 
transgenic hearts, whereas wild-type hearts showed increasing mRNA levels of IL6 
(Figure 5.5A). IL1β was not affected by CTX injection in wild-type and mIGF-1 
transgenic injured hearts (Figure 5.5A), indicating that certain pro-inflammatory 
cytokines have a specific role in the heart in response to CTX injury.  
 
The analysis of the anti-inflammatory cytokine IL10 by real time PCR showed a 
significant (p-value 0.0073) increase in mIGF-1 transgenic hearts after 24 hours from 
injury (36% compared to wild-type), and to a greater extent at one week (45% 
compared to wild-type), whereas the level of the cytokine is lower in wild-type 
injured heart compared to uninjured tissue (Figure 5.5B). IL4 was also significantly 
(p-value 0.03) upregulated in mIGF-1 transgenic hearts 1 week after injury, but to a 
lower extent than IL10 (20% compared to wild-type) (Figure 5.5B). 
 
Taken together these results showed that mIGF-1 overexpression induces repair of the 
damaged heart without scar formation, and by lowering specific molecules involved 
in the inflammatory response occurring normally after injury.  
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7. mIGF-1 promotes increased cell proliferation one month after CTX injection 
Although compelling evidence of cardiac renewal occurring throughout life in the 
myocardium has been extensively proved as part of cardiac homeostasis (chapter III) 
(326, 327), the complete regenerative program in cases of extended injury is 
precluded in mammalian heart by fibrotic tissue formation and consequent cardiac 
function impairment.  
 
Our analysis suggested that the process of regenerative growth and the formation of 
new myocardial tissue involve modulation of the inflammatory response and changes 
in cytokines signaling. The myocardial tissue restoration observed in mIGF-1 
overexpressing hearts could result from cardiac cell proliferation. To assess cardiac 
hyperplasia we assayed cell cycle by measuring the nuclear incorporation of 
bromodeoxyuridine (BrdU), a marker of DNA synthesis, 48 hours, 1 week, and 1 
month after CTX injection.  No differences in the proliferative state were found in 
injured heart 48 hours (13%+/-4% transgenic vs 16%+/-5% wild-type) and 1 week 
(27%+/-5% transgenic vs 32%+/-11% wild-type) after CTX injection (Fig 5.6C). The 
mIGF-1 transgene induced 14%+/-0.8% of total cells to enter cell cycle one month 
after infarct induction (Figure 5.6B and Figure 5.6C) compared to wild-type hearts 
(Figure 5.6A and Figure 5.6C). This increase is significant (p-value 0.0003), and 
explains the regeneration and myocardial reconstitution induced by mIGF-1 
overexpression in response to tissue damage. We found cardiac cells that had re-
entered to cell cycle (Figure 5.7A, B), although cells of diverse lineage were found in 
the myocardium and in the vessels (Figure 5.7A, B). The nature of these cells is still 
under investigation.  
 
8. mIGF-1 induces restoration of cardiac function after CTX injection 
To test whether mIGF-1-induced regeneration was accompanied also by a recovery of 
cardiac function, the left ventricle of 8 wild-type and mIGF-1 transgenic hearts was 
injected with CTX and analyzed with a high-resolution ultrasound system after one 
month. Transgenic hearts showed integrity of the posterior wall and normal 
echocardiography profiles (Figure 5.8B) compared to wild-type hearts (Figure 5.8A). 
Measurement of posterior wall thickness showed a significant decrease in the wild-
type hearts in both diastolic and systolic parameters compared to mIGF-1 transgenic 
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hearts (diastole-WT 1.13 +/- 0.12 mm, diastole-TG 1.48 +/- 0.10 mm; systole-WT 
1.42 +/- 0.17 mm, systole-TG 1.95 +/- 0.09 mm) (Figure 5.8D). We used two 
parameters to measure cardiac function. Mean values of ejection fraction (EF) and 
fractional shortening (FS) were significantly impaired in wild-type hearts when 
compared to mIGF-1 transgenic hearts (EF 61.5%+/- 6.55% compared to 78.27%+/- 
2.88%; FS 33.9%+/-3.7% compared to 46.66 +/-3.48%) (Figure 5.8C), suggesting that 
mIGF-1 induced morphological and functional regeneration. Taken together these 
data suggest that the regeneration program, following the early-induced repair 
program, is activated as a later step in mIGF-1 overexpressing hearts (Figure 5.9). 
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WT Heart 
Normalization 
(CPM) 
TG Heart 
Normalization 
(CPM) WT Heart (%) TG Heart (%) 
90 kDa Ribosomal S6 Kinases (S380) RSK1/2 Lane 7     
90 kDa Ribosomal S6 Kinases (T573) RSK1/2 Lane 5     
AMP-activated protein kinase alpha (T172) AMPKa Lane 9     
Bone marrow X (Eph-like) kinase (Y40) BMX (Etk) Lane 5     
Bruton's tyrosine kinase (Y223) Btk Lane 15     
Calcium/calmodulin-dependent kinase II (T286) CaMK2 Lane 15     
Cyclin-dependent kinase 1 (T161) CDK1 Lane 19     
Cyclin-dependent kinase 1 (Y15) CDK1 Lane 16     
elF4E binding protein (S65) (16) 4E-BP1 (16) Lane 6     
elF4E binding protein (S65) (17) 4E-BP1 (17) Lane 6     
elF4E binding protein (S65) (18) 4E-BP1 (18) Lane 6     
Extracellular signal-regulated kinase 1 (T202/Y204) ERK1 Lane 14 99 123 Control 24% 
Extracellular signal-regulated kinase 2 (T185/Y187) ERK2 Lane 14 53 62 Control 17% 
Glycogen synthase kinase-3 alpha (S21) GSK3a Lane 2     
Glycogen synthase kinase-3 beta (S9) GSK3b Lane 2     
I-kappa-B kinase alpha (S180) IKKa Lane 9     
I-kappa-B kinase beta (S181) IKKb Lane 9 49 43 Control -12% 
Lyn (Y507) (44) Lyn (44) Lane 20 214 184 Control -14% 
Lyn (Y507) (46) Lyn (46) Lane 20 108 50 Control -54% 
MAP kinase activated protein kinase 2 (T334) 
MAPKAPK2 Lane 
17     
MAP kinase interacting kinase 1 (T197/202) Mnk1 Lane 4     
MAPK/Erk kinase 1/2 (S217/221) MEK1/2 Lane 12 74 25 Control -66% 
MKK3/6(1) (S189/S207) MKK3/6 Lane 10     
MKK6(2) (S207) MKK6 Lane 10 69 85 Control 23% 
p38 MAPK (T180/Y182) p38a MAPK Lane 4     
p70 S6 kinase (T389) S6Ka p70 Lane 19     
p70 S6 kinase (T421/T424) S6Ka p70 Lane 17     
p85 S6 kinase 2 (T412) S6K2 p85 Lane 19     
p85 S6 kinase 2 (T444/S447) S6K2 p85 Lane 17     
Phosphoinositide-dependent protein kinase 1 (S241) PDK1 Lane 13 241 507 Control 110% 
PKC-related kinase 1 (T778) PRK1 Lane 13 488 555 Control 14% 
PKC-related kinase 2 (T816) PRK2 Lane 13 54 93 Control 72% 
Protein kinase B (T308) 
PKBa (Akt1) Lane 
11     
Protein kinase C alpha/beta (T638) PKCa/b Lane 6 115 104 Control -10% 
Protein kinase C delta (T505) PKCd Lane 14 113 129 Control 14% 
Protein kinase C zeta (T410)/lambda (T403) PKCz/l Lane 3     
Protein kinase D (Protein kinase mu) (S916) PKCm/PKD Lane 3 60 17 Control -72% 
Protein kinase theta (T538) PKCt Lane 10     
Raf (S259) (60) Raf1 (60) Lane 8 127 124 Control -2% 
Raf (S259) (70) Raf1 (70) Lane 8 114 98 Control -14% 
Retinoblastoma Protein (S780) Rb Lane 18 271 209 Control -23% 
Retinoblastoma Protein (S807/S811) Rb Lane 7     
The mammalian target of Rapamycin (S2448) mTOR Lane 13 33 21 Control -36% 
Type1 protein phosphatase alpha (T320) PP1a Lane 8     
Zap70 (Y319)/Syk (Y352) Zap70/Syk Lane 20     
 
Table 2: Phosphorylation profiling in wild-type and transgenic mIGF-1 heart tissue. 
Phosphoprotein screen of 31 phopshoproteins in wild-type and transgenic heart tissues 
was performed by Kinetworks analysis (Kinexus Bioinformatic Corp.). The trace 
quantity of each band is defined as CPM and is measured under its intensity profile 
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curve. Each value is normalized by the amount of protein in each sample. Each lane 
corresponds to a specific protein and the phosphorylated Tyrosine or Serine position 
is indicated. Transgenic increase or decrease of band intensity compared to wild-type 
(control) is expressed in percentage.  
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Echocardiography 13 week-old 23 week-old 
 NTG (n=8) TG (n=8) NTG (n=8) TG (n=8) 
LVM (mg) 98±5 119±6* 101±3 118±4* 
LWM/BW (mg/g) 3.1±0.1 3.8±0.2* 2.9±0.1 3.3±0.2 
S (mm) 0.73±0.01 0.82±0.03* 0.74±0.02 0.84±0.02* 
PW (mm) 0.59±0.02 0.70±0.02* 0.64±0.02 0.70±0.01* 
LVEDD (mm) 4.17±0.11 4.19±0.08 4,10±0.06 4,13±0.13 
LVESD (mm) 2.76±0.10 3.03±0.07* 2,64±0.06 2.82±0.15 
FS (%) 34±1 27±1* 35±1 32±2 
EF (%) 69±2 60±2* 71±2 66±3 
CO (ml/min) 26±1 28±2 38±3 31±3 
E/A 1.61±0.08 1.27±0.11* 1,49±0.08 1.21±0.07* 
Adur (ms) 35±1 40±1* 37±1 41±2* 
DT (ms) 41±1.7 43±0.8 42±2.1 46±1.1* 
IVRT (ms) 21±1 24±1 25±2 26±2 
RV/LV nd nd 0.25±0.02 0.3±0.01* 
 
 
 
Table 2: NTG: non transgenic, TG: transgenic, SAP: systolic arterial pressure, HR: 
heart rate, PR: PR interval, QT: QT interval, LVM: left ventricular mass, BW: body 
weight, S: septal thickness, PW: posterior wall thickness, LVEDD: left ventricular 
end-diastolic diameter, LVESD: left ventricular end-systolic diameter, FS: fractional 
shortening, EF: ejection fraction, CO: cardiac output, E/A: maximal speed of early on 
late mitral filling ratio, Adur: duration of the mitral A wave, DT: mean deceleration 
time of the E wave, IVRT: isovolumetric relaxation time and RV/LV: right to left 
ventricular diameters ratio. Nd: not determined. 
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All results are expressed as means±sem. *: P<0.05 (paired Student’s t tests for 
comparisons). Representative electrocardiograms obtained in non-transgenic (NTG) 
and IGF-1 transgenic (TG) mice in the D2 derivation. The plain arrows indicate the P 
waves that are amplified in the transgenic mice. The dotted arrows indicate a 
prolongation and non-homogenous depolarization of the ventricles in the TG mouse. 
 
 
 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VI 
 
DISCUSSION 
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The present study has revealed an intriguing function of local IGF-1 expression in the 
heart. We characterise for the first time the in vivo role at morphological and 
molecular level of the local IGF-1 isoform, mIGF-1, describing the physiological and 
pathological function of this isoform in remodeling cardiac muscle. We showed that 
germline mIGF-1 overexpression induces increased size of the entire heart during the 
first 4 months of postnatal life. Intriguingly, at six months the heart size of the mIGF-
1 transgenic mice is comparable to wild-type mice, indicating an acceleration of the 
remodeling program occurring normally in the heart during adult development. The 
morphological phenotype was related to an increased expression of specific markers 
associated with cardiac hypertrophy, such as ANP, and to a time-dependent activation 
of MAPKs. The continuous remodeling of the mIGF-1 heart during work-load activity 
is sustained by activation of the translational machinery during all phases of heart 
development.  
 
The mIGF-1 transgenic action also induces heart healing after myocardial infarction. 
We observed that heart remodeling under this pathological condition is triggered by 
an early step, characterised by lowering of the pro-inflammatory response and an 
increase of the signaling leading to anti-inflammatory pathways, and of a late step, 
occurring 1 month after infarct induction, where a massive increase of proliferating 
cells has been found around the infarct area.  
 
1. Local IGF-1 overexpression leads to physiological hypertrophy and to 
activation of MAPKs in a well-defined time-window 
Cardiac remodeling occurs during post-natal development to maintain a balance 
between physiological demands for contractile work and the capability of muscle 
tissue to meet those demands (119, 120).  In pathological conditions, remodeling 
responses impair contractile performance, leading to dilated cardiomyopathy and 
myocardium infarction (119, 120). To elucidate whether the hypertrophic phenotype 
in mIGF-1 transgenic hearts could lead to pathological conditions, we performed 
echocardiography analysis. Measurement of cardiac function by echocardiography 
and electrocardiography (Table 2) showed that mIGF-1 induces a 20% concentric left 
ventricular hypertrophy, confirming the histological analysis (Table 2 and Figure 
5.1A, B). Although systolic and diastolic components of the cardiac function were 
affected, the hearts were not dilated and cardiac output and blood pressure were 
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maintained normal and not reduced during development (Table 2). Affymetrix 
analysis performed in our laboratory (data not shown), revealed an upregulation in the 
transgenic hearts of genes implicated in contractile machinery, such as Troponin C, 
myosin heavy chain 2X, and myosin heavy chain IIX. We hypothesize that regulation 
of myosin expression could account for the hypertrophic response observed in hearts 
overexpressing mIGF-1. At the age of six months EKG analysis showed a comparable 
ratio heart weight/body weight, although the posterior wall and the septum remained 
larger compared to wild-type hearts (Table 2). 
 
MAPK signaling provides an important link between the external stimuli and the 
nucleus via phosphorylation and regulation of multiple transcription factors. 
Mechanical stretch, growth factors, and G-protein coupled receptor (GPCR) agonists 
activate MAPK signaling (328), using MAPK pathways as a nodal point in regulating 
cell growth and hypertrophy during heart development. Despite the critical 
importance of MAPK function in inducing cardiac hypertrophy in vitro and in vivo 
(329, 330) (Chapter 1), different reports linked MAPKs activation to maladaptive 
hypertrophy. A recent publication reported that transgenic mice overexpressing 
MEK1, which is a direct activator of ERK1/2, showed a hypertrophic phenotype 
associated with impaired diastolic function (173). Moreover, vascular MAPK 
activities in hypertensive rats in vivo (331) is accompanied by increased activity of 
aortic ERKs and JNKs, suggesting the involvement of hypertension in the activation 
of MAPKs.  
 
Our analysis showed that mIGF-1 induces activation of ERK1/2 and JNK at one week 
of age. In parallel to induction of JNK activity, we observed an increasing 
phosphorylation level of c-jun, which is one of the downstream target of the JNK 
pathway. The MAPK activation is related to a specific time-window of transgenic 
hearts development, since it was not observed in hearts of two weeks and one months 
of age (Figure 5.3A). The transient activation of this signaling could thus account for 
the physiological hypertrophy observed by histological and ecocardiographic analysis. 
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2. mIGF-1 overexpression is related to activation of phospho-S6 ribosomal 
protein   
Our data show that mIGF-1 induces sustained phosphorylation levels of S6 ribosomal 
protein during postnatal heart development (Figure 5.3C). S6 ribosomal protein is a 
downstream target of the p70S6 kinase, which is activated in response to nutrients 
and/or to activation of the insulin receptor through a well-defined signaling cascade 
(266, 332, 333). Upon activation of the S6 ribosomal protein, the translational 
machinery of the cell synthesizes ex novo proteins, as well as ribosomal proteins that 
cover the needs of an upregulated translational capacity. Both hypertrophic growth 
and cell proliferation are characterised by increased proteins synthesis. 
 
In skeletal muscle, as described in Chapter II, muscle growth and hypertrophy are 
mediated by activation of the AKT/mTOR pathway, leading to upregulation of the 
translational machinery (137). Previous studies indicate that IGF-1 induces skeletal 
myotube hypertrophy by the PI3K/AKT/mTOR pathway. Compelling evidence 
coming from lower organisms such as Drosophila Melanogaster, showed that loss or 
inhibition of either PI3K, mTOR or p70S6K resulted in decrease of cell size (134). 
Conversely, overexpression of the insulin receptor substrate IRS-1 or AKTor p70S6K 
was sufficient to cause hypertrophy of cells in which they were expressed (138, 139). 
This growth effect appears to be functionally conserved in mammals, as p70S6K 
knockout mice have reduced body size and cell growth (141).  
 
The sustained activation of the translational machinery observed in mIGF-1 
overexpressing hearts suggested that a continuous need of ex novo protein synthesis is 
required to maintain the rapid growth and remodeling of the mIGF-1 transgenic heart. 
However, as previously emphasized, the precise pathway in mammalian cells 
connecting PI3K to the activation of p70S6K and the translational machinery is a 
matter of some dispute (134). It is interesting to note that, independently from AKT, 
PDK1 has been found to directly phosphorylate p70S6K (324), indicating that AKT 
has a dispensable role for signaling to p70S6K. Interestingly, our data showed that the 
phosphorylation state of AKT is not affected (Figure 5.3C and Table 1), and it is not 
regulated in parallel to activation of S6 ribosomal protein. On the contrary, the mIGF-
1 transgene induced increased activity of PDK1 (Table 1). 
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Together with the data mentioned above, the phosphoprotein profile (Table 1) opened 
an interesting field of analysis, since several phoshpoproteins are regulated by mIGF-
1. Among them, PKC-related kinase 2 was strongly activated in transgenic hearts 
(Table 1), whereas the phosphorylation level of Lyn and Protein Kinase D are lower 
in mIGF-1 transgenic hearts compared to wild-type. Whether these different signals 
play a role in hypertrophy and/or regeneration after myocardial infarct has to be 
analyzed in detail. Nevertheless, the possibilities arising from our studies uncover a 
new physiologically activated targets of mIGF-1 signaling. 
 
3. mIGF-1 induces cardiac regeneration after CTX injury by lowering the pro-
inflammatory response and inducing cell proliferation 
Although hypertrophy can increase cell mass in response to stress, it is inadequate to 
restore cardiac function following myocyte loss during myocardial infarction and 
ischemia-reperfusion. In contrast to skeletal muscle, which can regenerate following 
injury, the mammalian heart has limited restorative capacity.  
 
The regenerative potential of myocardium is of particular interest, as myocardial 
infarction is one of the main diseases in humans. The incredible capacity of the MRL 
mice to prevent scar formation and to heal injured tissues, opens the possibility to use 
this animal model as a potential font of genetic studies to understand the molecular 
mechanisms of regeneration in mammalian tissues. Interestingly, genetic analyses of 
MRL mice suggested that the process of regenerative growth and patterning for the 
formation of new structures involves modulation of the inflammatory response and 
changes in the cytokines signaling (304).  
 
To study the regenerative function of mIGF-1, wild-type and transgenic hearts were 
injected with a sublethal dose of CTX venom. The cobra toxin from Naja mossambica 
mossambica is known to cause muscle necrosis (334). The cardiotoxin model was 
chosen over other models of myocardial lesion because it produces a well-delineated 
transmural lesion, and reduces the risk of ventricular fibrillation (335). Intriguingly, 
our analysis revealed that one month after CTX injection the transgenic hearts 
completely regenerated the injured tissue, while wild-type hearts showed evident scar 
formation (Figure 5.4B, and C). From these data, we can argue that the recovery of 
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the mIGF-1 transgenic hearts could be due in part to the limited extension of CTX-
induced injury.  
 
Modulation of specific anti-apoptotic proteins as a protective mechanism could 
account for mIGF-1-induced cell survival. Interestingly, our analysis showed no 
differences in the apoptotic profile (data not shown) measured by the presence of 
apoptotic nuclei in TUNEL staining, and by the expression of specific pro- and anti-
apoptotic markers, such as caspase 3, Bcl-2, Bax and Bcl-XL (data not shown). On 
the other hand, it has been reported that myocardial necrosis triggers Complement 
activation, free radical generation, chemokine upregulation, and cytokine cascades 
(325). Our data showed that the mRNA levels of the anti-inflammatory cytokines 
IL10 and IL4 are upregulated at 24 hours and one week after CTX injection, whereas 
wild-type hearts did not show changing in the anti-inflammatory interleukins, beside a 
slight decrease of IL10 in response to injury (Figure 5.5B). Interestingly, the pro-
inflammatory IL6 was downregulated in the mIGF-1transgenic hearts compared to 
wild-type hearts at 24 hours after CTX injection, as analyzed by reverse transcriptase 
PCR (Figure 5.5B). No change was observed for IL1β, or other markers of 
inflammation, such as IL12, TGF-β, and INF-γ (data not shown), indicating a specific 
response of the heart to infarction.   
 
The regenerative process implicates a clear restoration of tissue integrity without scar 
formation. Several possibilities could explain the complete restructuring of 
myocardial tissue by mIGF-1. One mechanism could involve activation of MMPs that 
reduce fibrotic tissue forming around the injured area. Collagen release is a 
continuous process that has been observed to be present in the infarcted area for 
months in rats, and years in humans (198), becoming deleterious for heart 
functionality when overactivated. Our analysis showed that neither MMP2 nor MMP9 
were activated by mIGF-1 during the early and late steps of tissue regeneration (data 
not shown), indicating that these specific MMPs are not involved in mIGF-1 
signaling, but not excluding the possibility that other MMPs may play an important 
role.  
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Another mechanism may involve proliferation of cells that constitute the structure of 
the heart, such as cardiomyocytes and endothelial cells, able to re-populate the 
infarcted area with newly forming cells. Our data showed clearly the mIGF-1 induced 
increased cell proliferation around the infarcted area compared to wild-type hearts, 
but only after one month after CTX injection (Figure 5.6A, B, C).  Cardiomyocytes 
and endothelial cells incorporated BrdU at the border of the injured tissue (Figure 
5.7A), although further analyses are necessary to quantify and better characterise the 
proliferative capacity of these cells. 
 
A fascinating hypothesis comes from our analysis on stem cells present in wild-type 
and transgenic hearts, as described in Chapter VII. We found that mIGF-1 hearts and 
wild-type hearts contain an enriched CD34+ side population (SP), and that mIGF-1 
overexpression recruits an increasing number of these cells into the heart. The CD34+ 
cells have the ability to form colonies composed of myeloid and erythroid cells,when 
plated in a media enriched for factors stimulating differentiation of all components of 
blood. It will be interesting in the future to analyse whether these cells contribute to 
tissue replacement upon CTX injection, and whether mIGF-1 could induce their 
proliferative and differentiation response to injury. Whatever the underlying 
mechanism, our data showed that mIGF-1 overexpression induces specific signaling 
implicated in heart remodeling, which is not associated with maladaptive processes, 
and highlights an intriguing function of mIGF-1 in pathological conditions as a 
regenerative factor. 
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CHAPTER VII 
 
FUTURE DIRECTIONS: mIGF-1 AND STEM 
CELLS RECRUITMENT 
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1. STEM CELLS: A HOPE FOR AMBITIOUS SCIENTISTS 
mIGF-1 is a potent regenerative agent, mediating the recruitment of bone marrow 
cells to sites of tissue damage, and augmenting local repair mechanisms (1). The 
concept that enhanced myocardial repair induced by overexpression of mIGF-1 in the 
heart could depend in part on the recruitment of stem cells at the injured site, was 
verified by these studies.  
 
Several practical difficulties were encountered in this analysis. One problem was 
represented by the impossibility to study a FACS dot plot profile in adult hearts, 
where extraction of total heart cells, although possible, is not optimized and 
compatible with the requirement of the FACS machine.  Another impediment was that 
whereas adult hearts were successful in the analysis, CTX injection in one month old 
mice induced high mortality, with consequent impairment of statistical significance in 
each experiment. Thus, our analysis was performed on 2 days postnatal hearts in 
physiological conditions. 
 
Briefly, hearts were excised and deeply washed with PBS to remove the excess of 
blood. The hearts were then digested at 37°C with a mixture of collagenase type II 
and pancreatin at 95 U/ml and 0.6 mg/ml respectively. All cells were stained by 
Hoechst (10µg/ml each 106 cells) at 37°C for 90 minutes. Whether necessary, cells 
where treated with Verapamil at 50µM to block the MDR-mediated efflux of Hoechst 
dye, or with antibodies specific for different lineages at 1:50. Sca1-FITC, c-Kit-PE, 
CD34-FITC, CD71-PE, FLK1-PE and CD45-CY-Chrome were all purchased from 
Pharmingen. FITC-, PE-, and CY-Chrome-Rat IgG2b (Pharmingen) were used as 
control antibodies. The analysis was performed with MoFlo triple-laser flow 
cytometer and SUMMIT software (Cytomation, Fort Collins, CO), at the Santa Lucia 
Research Center in Rome, thanks to the generous assistance of Dr. Giovanna 
Borsellino. To test their ability to differentiate in hematopoietic cell colonies, side 
population (SP) cells were sorted and plated in Methocult (Stem cell technology, Inc), 
 
Our results showed that heart, like bone marrow, contains a side population (SP), 
which is considered to be the “stem-like” cell population (Figure 7.1A). Interestingly, 
we found that mIGF-1 transgenic hearts contain a mean percentage of cells in the SP 
 111 
double compared to wild-type hearts (3.1%+/-1.1%) (Figure 7.1A). All the cells of the 
heart express CD45, c-kit, Sca1, CD71, CD34 and FLK1 (Figure7.1B, 7.2A), but the 
heart SP is only positive for MDR1, as tested by sensitivity to verapamil (Figure 
7.1A), and CD34 (Figure 7.1C, 7.2B), indicating that the supposed stem cell markers 
are widely expressed in other cell types (336), and that the SP of the heart is 
specifically marked by an endothelial and/or hematopoietic lineage. On the basis of 
recent publications, Sca-1+ cells and c-Kit+ cells have confined clonogenicity and 
transdifferentiative potentiality (316, 317) among the stem cells isolated and/or 
studied in the heart. Whether CD34+ cells retain multipotentiality is still unclear, 
although a preliminary result showed clearly hematopoietic trans-differentiation 
capacity (Figure 7.1D), without distinction between wild-type and transgenic cells. 
Interestingly, in addition to these data, we found that mIGF-1 induced overexpression 
of MCP-2, a known chemoattractant of myeloid cells, in all stages of heart 
development (Figure 7.3A), and that in adult heart mIGF-1 overexpression correlates 
with increasing amount of CD11b positive cells (Figure 7.3B).   
 
We can argue from these preliminary data, that mIGF-1 expression recruits to the 
developing heart CD34+ cells and cells positive for myeloid markers. Whether the 
two cells represent the same population or whether these two populations separately 
contribute to the regenerative potentiality of the transgene is under investigation. To 
date, the usage of bone marrow cells is under intense investigation, and clinical 
approaches already claim the potentiality of autologous bone marrow stem cells to 
repair an infarcted heart. Moreover, intense research is now focusing on the usage of 
cardiac stem cells and/or engineered skeletal muscle cells that can graft easily in the 
heart and become functional units of this organ.  It is notable that populations of bone 
marrow stem cells, as well as of possible cardiac stem cells, are both composed of 
heterogeneous cells that are usually represented by several different cell membrane 
markers or intracellular differentiation lineage markers. The potentiality of single cell 
types is difficult to trace, although several studies provided convincing results on this 
matter (337). Therefore, whether the pluripotency of one cell or of a heterogeneous 
group of cells markedly improve tissue functionality is still unclear. 
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 From our analysis, we would like to propose an alternative strategy to heal a 
damaged tissue, which employs the usage of genetic modified myeloid cells, bearing 
mIGF-1 transgene under the control of a cardiac-specific promoter. The innate ability 
of these cells to home into damaged muscles constitutes a natural vehicle to deliver 
genes in target tissues. Once incorporated into the damaged muscle bed, activation of 
cardiac-specific mIgf-1 gene in the fused or transdifferentiated myeloid nuclei will 
enhance subsequent recruitment and incorporation of additional circulating cells or 
resident cells, mediating heart regeneration.  
 
A hope to mend a broken heart… 
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Figure 7.3: mIGF-1-mediated recruitment of CD11b+ cells. A) RT-PCR of monocyte chemoattractant
protein 2 (MCP2) during postnatal development; B) Immunostaining of 4 months old hearts with CD11b
antibody, recognizing monocytes, NK cells, and leukocytes.
CONTROL
CONTROL
CD11b STAINING WT
TG
2D
 T
G
2W
 W
T
115
 116 
REFERENCES 
 
1. A. Musaro et al., Proc Natl Acad Sci U S A 101, 1206 (Feb 3, 2004). 
2. A. Musaro et al., Nat Genet 27, 195 (Feb, 2001). 
3. M. C. DeRuiter, R. E. Poelmann, I. VanderPlas-de Vries, M. M. Mentink, A. 
C. Gittenberger-de Groot, Anat Embryol (Berl) 185, 461 (1992). 
4. J. M. Icardo, J Exp Zool 275, 144 (Jun 1-15, 1996). 
5. F. J. Manasek, J Morphol 125, 329 (Jul, 1968). 
6. M. C. Fishman, K. R. Chien, Development 124, 2099 (Jun, 1997). 
7. D. Srivastava, E. N. Olson, Nature 407, 221 (Sep 14, 2000). 
8. P. P. Tam, M. Parameswaran, S. J. Kinder, R. P. Weinberger, Development 
124, 1631 (May, 1997). 
9. D. Y. Stainier, R. K. Lee, M. C. Fishman, Development 119, 31 (Sep, 1993). 
10. R. K. Lee, D. Y. Stainier, B. M. Weinstein, M. C. Fishman, Development 120, 
3361 (Dec, 1994). 
11. M. Heikinheimo, J. M. Scandrett, D. B. Wilson, Dev Biol 164, 361 (Aug, 
1994). 
12. T. P. Yamaguchi, D. J. Dumont, R. A. Conlon, M. L. Breitman, J. Rossant, 
Development 118, 489 (Jun, 1993). 
13. T. J. Lints, L. M. Parsons, L. Hartley, I. Lyons, R. P. Harvey, Development 
119, 419 (Oct, 1993). 
14. F. Charron, M. Nemer, Semin Cell Dev Biol 10, 85 (Feb, 1999). 
15. K. Gajewski, N. Fossett, J. D. Molkentin, R. A. Schulz, Development 126, 
5679 (Dec, 1999). 
16. J. F. Reiter et al., Genes Dev 13, 2983 (Nov 15, 1999). 
17. M. Koutsourakis, A. Langeveld, R. Patient, R. Beddington, F. Grosveld, 
Development 126, 723 (May, 1999). 
18. J. D. Molkentin, Q. Lin, S. A. Duncan, E. N. Olson, Genes Dev 11, 1061 (Apr 
15, 1997). 
19. C. T. Kuo et al., Genes Dev 11, 1048 (Apr 15, 1997). 
20. J. D. Molkentin, K. M. Tymitz, J. A. Richardson, E. N. Olson, Mol Cell Biol 
20, 5256 (Jul, 2000). 
21. F. Charron, P. Paradis, O. Bronchain, G. Nemer, M. Nemer, Mol Cell Biol 19, 
4355 (Jun, 1999). 
 117 
22. C. Grepin, L. Robitaille, T. Antakly, M. Nemer, Mol Cell Biol 15, 4095 (Aug, 
1995). 
23. N. Narita, M. Bielinska, D. B. Wilson, Dev Biol 189, 270 (Sep 15, 1997). 
24. R. P. Harvey, Dev Biol 178, 203 (Sep 15, 1996). 
25. B. G. Bruneau et al., Dev Biol 217, 266 (Jan 15, 2000). 
26. I. Lyons et al., Genes Dev 9, 1654 (Jul 1, 1995). 
27. M. Tanaka, Z. Chen, S. Bartunkova, N. Yamasaki, S. Izumo, Development 
126, 1269 (Mar, 1999). 
28. C. C. Wang et al., Dev Biol 224, 152 (Aug 15, 2000). 
29. M. Tanaka, N. Yamasaki, S. Izumo, Mol Cell Biol 20, 2874 (Apr, 2000). 
30. D. Wang et al., Cell 105, 851 (Jun 29, 2001). 
31. Y. Saga et al., Development 126, 3437 (Aug, 1999). 
32. S. Kitajima, A. Takagi, T. Inoue, Y. Saga, Development 127, 3215 (Aug, 
2000). 
33. A. Redkar, M. Montgomery, J. Litvin, Development 128, 2269 (Jun, 2001). 
34. M. V. de la Cruz et al., Cardiol Young 11, 588 (Nov, 2001). 
35. Z. Z. Bao, B. G. Bruneau, J. G. Seidman, C. E. Seidman, C. L. Cepko, Science 
283, 1161 (Feb 19, 1999). 
36. R. J. Garriock, S. A. Vokes, E. M. Small, R. Larson, P. A. Krieg, Dev Genes 
Evol 211, 257 (May, 2001). 
37. B. G. Bruneau et al., Mol Cell Biol 21, 1730 (Mar, 2001). 
38. G. F. Wang, W. Nikovits, Jr., Z. Z. Bao, F. E. Stockdale, J Biol Chem 276, 
28835 (Aug 3, 2001). 
39. H. Kokubo, Y. Lun, R. L. Johnson, Biochem Biophys Res Commun 260, 459 
(Jul 5, 1999). 
40. O. Nakagawa, M. Nakagawa, J. A. Richardson, E. N. Olson, D. Srivastava, 
Dev Biol 216, 72 (Dec 1, 1999). 
41. C. Leimeister, A. Externbrink, B. Klamt, M. Gessler, Mech Dev 85, 173 (Jul, 
1999). 
42. B. G. Bruneau, Circ Res 90, 509 (Mar 22, 2002). 
43. C. Biben, R. P. Harvey, Genes Dev 11, 1357 (Jun 1, 1997). 
44. D. Srivastava et al., Nat Genet 16, 154 (Jun, 1997). 
 118 
45. T. Thomas, H. Yamagishi, P. A. Overbeek, E. N. Olson, D. Srivastava, Dev 
Biol 196, 228 (Apr 15, 1998). 
46. A. B. Firulli, D. G. McFadden, Q. Lin, D. Srivastava, E. N. Olson, Nat Genet 
18, 266 (Mar, 1998). 
47. P. Riley, L. Anson-Cartwright, J. C. Cross, Nat Genet 18, 271 (Mar, 1998). 
48. P. R. Riley, M. Gertsenstein, K. Dawson, J. C. Cross, Dev Biol 227, 156 (Nov 
1, 2000). 
49. H. Yamagishi et al., Dev Biol 239, 190 (Nov 15, 2001). 
50. B. G. Bruneau et al., Dev Biol 211, 100 (Jul 1, 1999). 
51. C. M. Liberatore, R. D. Searcy-Schrick, K. E. Yutzey, Dev Biol 223, 169 (Jul 
1, 2000). 
52. B. G. Bruneau et al., Cell 106, 709 (Sep 21, 2001). 
53. S. Angelo et al., Mech Dev 95, 231 (Jul, 2000). 
54. D. Yelon et al., Development 127, 2573 (Jun, 2000). 
55. Q. Lin, J. Schwarz, C. Bucana, E. N. Olson, Science 276, 1404 (May 30, 
1997). 
56. Y. Qiu et al., Genes Dev 11, 1925 (Aug 1, 1997). 
57. P. J. Gage, H. Suh, S. A. Camper, Development 126, 4643 (Oct, 1999). 
58. K. Kitamura et al., Development 126, 5749 (Dec, 1999). 
59. C. R. Lin et al., Nature 401, 279 (Sep 16, 1999). 
60. M. F. Lu, C. Pressman, R. Dyer, R. L. Johnson, J. F. Martin, Nature 401, 276 
(Sep 16, 1999). 
61. C. T. Basson et al., Nat Genet 15, 30 (Jan, 1997). 
62. C. T. Basson et al., Proc Natl Acad Sci U S A 96, 2919 (Mar 16, 1999). 
63. Q. Y. Li et al., Nat Genet 15, 21 (Jan, 1997). 
64. S. J. Cross et al., J Med Genet 37, 785 (Oct, 2000). 
65. N. Fossett, R. A. Schulz, Trends Cardiovasc Med 11, 185 (Jul, 2001). 
66. S. G. Tevosian et al., Cell 101, 729 (Jun 23, 2000). 
67. A. F. Stewart et al., J Biol Chem 269, 3147 (Feb 4, 1994). 
68. Z. Chen, G. A. Friedrich, P. Soriano, Genes Dev 8, 2293 (Oct 1, 1994). 
69. C. B. Moens, B. R. Stanton, L. F. Parada, J. Rossant, Development 119, 485 
(Oct, 1993). 
70. Y. Hiroi et al., Nat Genet 28, 276 (Jul, 2001). 
 119 
71. H. Kuo et al., Development 126, 4223 (Oct, 1999). 
72. H. Shiratori et al., Mol Cell 7, 137 (Jan, 2001). 
73. Y. Zou et al., Development 124, 793 (Feb, 1997). 
74. L. Li, Z. Liu, B. Mercer, P. Overbeek, E. N. Olson, Dev Biol 187, 311 (Jul 15, 
1997). 
75. P. S. Chang, L. Li, J. McAnally, E. N. Olson, J Biol Chem 276, 17206 (May 
18, 2001). 
76. D. Durocher, M. Nemer, Dev Genet 22, 250 (1998). 
77. E. C. Svensson et al., Nat Genet 25, 353 (Jul, 2000). 
78. C. L. Cai et al., Dev Cell 5, 877 (Dec, 2003). 
79. R. G. Kelly, N. A. Brown, M. E. Buckingham, Dev Cell 1, 435 (Sep, 2001). 
80. R. G. Kelly, M. E. Buckingham, Trends Genet 18, 210 (Apr, 2002). 
81. K. L. Waldo et al., Development 128, 3179 (Aug, 2001). 
82. M. D. Schneider, V. Gaussin, K. M. Lyons, Cytokine Growth Factor Rev 14, 1 
(Feb, 2003). 
83. T. M. Schultheiss, J. B. Burch, A. B. Lassar, Genes Dev 11, 451 (Feb 15, 
1997). 
84. Y. Shi, S. Katsev, C. Cai, S. Evans, Dev Biol 224, 226 (Aug 15, 2000). 
85. E. N. Olson, M. D. Schneider, Genes Dev 17, 1937 (Aug 15, 2003). 
86. A. J. Harwood, Cell 105, 821 (Jun 29, 2001). 
87. S. Zaffran, M. Frasch, Circ Res 91, 457 (Sep 20, 2002). 
88. M. J. Marvin, G. Di Rocco, A. Gardiner, S. M. Bush, A. B. Lassar, Genes Dev 
15, 316 (Feb 1, 2001). 
89. E. Tzahor, A. B. Lassar, Genes Dev 15, 255 (Feb 1, 2001). 
90. V. A. Schneider, M. Mercola, Genes Dev 15, 304 (Feb 1, 2001). 
91. P. Pandur, M. Lasche, L. M. Eisenberg, M. Kuhl, Nature 418, 636 (Aug 8, 
2002). 
92. C. A. Eisenberg, R. G. Gourdie, L. M. Eisenberg, Development 124, 525 (Jan, 
1997). 
93. C. A. Eisenberg, L. M. Eisenberg, Dev Dyn 216, 45 (Sep, 1999). 
94. P. Kastner et al., Development 124, 4749 (Dec, 1997). 
95. H. M. Sucov et al., Genes Dev 8, 1007 (May 1, 1994). 
96. J. Chen, S. W. Kubalak, K. R. Chien, Development 125, 1943 (May, 1998). 
 120 
97. C. M. Tran, H. M. Sucov, Development 125, 1951 (May, 1998). 
98. J. Xavier-Neto et al., Development 126, 2677 (Jun, 1999). 
99. K. Niederreither et al., Development 128, 1019 (Apr, 2001). 
100. Y. Y. Zhao et al., J Biol Chem 273, 10261 (Apr 24, 1998). 
101. K. F. Lee et al., Nature 378, 394 (Nov 23, 1995). 
102. M. Gassmann et al., Nature 378, 390 (Nov 23, 1995). 
103. S. A. Crone, K. F. Lee, Ann N Y Acad Sci 971, 547 (Oct, 2002). 
104. M. H. Soonpaa, L. J. Field, Am J Physiol 272, H220 (Jan, 1997). 
105. F. J. Clubb, Jr., S. P. Bishop, Lab Invest 50, 571 (May, 1984). 
106. V. Baldin, J. Lukas, M. J. Marcote, M. Pagano, G. Draetta, Genes Dev 7, 812 
(May, 1993). 
107. S. X. Skapek, J. Rhee, D. B. Spicer, A. B. Lassar, Science 267, 1022 (Feb 17, 
1995). 
108. X. Q. Qin et al., Mol Cell Biol 15, 742 (Feb, 1995). 
109. M. H. Soonpaa, K. K. Kim, L. Pajak, M. Franklin, L. J. Field, Am J Physiol 
271, H2183 (Nov, 1996). 
110. E. Zacksenhaus et al., Genes Dev 10, 3051 (Dec 1, 1996). 
111. H. L. Weiner, J. L. Swain, Proc Natl Acad Sci U S A 86, 2683 (Apr, 1989). 
112. X. Zhu, J. Sasse, D. McAllister, J. Lough, Dev Dyn 207, 429 (Dec, 1996). 
113. T. Mima, H. Ueno, D. A. Fischman, L. T. Williams, T. Mikawa, Proc Natl 
Acad Sci U S A 92, 467 (Jan 17, 1995). 
114. Y. Liu et al., Lab Invest 73, 771 (Dec, 1995). 
115. P. Anversa, T. Palackal, E. H. Sonnenblick, G. Olivetti, J. M. Capasso, J Clin 
Invest 85, 994 (Apr, 1990). 
116. K. Reiss et al., Exp Cell Res 225, 44 (May 25, 1996). 
117. M. A. Pfeffer, C. H. Hennekens, Am J Cardiol 75, 1173 (Jun 1, 1995). 
118. J. M. Pfeffer, T. A. Fischer, M. A. Pfeffer, Annu Rev Physiol 57, 805 (1995). 
119. N. Frey, E. N. Olson, Annu Rev Physiol 65, 45 (2003). 
120. W. R. MacLellan, M. D. Schneider, Annu Rev Physiol 62, 289 (2000). 
121. J. D. Molkentin, I. G. Dorn, 2nd, Annu Rev Physiol 63, 391 (2001). 
122. S. Miyata, W. Minobe, M. R. Bristow, L. A. Leinwand, Circ Res 86, 386 (Mar 
3, 2000). 
123. N. Frey, T. A. McKinsey, E. N. Olson, Nat Med 6, 1221 (Nov, 2000). 
 121 
124. T. Hirano, K. Nakajima, M. Hibi, Cytokine Growth Factor Rev 8, 241 (Dec, 
1997). 
125. H. Hirota et al., Cell 97, 189 (Apr 16, 1999). 
126. Z. Sheng et al., J Biol Chem 272, 5783 (Feb 28, 1997). 
127. G. L. Kukielka et al., Circulation 92, 1866 (Oct 1, 1995). 
128. H. Hirota, K. Yoshida, T. Kishimoto, T. Taga, Proc Natl Acad Sci U S A 92, 
4862 (May 23, 1995). 
129. K. Kunisada et al., Circulation 98, 346 (Jul 28, 1998). 
130. K. Kunisada et al., Proc Natl Acad Sci U S A 97, 315 (Jan 4, 2000). 
131. T. G. Parker, S. E. Packer, M. D. Schneider, J Clin Invest 85, 507 (Feb, 1990). 
132. E. Piek, C. H. Heldin, P. Ten Dijke, Faseb J 13, 2105 (Dec, 1999). 
133. T. Shioi et al., Mol Cell Biol 22, 2799 (Apr, 2002). 
134. D. J. Glass, Nat Cell Biol 5, 87 (Feb, 2003). 
135. M. C. Delaughter, G. E. Taffet, M. L. Fiorotto, M. L. Entman, R. J. Schwartz, 
Faseb J 13, 1923 (Nov, 1999). 
136. K. Reiss et al., Proc Natl Acad Sci U S A 93, 8630 (Aug 6, 1996). 
137. S. C. Bodine et al., Nat Cell Biol 3, 1014 (Nov, 2001). 
138. J. Montagne et al., Science 285, 2126 (Sep 24, 1999). 
139. R. Bohni et al., Cell 97, 865 (Jun 25, 1999). 
140. T. Shioi et al., Circulation 107, 1664 (Apr 1, 2003). 
141. H. Shima et al., Embo J 17, 6649 (Nov 16, 1998). 
142. C. B. Klee, H. Ren, X. Wang, J Biol Chem 273, 13367 (May 29, 1998). 
143. G. R. Crabtree, Cell 96, 611 (Mar 5, 1999). 
144. L. Sun et al., Immunity 8, 703 (Jun, 1998). 
145. M. M. Lai, P. E. Burnett, H. Wolosker, S. Blackshaw, S. H. Snyder, J Biol 
Chem 273, 18325 (Jul 17, 1998). 
146. J. D. Molkentin et al., Cell 93, 215 (Apr 17, 1998). 
147. O. F. Bueno et al., Proc Natl Acad Sci U S A 99, 4586 (Apr 2, 2002). 
148. M. A. Sussman et al., Science 281, 1690 (Sep 11, 1998). 
149. B. Ding et al., Circ Res 84, 729 (Apr 2, 1999). 
150. W. Zhang et al., Circ Res 84, 722 (Apr 2, 1999). 
151. B. Rothermel et al., J Biol Chem 275, 8719 (Mar 24, 2000). 
152. T. J. Kingsbury, K. W. Cunningham, Genes Dev 14, 1595 (Jul 1, 2000). 
 122 
153. J. J. Fuentes et al., Hum Mol Genet 9, 1681 (Jul 1, 2000). 
154. B. A. Rothermel et al., Proc Natl Acad Sci U S A 98, 3328 (Mar 13, 2001). 
155. H. W. Lim, J. D. Molkentin, Nat Med 6, 3 (Jan, 2000). 
156. H. A. Rockman, W. J. Koch, R. J. Lefkowitz, Nature 415, 206 (Jan 10, 2002). 
157. R. J. Lefkowitz, H. A. Rockman, W. J. Koch, Circulation 101, 1634 (Apr 11, 
2000). 
158. S. Engelhardt, L. Hein, U. Keller, K. Klambt, M. J. Lohse, Circ Res 90, 814 
(Apr 19, 2002). 
159. C. Gaudin et al., J Clin Invest 95, 1676 (Apr, 1995). 
160. D. M. Roth et al., Circulation 105, 1989 (Apr 23, 2002). 
161. C. L. Antos et al., Circ Res 89, 997 (Nov 23, 2001). 
162. G. W. Dorn, 2nd, N. M. Tepe, J. N. Lorenz, W. J. Koch, S. B. Liggett, Proc 
Natl Acad Sci U S A 96, 6400 (May 25, 1999). 
163. W. J. Koch, R. J. Lefkowitz, H. A. Rockman, Annu Rev Physiol 62, 237 
(2000). 
164. P. Paradis, N. Dali-Youcef, F. W. Paradis, G. Thibault, M. Nemer, Proc Natl 
Acad Sci U S A 97, 931 (Jan 18, 2000). 
165. N. Wettschureck et al., Nat Med 7, 1236 (Nov, 2001). 
166. S. Yusuf et al., N Engl J Med 342, 145 (Jan 20, 2000). 
167. M. Ichida, T. Finkel, J Biol Chem 276, 3524 (Feb 2, 2001). 
168. J. J. Hunter, N. Tanaka, H. A. Rockman, J. Ross, Jr., K. R. Chien, J Biol Chem 
270, 23173 (Sep 29, 1995). 
169. M. Abdellatif et al., Mol Cell Biol 18, 6729 (Nov, 1998). 
170. A. Sotiropoulos, D. Gineitis, J. Copeland, R. Treisman, Cell 98, 159 (Jul 23, 
1999). 
171. P. H. Sugden, Circ Res 84, 633 (Apr 2, 1999). 
172. O. F. Bueno et al., Circ Res 88, 88 (Jan 19, 2001). 
173. O. F. Bueno et al., Embo J 19, 6341 (Dec 1, 2000). 
174. A. Clerk, A. Michael, P. H. Sugden, J Cell Biol 142, 523 (Jul 27, 1998). 
175. J. Gillespie-Brown, S. J. Fuller, M. A. Bogoyevitch, S. Cowley, P. H. Sugden, 
J Biol Chem 270, 28092 (Nov 24, 1995). 
176. G. R. Post, D. Goldstein, D. J. Thuerauf, C. C. Glembotski, J. H. Brown, J 
Biol Chem 271, 8452 (Apr 5, 1996). 
 123 
177. J. Thorburn et al., Mol Biol Cell 6, 1479 (Nov, 1995). 
178. I. Komuro et al., Faseb J 10, 631 (Apr, 1996). 
179. G. Choukroun et al., J Clin Invest 102, 1311 (Oct 1, 1998). 
180. M. T. Ramirez et al., J Biol Chem 272, 14057 (May 30, 1997). 
181. M. Yano, S. Kim, Y. Izumi, S. Yamanaka, H. Iwao, Circ Res 83, 752 (Oct 5, 
1998). 
182. Y. Wang et al., J Biol Chem 273, 5423 (Mar 6, 1998). 
183. T. Minamino et al., Proc Natl Acad Sci U S A 99, 3866 (Mar 19, 2002). 
184. G. Choukroun et al., J Clin Invest 104, 391 (Aug, 1999). 
185. T. P. Garrington, G. L. Johnson, Curr Opin Cell Biol 11, 211 (Apr, 1999). 
186. J. Han, Y. Jiang, Z. Li, V. V. Kravchenko, R. J. Ulevitch, Nature 386, 296 
(Mar 20, 1997). 
187. T. T. Yang, Q. Xiong, H. Enslen, R. J. Davis, C. W. Chow, Mol Cell Biol 22, 
3892 (Jun, 2002). 
188. Y. Jiang et al., J Biol Chem 272, 30122 (Nov 28, 1997). 
189. S. A. Cook, P. H. Sugden, A. Clerk, J Mol Cell Cardiol 31, 1429 (Aug, 1999). 
190. S. Nemoto, Z. Sheng, A. Lin, Mol Cell Biol 18, 3518 (Jun, 1998). 
191. D. Zhang et al., Nat Med 6, 556 (May, 2000). 
192. C. L. Zhang et al., Cell 110, 479 (Aug 23, 2002). 
193. T. J. Ryan et al., Circulation 100, 1016 (Aug 31, 1999). 
194. J. Honold, B. Assmus, R. Lehman, A. M. Zeiher, S. Dimmeler, Nephrol Dial 
Transplant 19, 1673 (Jul, 2004). 
195. Y. Sun, K. T. Weber, Cardiovasc Res 46, 250 (May, 2000). 
196. Y. Sun, J. Q. Zhang, J. Zhang, S. Lamparter, J Lab Clin Med 135, 316 (Apr, 
2000). 
197. A. Desmouliere, A. Geinoz, F. Gabbiani, G. Gabbiani, J Cell Biol 122, 103 
(Jul, 1993). 
198. Y. Sun, K. T. Weber, J Mol Cell Cardiol 28, 851 (May, 1996). 
199. A. Desmouliere, M. Redard, I. Darby, G. Gabbiani, Am J Pathol 146, 56 (Jan, 
1995). 
200. S. E. Campbell, L. C. Katwa, J Mol Cell Cardiol 29, 1947 (Jul, 1997). 
201. D. LeRoith, H. Werner, D. Beitner-Johnson, C. T. Roberts, Jr., Endocr Rev 16, 
143 (Apr, 1995). 
 124 
202. A. A. Butler, D. LeRoith, Endocrinology 142, 1685 (May, 2001). 
203. J. Baker, J. P. Liu, E. J. Robertson, A. Efstratiadis, Cell 75, 73 (Oct 8, 1993). 
204. J. P. Liu, J. Baker, A. S. Perkins, E. J. Robertson, A. Efstratiadis, Cell 75, 59 
(Oct 8, 1993). 
205. F. Frasca et al., Mol Cell Biol 19, 3278 (May, 1999). 
206. M. Holzenberger et al., Endocrinology 141, 2557 (Jul, 2000). 
207. J. L. Liu et al., Mol Endocrinol 12, 1452 (Sep, 1998). 
208. J. G. Simmons, J. J. Van Wyk, E. C. Hoyt, P. K. Lund, Growth Factors 9, 205 
(1993). 
209. E. C. Hoyt, J. E. Hepler, J. J. Van Wyk, P. K. Lund, DNA Cell Biol 11, 433 
(Jul-Aug, 1992). 
210. A. Shimatsu, P. Rotwein, Nucleic Acids Res 15, 7196 (Sep 11, 1987). 
211. P. K. Lund, Recent Prog Horm Res 49, 125 (1994). 
212. M. Jansen et al., Nature 306, 609 (Dec 8-14, 1983). 
213. E. C. Hoyt, J. J. Van Wyk, P. K. Lund, Mol Endocrinol 2, 1077 (Nov, 1988). 
214. M. Adamo, W. L. Lowe, Jr., D. LeRoith, C. T. Roberts, Jr., Endocrinology 
124, 2737 (Jun, 1989). 
215. J. Shemer, M. L. Adamo, C. T. Roberts, Jr., D. LeRoith, Endocrinology 131, 
2793 (Dec, 1992). 
216. J. E. Hepler, J. J. Van Wyk, P. K. Lund, Endocrinology 127, 1550 (Sep, 1990). 
217. P. Rotwein, K. M. Pollock, D. K. Didier, G. G. Krivi, J Biol Chem 261, 4828 
(Apr 15, 1986). 
218. L. S. Mathews et al., Endocrinology 123, 2827 (Dec, 1988). 
219. W. H. Daughaday et al., Nature 235, 107 (Jan 14, 1972). 
220. E. R. Froesch, J. Zapf, Prog Clin Biol Res 200, 75 (1985). 
221. A. J. D'Ercole, A. D. Stiles, L. E. Underwood, Proc Natl Acad Sci U S A 81, 
935 (Feb, 1984). 
222. T. Ludwig et al., Dev Biol 177, 517 (Aug 1, 1996). 
223. A. Louvi, D. Accili, A. Efstratiadis, Dev Biol 189, 33 (Sep 1, 1997). 
224. S. Yakar et al., Proc Natl Acad Sci U S A 96, 7324 (Jun 22, 1999). 
225. F. Lupu, J. D. Terwilliger, K. Lee, G. V. Segre, A. Efstratiadis, Dev Biol 229, 
141 (Jan 1, 2001). 
226. B. A. Barres et al., Cell 70, 31 (Jul 10, 1992). 
 125 
227. G. A. Werther, H. Cheesman, V. Russo, Brain Res 617, 339 (Jul 23, 1993). 
228. W. Ni, K. Rajkumar, J. I. Nagy, L. J. Murphy, Brain Res 769, 97 (Sep 19, 
1997). 
229. M. J. Carson, R. R. Behringer, R. L. Brinster, F. A. McMorris, Neuron 10, 729 
(Apr, 1993). 
230. J. R. O'Kusky, P. Ye, A. J. D'Ercole, J Neurosci 20, 8435 (Nov 15, 2000). 
231. D. A. Tiangco, K. C. Papakonstantinou, K. A. Mullinax, J. K. Terzis, J 
Reconstr Microsurg 17, 247 (May, 2001). 
232. S. Yakar, C. J. Rosen, Exp Biol Med (Maywood) 228, 245 (Mar, 2003). 
233. C. J. Rosen, L. R. Donahue, Proc Soc Exp Biol Med 219, 1 (Oct, 1998). 
234. J. Rubin et al., J Clin Endocrinol Metab 87, 4273 (Sep, 2002). 
235. D. Bikle et al., J Bone Miner Res 16, 2320 (Dec, 2001). 
236. M. Zhang et al., J Biol Chem 277, 44005 (Nov 15, 2002). 
237. A. Musaro, N. Rosenthal, Mol Cell Biol 19, 3115 (Apr, 1999). 
238. M. Renganathan, M. L. Messi, O. Delbono, J Biol Chem 273, 28845 (Oct 30, 
1998). 
239. M. V. Chakravarthy, M. L. Fiorotto, R. J. Schwartz, F. W. Booth, Mech 
Ageing Dev 122, 1303 (Sep, 2001). 
240. D. Dardevet, C. Sornet, D. Attaix, V. E. Baracos, J. Grizard, Endocrinology 
134, 1475 (Mar, 1994). 
241. P. E. Willis, S. G. Chadan, V. Baracos, W. S. Parkhouse, Am J Physiol 275, 
E525 (Sep, 1998). 
242. A. De Luca, S. Pierno, D. Cocchi, D. Conte Camerino, Br J Pharmacol 121, 
369 (Jun, 1997). 
243. K. A. Woods, C. Camacho-Hubner, M. O. Savage, A. J. Clark, N Engl J Med 
335, 1363 (Oct 31, 1996). 
244. H. L. Keller, B. St Pierre Schneider, L. A. Eppihimer, J. G. Cannon, Muscle 
Nerve 22, 347 (Mar, 1999). 
245. K. M. Thrailkill et al., Diabetes Care 22, 585 (Apr, 1999). 
246. D. R. Clemmons et al., J Clin Endocrinol Metab 85, 1518 (Apr, 2000). 
247. J. I. Jones, D. R. Clemmons, Endocr Rev 16, 3 (Feb, 1995). 
248. Y. Oh, Breast Cancer Res Treat 47, 283 (Feb, 1998). 
 126 
249. L. J. Schedlich, T. F. Young, S. M. Firth, R. C. Baxter, J Biol Chem 273, 
18347 (Jul 17, 1998). 
250. V. Hwa, Y. Oh, R. G. Rosenfeld, Endocr Rev 20, 761 (Dec, 1999). 
251. E. M. Spencer, K. Chan, Prog Growth Factor Res 6, 209 (1995). 
252. B. E. Forbes et al., J Biol Chem 273, 4647 (Feb 20, 1998). 
253. J. L. Fowlkes, K. M. Thrailkill, C. George-Nascimento, C. K. Rosenberg, D. 
M. Serra, Endocrinology 138, 2280 (Jun, 1997). 
254. S. Rajaram, D. J. Baylink, S. Mohan, Endocr Rev 18, 801 (Dec, 1997). 
255. M. R. Schneider, H. Lahm, M. Wu, A. Hoeflich, E. Wolf, Faseb J 14, 629 
(Apr, 2000). 
256. V. D. Longo, C. E. Finch, Science 299, 1342 (Feb 28, 2003). 
257. H. Kato, T. N. Faria, B. Stannard, C. T. Roberts, Jr., D. LeRoith, Mol 
Endocrinol 8, 40 (Jan, 1994). 
258. K. I. Rother et al., J Biol Chem 273, 17491 (Jul 10, 1998). 
259. D. Accili, Y. Kido, J. Nakae, D. Lauro, B. C. Park, Curr Mol Med 1, 9 (Mar, 
2001). 
260. H. Stocker, E. Hafen, Curr Opin Genet Dev 10, 529 (Oct, 2000). 
261. S. Tanaka, T. Ito, J. R. Wands, J Biol Chem 271, 14610 (Jun 14, 1996). 
262. S. Oldham et al., Development 129, 4103 (Sep, 2002). 
263. T. Shioi et al., Embo J 19, 2537 (Jun 1, 2000). 
264. D. P. Brazil, B. A. Hemmings, Trends Biochem Sci 26, 657 (Nov, 2001). 
265. J. Verdu, M. A. Buratovich, E. L. Wilder, M. J. Birnbaum, Nat Cell Biol 1, 
500 (Dec, 1999). 
266. T. Schmelzle, M. N. Hall, Cell 103, 253 (Oct 13, 2000). 
267. A. Dufner, G. Thomas, Exp Cell Res 253, 100 (Nov 25, 1999). 
268. S. Oldham, J. Montagne, T. Radimerski, G. Thomas, E. Hafen, Genes Dev 14, 
2689 (Nov 1, 2000). 
269. X. Long et al., Curr Biol 12, 1448 (Sep 3, 2002). 
270. M. Hertweck, C. Gobel, R. Baumeister, Dev Cell 6, 577 (Apr, 2004). 
271. M. L. Leong, A. C. Maiyar, B. Kim, B. A. O'Keeffe, G. L. Firestone, J Biol 
Chem 278, 5871 (Feb 21, 2003). 
272. P. Kermer et al., Brain Res Mol Brain Res 85, 144 (Dec 28, 2000). 
 127 
273. H. Tran, A. Brunet, E. C. Griffith, M. E. Greenberg, Sci STKE 2003, RE5 
(Mar 4, 2003). 
274. T. N. Stitt et al., Mol Cell 14, 395 (May 7, 2004). 
275. H. Ito et al., Circulation 87, 1715 (May, 1993). 
276. R. Foncea et al., J Biol Chem 272, 19115 (Aug 1, 1997). 
277. T. Matsui et al., J Biol Chem 277, 22896 (Jun 21, 2002). 
278. V. C. Tu, J. J. Bahl, Q. M. Chen, J Pharmacol Exp Ther 300, 1101 (Mar, 
2002). 
279. M. O. Boluyt et al., Circ Res 81, 176 (Aug, 1997). 
280. J. Sadoshima, S. Izumo, Circ Res 77, 1040 (Dec, 1995). 
281. T. H. Bark, M. A. McNurlan, C. H. Lang, P. J. Garlick, Am J Physiol 275, 
E118 (Jul, 1998). 
282. A. Cittadini et al., Circulation 93, 800 (Feb 15, 1996). 
283. R. L. Duerr et al., J Clin Invest 95, 619 (Feb, 1995). 
284. D. Grimm, D. Cameron, D. P. Griese, G. A. Riegger, E. P. Kromer, 
Cardiovasc Res 40, 297 (Nov, 1998). 
285. N. C. Sundgren et al., Am J Physiol Regul Integr Comp Physiol 285, R1481 
(Dec, 2003). 
286. J. Kajstura, W. Cheng, K. Reiss, P. Anversa, Exp Cell Res 215, 273 (Dec, 
1994). 
287. Q. Li et al., J Clin Invest 100, 1991 (Oct 15, 1997). 
288. M. Buerke et al., Proc Natl Acad Sci U S A 92, 8031 (Aug 15, 1995). 
289. R. K. Avramoglu et al., J Biol Chem 273, 6057 (Mar 13, 1998). 
290. M. Y. Donath, E. R. Froesch, J. Zapf, Growth Horm IGF Res 8 Suppl B, 167 
(Apr, 1998). 
291. M. Y. Donath et al., J Clin Endocrinol Metab 83, 3177 (Sep, 1998). 
292. D. G. Johnston et al., Horm Res 38 Suppl 1, 68 (1992). 
293. A. Cuocolo et al., Eur J Nucl Med 23, 390 (Apr, 1996). 
294. R. A. Clark, G. S. Ashcroft, M. J. Spencer, H. Larjava, M. W. Ferguson, Br J 
Dermatol 135, 46 (Jul, 1996). 
295. R. J. Goss, R. Holt, J Exp Zool 261, 451 (Apr 1, 1992). 
296. J. P. Brockes, A. Kumar, Nat Rev Mol Cell Biol 3, 566 (Aug, 2002). 
297. J. O. Oberpriller, J. C. Oberpriller, J Exp Zool 187, 249 (Feb, 1974). 
 128 
298. W. S. Kim, D. L. Stocum, Dev Biol 114, 170 (Mar, 1986). 
299. E. M. Tanaka, D. N. Drechsel, J. P. Brockes, Curr Biol 9, 792 (Jul 29-Aug 12, 
1999). 
300. A. Simon, J. P. Brockes, Exp Cell Res 281, 101 (Nov 15, 2002). 
301. E. M. Tanaka, Cell 113, 559 (May 30, 2003). 
302. G. K. Michalopoulos, M. C. DeFrances, Science 276, 60 (Apr 4, 1997). 
303. J. P. Brockes, A. Kumar, C. P. Velloso, J Anat 199, 3 (Jul-Aug, 2001). 
304. M. Harty, A. W. Neff, M. W. King, A. L. Mescher, Dev Dyn 226, 268 (Feb, 
2003). 
305. K. R. Chien, E. N. Olson, Cell 110, 153 (Jul 26, 2002). 
306. M. H. Soonpaa, L. J. Field, Circ Res 83, 15 (Jul 13, 1998). 
307. A. P. Beltrami et al., N Engl J Med 344, 1750 (Jun 7, 2001). 
308. J. Kajstura et al., Proc Natl Acad Sci U S A 95, 8801 (Jul 21, 1998). 
309. F. Quaini et al., N Engl J Med 346, 5 (Jan 3, 2002). 
310. D. J. Anderson, F. H. Gage, I. L. Weissman, Nat Med 7, 393 (Apr, 2001). 
311. D. Orlic et al., Nature 410, 701 (Apr 5, 2001). 
312. C. Toma, M. F. Pittenger, K. S. Cahill, B. J. Byrne, P. D. Kessler, Circulation 
105, 93 (Jan 1, 2002). 
313. C. E. Murry et al., Nature 428, 664 (Apr 8, 2004). 
314. P. Seale, M. A. Rudnicki, Dev Biol 218, 115 (Feb 15, 2000). 
315. B. Leobon et al., Proc Natl Acad Sci U S A 100, 7808 (Jun 24, 2003). 
316. A. P. Beltrami et al., Cell 114, 763 (Sep 19, 2003). 
317. H. Oh et al., Proc Natl Acad Sci U S A 100, 12313 (Oct 14, 2003). 
318. J. Yamaguchi et al., Circulation 107, 1322 (Mar 11, 2003). 
319. J. S. Forrester, M. J. Price, R. R. Makkar, Circulation 108, 1139 (Sep 2, 2003). 
320. B. E. Strauer, M. Brehm, T. Zeus, H. W. Muller, P. Wernet, Med Klin 
(Munich) 98 Suppl 2, 14 (Dec 15, 2003). 
321. A. Subramaniam et al., J Biol Chem 266, 24613 (Dec 25, 1991). 
322. A. Musaro, K. J. McCullagh, F. J. Naya, E. N. Olson, N. Rosenthal, Nature 
400, 581 (Aug 5, 1999). 
323. C. Rommel et al., Nat Cell Biol 3, 1009 (Nov, 2001). 
324. N. Pullen et al., Science 279, 707 (Jan 30, 1998). 
 129 
325. G. Ren, O. Dewald, N. G. Frangogiannis, Curr Drug Targets Inflamm Allergy 
2, 242 (Sep, 2003). 
326. B. Nadal-Ginard, J. Kajstura, P. Anversa, A. Leri, J Clin Invest 111, 1457 
(May, 2003). 
327. B. Nadal-Ginard, J. Kajstura, A. Leri, P. Anversa, Circ Res 92, 139 (Feb 7, 
2003). 
328. S. Kim, H. Iwao, Jpn J Pharmacol 80, 97 (Jun, 1999). 
329. H. E. Morgan, K. M. Baker, Circulation 83, 13 (Jan, 1991). 
330. D. Zechner, D. J. Thuerauf, D. S. Hanford, P. M. McDonough, C. C. 
Glembotski, J Cell Biol 139, 115 (Oct 6, 1997). 
331. S. Kim et al., Biochem Biophys Res Commun 236, 199 (Jul 9, 1997). 
332. S. Oldham, E. Hafen, Trends Cell Biol 13, 79 (Feb, 2003). 
333. A. F. Shamji, P. Nghiem, S. L. Schreiber, Mol Cell 12, 271 (Aug, 2003). 
334. J. B. Harris, M. J. Cullen, Electron Microsc Rev 3, 183 (1990). 
335. C. Rajnoch et al., J Thorac Cardiovasc Surg 121, 871 (May, 2001). 
336. P. Anversa, B. Nadal-Ginard, Nature 415, 240 (Jan 10, 2002). 
337. Y. Jiang et al., Nature 418, 41 (Jul 4, 2002). 
 
 
 
 
